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Abstract 
 
Paediatric glioblastoma multiforme (pGBM) is an aggressive childhood brain 
tumour with less than 10% of children surviving two years post diagnosis. 
There is no cure, and treatment options are limited and ineffective. Gene 
expression profiling, whole-exome sequencing and genome wide copy 
number analyses have revealed a number of ‘oncohistone’ mutations 
amongst pGBM. Acetylation and deacetylation of histones and non-histone 
proteins is controlled by histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). HDACs, critical for development, are involved in 
modulating key cellular processes, including DNA damage repair, cell cycle 
control, apoptosis, transcriptional regulation and metabolism. Their 
functioning in cancer is impaired and the potential use of HDAC inhibitors for 
cancer treatment is an active area of both basic and clinical research. There 
are 11 HDAC family members, grouped according to their structure, cellular 
localization and homology with yeast HDAC proteins. 
Little is known about HDAC expression in pGBM. The hypothesis for this 
study was that HDACs would be over-expressed in pGBM, given the wide 
use of HDACi research. The aims of this project were to; 1) systematically 
analyse HDAC expression in pGBM using publicly available datasets, 2) 
Begin to characterise HDAC expression in two, well-characterised paedatric 
GBM cell lines in order to identify specific HDAC family members that are 
dysregulated in pGBM. 
 
 vi 
Bioinformatic analysis of mRNA expression of HDACs from microarray data 
were conducted using the R2 Genomics and Visualisation Platform. HDAC 
expression was analysed at the mRNA and protein level in cell lines, under 
normoxic and hypoxic (1% O2, 48 hours) conditions. HDAC10 was 
expressed at the lowest levels in all pGBM datasets and across all other 
brain tumour types analysed, including adult GBM and a range of paediatric 
brain tumours. Survival analysis revealed low expression of HDACs 3, 10 
and 11 to significantly decrease survival probability in pGBM by 18-72 
months. In vitro studies found HDAC10 to be significantly decreased in 
pGBM compared to the foetal astrocyte control, at both the protein and 
mRNA level. This investigation found hypoxia did not significantly effect 
HDAC expression in either pGBM or foetal astrocyte cell lines. 
 
This is the first study to our knowledge to systematically investigate 
expression of HDACs 1-11 in pGBM and provides insight into an HDAC that 
warrants further investigation in this neoplasm. 
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Chapter 1 Introduction 
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1.0 Brain Tumours 
 
Until the recent release of ‘The 2016 World Health Organization (WHO) 
Classification of Tumours of the Central Nervous System (Louis et al., 2016), 
brain tumours have been classified based on their histological and structural 
characterization and immunohistochemical expression of proteins 
associated with cell lineage. The updated classification recognizes and 
incorporates molecular parameters to distinguish between tumour entities 
previously thought of as one and the same. Whilst WHO grading is still made 
on the basis of histological criteria, (table 1.1) genotypic and molecular 
characteristics override histological phenotypic diagnosis when the two differ 
and serve to further categorise tumours providing prognostic and therapeutic 
insight (Louis et al., 2016). 
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Table 1.1: The World Health Organisation’s histological grading criteria 
for all brain tumours (Louis et al., 2007) 
 
GRADE HISTOLOGICAL CRITERIA 
Grade I Low proliferative potential with possibility of cure 
Grade II 
Low proliferative activity but 
generally infiltrative and often recur. 
Some progress to become 
malignant 
Grade III 
Histological evidence of malignancy 
including nuclear atypia and mitotic 
activity 
Grade IV 
Cytologically malignant, high mitotic 
activity, areas of necrosis, 
widespread infiltration, cellular 
pleomorphism, microvascular 
proliferation, rapid disease 
progression with fatal outcome 
 
 
Within the reclassification, glioblastoma has been divided into molecular 
subtypes; glioblastoma, isocitrate-dehydrogenase (IDH)-wildtype; 
glioblastoma, IDH-mutant (an important and frequently occurring mutation in 
adult GBM); and glioblastoma, not otherwise specified (NOS) (Louis et al., 
2007). A new variant has also been recognised and termed epithelioid 
glioblastoma which features large epithelioid cells, eosinophilic cytoplasm, 
vesicular chromatin and prominent nucleoli (Louis et al., 2016). Patterns of 
glioblastoma have been described as glioblastoma with primitive neuronal 
component, which displays nodules containing primitive cells with neuronal 
differentiation; small cell glioblastoma, which contains small neoplastic cells 
often with EGFR amplification; and granular cell glioblastoma, which is 
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described as having granular to macrophage-like, lysosome-rich cells (Louis 
et al., 2016). Key characteristics of the new subtype classifications of 
glioblastoma are summarised in table 1.2 below. 
 
Table 1.2 Summary of the 2016 reclassification and subgrouping of adult 
glioblastoma (Louis et al., 2016) 
Subgrouping is based on prevalent, well characterised mutations seen 
in adult GBM. 
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Since the change in classification was very recent, much of the literature 
discussed will still contain the older classifications. 
 
Symptoms and Diagnosis of GBM 
 
A patient’s clinical presentation can vary based on where the tumour is 
located within the brain and the size of the tumour. Headaches and nausea 
are common due to the increased intracranial pressure but non-specific 
symptoms such as personality changes and not experiencing any symptoms 
at all is also possible (Louis et al., 2007).  
 
There are a number of imaging techniques that can be employed when 
looking to diagnose a brain tumour (Table 1.3). Magnetic resonance imaging 
(MRI) techniques are used primarily to determine location and size of the 
tumour, plan biopsies and assess the impact on blood vessels, and 
surrounding brain, whilst computed tomography (CT) can detect 
haemorrhage and hydrocephalus (Mabray, Barajas, & Cha, 2015).  
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Table 1.3: Imaging techniques and their uses in diagnosis and 
treatment of brain tumours 
 
IMAGE TECHNIQUE USE IN IMAGING BRAIN TUMOURS 
Computed tomography (CT) 
Can detect herniation, 
hydrocephalus, haemorrhage, 
calcification and overall effect of 
brain 
Pre- and post-contrast T1 Shows necrosis and enhancement characteristics 
T2/fluid attenuated inversion 
recovery (FLAIR) Shows peri-tumoural edema 
T2 susceptibility sequence (SWI) 
Shows blood, calcifications and 
radiation induced chronic micro-
haemorrhages 
Diffusion weighted imaging 
(DWI)/apparent diffusion 
coefficient (ADC) 
Reduced in highly cellular parts of 
the tumour 
Diffusion tensor imaging (DTI) Good for surgical planning and navigation 
Perfusion (dynamic susceptibility 
contrast enhanced (DSC)) 
Shows tumour and tissue 
vasculature 
Magnetic resonance (MR) 
spectroscopy 
Shows metabolic profile of the 
tumour 
Functional magnetic resonance 
imaging (fMRI) Pre-operative functional mapping 
 
 
Epidemiology of Glioblastoma 
 
The Office for National Statistics in England registered an average of 6000 
new cases per year of all central nervous system (CNS) tumours, for the 
ages of 0-84 years between 1995 and 2003, with a slight male 
predominance of 1.17:1 male to female ratio (Arora et al., 2009). There was 
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a recorded annual average of 330 new CNS tumours in 0-14 year olds. 
Similar to the 0-84 year cohort, a slight male predominance of 3.72 
compared to 3.39 per 100,000 person-years was also noted for this age 
group (Arora et al., 2009). As age increased, malignancy of the tumours was 
seen to decrease in proportion and tumour location changed from 
predominantly infratentorial to an increase in supratentorial locations (Arora 
et al., 2009). 
 
In the United States, malignant CNS tumours account for 21% and 10% of 
all cancers in children and adolescents respectively, making them the 
second and third most common cancer amongst these age groups (Ward, 
DeSantis, Robbins, Kohler, & Jemal, 2014). In 2014, it was estimated that 
2240 children and 540 adolescents would be diagnosed with a malignant 
CNS tumour, of which 35% would be astrocytomas (Ward et al., 2014). A 
report from the Automated Childhood Cancer Information Systems (ACCIS) 
project between 1978-1997 across 19 European countries found age-
standardized incidence rates (ASR) for all CNS tumours of 29.9 per million 
children (under 15 years old) with astrocytoma accounting for 40% (Peris-
Bonet et al., 2006). Again, a slight but significant male predominance was 
found amongst males over females. The frequency of CNS tumours 
appeared to increase by an average of 1.7% per year but it is likely this is 
down to improved diagnostics over time. For all CNS tumours, 5-year 
survival increased significantly from 52% to 67% over the time-period (Peris-
Bonet et al., 2006). 
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1.1 Paediatric Glioblastoma 
 
The 2016 WHO update marks the first time that paediatric diffuse gliomas 
have stood apart from their adult counterpart, based on multiple studies 
describing their biological and molecular differences. One particular genetic 
abnormality that has shown a surprising homogeneity amongst these 
gliomas along the midline locations, such as the brainstem and thalamus, is 
the K27M mutation in the histone H3 gene H3F3A and HIST1H3B (Louis et 
al., 2016) (Schwartzentruber et al., 2012). This entity is termed diffuse 
midline glioma, H3 K27M-mutant and incorporates diffuse intrinsic pontine 
gliomas (DIPG) with paediatric Glioblastomas (Louis et al., 2016). Figure 1.1 
shows the histology found in this neoplasm. 
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Figure 1.1: Magnetic resonance imaging (MRI) and histology of 
diffuse midline glioma, H3 K27M-mutant.  
Taken from the WHO 2016 updated classification of central nervous 
system tumours (Louis et al., 2016). Histology on the left shows staining 
of the K27M mutant protein (indicated by arrows); to the right, staining 
shows p53 staining (indicated by arrows), indicative of mutant p53 – a 
known prevalent mutation in GBM.  
 
Paediatric GBMs are derived from astrocytes; star-shaped glial cells which 
are commonly described as being the ‘glue’ of the brain in the way they 
support nerve cells and hold the brain together. Paediatric GBM cell lines 
show a range of astrocytic morphologies, showing a variety of stellate, 
bipolar, polygonal (irregular with more than 4 sides) and cuboidal (square 
shaped) cells (Bax, Little, et al., 2009). Cells express a range of glial; GFAP, 
S100 and vimentin; and stem cell markers; nestin, and CD133; at varying 
intensities (Bax, Little, et al., 2009). 
 
Diffuse Midline Glioma 
H3 K27M-mutant 
in the Thalamus
Left:Rim-enhancing mass 
on post-contrast T1 MRI 
(indicated by white arrow)
Diffuse Midline Glioma 
H3 K27M-mutant
Left: H3 K27M-mutant protein expression 
(shown by arrows); Right: Strong p53 
staining (shown by arrows).
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1.1.1 Epidemiology in Paediatric Glioblastoma 
In a retrospective study of infants ranging from 0.2 – 2.9 years of age, five-
year overall survival for patients with GBM was 80% and event free survival 
40% (Sanders et al., 2007). Overall survival was improved for patients with 
high grade astrocytoma who had initial complete surgical resection by 10% 
at 5 years and 40% at 10 years (Sanders et al., 2007). Age at diagnosis was 
found to be a significant predictor of the hazard of death ratio (a ratio of 
hazard frequency in one group divided by hazard frequency in another 
group). For each year older at diagnosis a patient was, the hazard of death 
doubled (Sanders et al., 2007). Younger children usually have a significantly 
increased long-term survival, even when compared to older children 
(Sanders et al., 2007), suggesting not only a difference between adult and 
paediatric tumours, but also between age groups amongst infants, children 
and adolescents.  
 
One study carried out on paediatric GBM between 2002 and 2007 showed a 
strong male predominance at 2:1 (male:female) (Suri et al., 2009). This is in 
disagreement with the 2007 WHO guidelines which report a 1:26 
male:female ratio in the USA and a 1:28 ratio in Switzerland (Louis et al., 
2007). The disparity is likely to be for a number of reasons, firstly and 
perhaps most importantly is the lack of discrimination between paediatrics 
and adults in the WHO guidelines. The majority (99%) of cases assessed by 
the WHO were from adult glioblastoma patients, with 80% being over the 
age of 50. This is compared to the exclusively paediatric study conducted by 
Suri et al., giving a difference in mean age of patients between the studies of 
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50 years. There was also a large difference in sample numbers between the 
studies. Another important factor to consider is the difference in location 
between the studies since the first study by Suri et al was carried out in 
India. A report from the European protocol ‘HIT-GBM-C’ showed 5 year 
survival to be 63 ± 12% for complete surgical resection followed by radiation 
and chemotherapy compared with 19 ± 4% when all patients with all 
treatment options were included (Wolff et al., 2010). The HIT-GBM-C 
protocol will be discussed in section 1.4. 
 
A population based study in Europe showed paediatric glioblastoma to 
account for 2.8% of central nervous system (CNS) tumours in children and 
6.8% of tumours in the pons (Kaatsch, Rickert, Kühl, Schüz, & Michaelis, 
2001). 
 
Location of the tumour was another prognostic indicator with poorer 
prognosis for patients with tumours in the pontine locations and the best 
outcome for those with a tumour in the cerebral hemispheres (Wolff, 
Classen, et al., 2008). In children with tumours located outside of the pons, 
total surgical resection was found to be the strongest predictor of survival 
(Kramm et al., 2006).  
 
Surprisingly, in an earlier study, Wolff et al., 2002 found tumour location to 
have no prognostic relevance in their cohort of paediatric patients with high 
grade glioma (HGG). However, the study does not specify whether or not 
there were any tumours in the pons in their cohort and this factor alone could 
explain the finding that tumour location was not prognostically relevant. 
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Another study found neither age nor gender to be prognostically relevant for 
HGG (Rickert et al., 2001). 
 
There have been a range of studies, over the past 20 years, in different age 
groups, countries and in a mixture of HGG (including grade III and IV 
astrocytomas) and pGBM, some of which include tumours located in the 
pons, and some without. Given the differences between studies, it is 
unsurprising there are conflicting reports regarding which factors are 
prognostically relevant, but it is agreed that complete surgical resection 
provides the best chance for longer term survival. A potential reason for 
some of these conflicting results may be the differences in the range of 
mutations and molecular subgroups included within each study.  
 
1.1.2 Genetic and Molecular Markers in Paediatric Glioblastoma 
In 2012, a number of important mutations were identified amongst paediatric 
GBM’s (Schwartzentruber et al., 2012), providing the ability to sub-classify 
these tumours for the first time. There were 3 mutations in the H3F3A gene 
which codes for the histone variant H3.3 (Schwartzentruber et al., 2012). 
These mutations were all single nucleotide variants (SNV), the first changing 
lysine 27 to methionine (K27M), the second, glycine 34 to arginine (G34R), 
and the third, glycine 34 to valine (G34V) (Schwartzentruber et al., 2012). 
These mutations are positioned in the amino-terminal tail and are at or near 
locations which undergo post translational modifications concerned with 
repression of activation of genes (Schwartzentruber et al., 2012). Other 
mutations were found in ATRX which codes for a transcription/chromatin 
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remodelling complex and DAXX which plays a role in recruiting H3.3 to DNA 
and heterodimerizes with ATRX (Schwartzentruber et al., 2012). 44% of 
paediatric GBMs tested were found to have at least 1 of these mutations 
(Schwartzentruber et al., 2012). All H3F3A mutations were found to be 
mutually exclusive with IDH1 mutations (Sturm et al., 2012). Overall survival 
was found to be significantly decreased in children harbouring the K27 
mutation in comparison with the G34 mutation and this was independent of 
the location of the tumour (Sturm et al., 2012). 
 
Wu et al. (Wu et al., 2012) found the histone H3.3 K27M mutation in the 
H3F3A gene, along with the same K27M mutation in the HIST1H3B gene 
which encodes the histone H3.1 isoform in 78% of DIPGs and 22% of non-
brainstem paediatric GBMs. They also identified the H3.3 G34R mutation in 
14% of the non-brainstem paediatric GBMs but found no DIPGs with this 
mutation (Wu et al., 2012). In all the cases where germline DNA was 
available, the mutations identified were found to be somatic. Expanding the 
study to include low-grade brainstem gliomas, low-grade non-brainstem 
gliomas, ependymomas, medulloblastomas and non-central nervous system 
paediatric tumours revealed no mutations in any of the 16 histone H3 genes 
demonstrating this set of mutations are unique to paediatric GBM and DIPG 
(Wu et al., 2012).  
 
The K27 and G34 residues are located close to the nucleosome core on the 
N-terminal tail of histone H3 so are implicated in regulation and accessibility 
of the chromatin structure (Wu et al., 2012). Changes at these residues 
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could have multiple consequences such as changing the interaction between 
the DNA and the histones or other components which bind to them, 
alterations of the nucleosome or chromatin structure and function as well as 
methylation and acetylation at these points which influences gene repression 
and activation (Wu et al., 2012). H3.1 is replication-dependent, being 
synthesized in S phase of the cell cycle where as H3.3 is replication-
independent (Wu et al., 2012). Bjerke et al. (Bjerke et al., 2013) showed 
there was significantly different gene expression between G34 mutated 
tumours and both K27 mutated and wildtype tumours. Patients with K27 
mutant tumours had an average age of 7 years old, much younger than that 
of patients harbouring the G34 mutation who had an average age of 14 
years (Bjerke et al., 2013). Those with the K27 mutation also had a 
significantly worse prognosis when compared to patients with the G34 
mutations and H3F3A wildtype patients (Bjerke et al., 2013). They found no 
significant difference between G34R and G34V tumours but acknowledge a 
lack of samples for the latter mutation (Bjerke et al., 2013). Interestingly 
Bjerke et al. (Bjerke et al., 2013) found MYCN to be significantly differentially 
bound along with increased expression in the G34 mutant paediatric GBM 
cell line KNS42 (Bjerke et al., 2013). However, this was not through gene 
amplification so must use an alternative mechanism (Bjerke et al., 2013). 
MYCN was not the only differentially bound and expressed gene in G34 
mutant tumours, a number of cell fate, stem cell maintenance and forebrain 
development-associated genes were also identified to be driven by the 
mutation (Bjerke et al., 2013).   
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Di- and trimethylation (me2 and me3 respectively) of H3K27 were found to 
be decreased in cells harbouring the H3.3 and H3.1 K27M mutation in 
comparison to neural stem cells and an adult GBM (Chan et al., 2013). 
However, it is worth noting this was not compared to a non-K27-mutant 
paediatric GBM or DIPG, and arguably, comparing to an adult GBM is 
inappropriate since it is well understood that these are very different 
tumours. This pattern was also observed in astrocytes with the same 
mutation suggesting that the decreases in H3K27me2/m3 is cell type-
independent (Chan et al., 2013). This decrease appears to increase over 
time following transfection, reaching a 70-80% decrease at 120 hours (Chan 
et al., 2013). Due to the lack of H3.3K27M mutations in adult GBM, Chan et 
al. (Chan et al., 2013) suggest that the mutation may selectively target 
neural precursor cells and neural stem cells during brain development and 
be the primary driver of tumourigenesis in paediatric DIPG.   
 
Paediatric GBM’s were found to have significantly increased expression of 
genes associated with angiogenesis compared to WHO grade III anaplastic 
astrocytomas (Paugh et al., 2010). 
DNA copy number changes were found in 100% (Giunti et al., 2014) and 
85% of paediatric GBM’s with an average of 6.1 (Rickert et al., 2001) and 
5.7 regions of copy number imbalances per tumour (Paugh et al., 2010). The 
most frequent copy number changes were gains on 1q, 3q, 2q and 17q and 
losses on 6q, 8q, 10q, 13q, and 17p (Rickert et al., 2001). Paugh et al., 2010 
found a significant decrease in survival in pGBM patients with 1q gain but 
were unable to analyse whether this was independent of treatment.  
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Phosphatidylinositol 3-kinases (PI3K) are involved in cellular signaling 
pathways such as proliferation, differentiation and migration. Mutations have 
been found in 21% of paediatric GBM in PIK3CA which encodes a catalytic 
subunit of class IA of the multiprotein enzyme (Gallia et al., 2006).  
One study (Donson, Addo-Yobo, Handler, Gore, & Foreman, 2007) found 
promoter methylation of the O6-methylguanine-DNA methyltransferase 
(MGMT) gene, a well known predictor of temozolomide efficacy in aGBM, to 
be significantly associated with increased survival, with an average of 13.5 
months compared with 2.5 months survival for those with an unmethylated 
promoter. 
In a 2007 study, pGBM patients who had activated Ras were highly likely to 
also have activated Akt and this was significantly associated with poorer 
survival. Patients with inactive Ras or Akt were alive and disease free at 4 
years follow up (Faury et al., 2007). This suggests there may be prognostic 
subgroups in pGBM depending on activation of Ras and Akt. Molecular 
profiling agreed with the protein analysis finding a clear distinction between 
Ras-active samples and Ras-non-active samples (Faury et al., 2007). Ras-
active samples were found to over-express neural stem cell markers 
(CD133, nestin, maternal embryonic leucine zipper kinase (MELK), vimentin 
and Dlx2) as well as genes involved in protein synthesis, translation, 
transcription, DNA repair and synthesis. Whilst Ras-non-active samples 
overexpressed vimentin, and genes involved in apoptosis (Faury et al., 
2007). Finally the study found that Y-box-protein-1 (YB-1) (thought to 
contribute to oncogenesis in some cancers through Akt phosphorylation) 
was overexpressed in the nucleus of Akt-active samples (Faury et al., 2007). 
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Progression free survival at 5 years was significantly decreased in patients 
whose malignant gliomas overexpressed p53 (17 ± 6 %) compared with 
those who had only low expression of the protein (44 ± 6 %) (Pollack et al., 
2002). Another study found p53 missense mutations in 38% of paediatric 
HGG, with 56% of those being located in the brain stem (Cheng et al., 
1999). 75% of the HGG’s had aberrant p53 expression, half of which also 
carried a mutation (Cheng et al., 1999).  
 
Hierarchical clustering identified 3 subgroups within pGBM with significantly 
overexpressed genes implicated in cell cycle regulation, neuronal 
differentiation and extracellular matrix receptor interactions and cell 
adhesion (Paugh et al., 2010) but interestingly infants were found to have a 
more heterogenous genetic profile and subsequently did not fit into any one 
group. However a larger sample size of this age group may rectify this issue.  
 
1.2 Brain Development and Brain Tumours 
 
It has been suggested that DIPG are a result of an issue during 
neurodevelopment. DIPG are thought to arise from pontine-like precursor 
cells expressed in the ventral pons (Monje et al., 2011). Dysregulation of the 
hedgehog pathway in the ventral pons, normally active throughout 
development, has been shown to cause hypertrophy in a DIPG model 
demonstrating a potential molecular origin for this tumour (Monje et al., 
2011). Aberrant proliferation of pontine-like precursor cells, caused by 
dysregulation of neuronal activity during development, express SOX2, 
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nestin, Olig2 and vimentin (Monje et al., 2011), also found to be expressed 
in DIPG, demonstrating that disruption of neurodevelopmental processes 
can lead to tumourigenesis. During embryogenesis, Olig1 and Olig2 are 
expressed in the peri-ventricular zone and regulate neural cell proliferation 
and differentiation (Gupta, Djalilvand, & Brat, 2005). Oligodendroglia are 
thought to be active in the ventral pons throughout childhood (Panditharatna, 
Yaeger, Kilburn, Packer, & Nazarian, 2015).  
 
Much more research is required into the area of the role of aberrant 
neurodevelopment and the impact this has on the development of childhood 
brain tumours. It is important to appreciate that an immature brain is vastly 
different to a fully matured adult brain. This has been demonstrated in the 
research conducted so far in paediatric and adult GBM, showing the vast 
differences that exist between two tumours that were once regarded as the 
same disease. 
 
1.3 Paediatric GBM vs. Adult GBM 
 
Although histologically very similar, molecularly and biologically paediatric 
GBM is a separate disease to adult GBM necessitating a different approach 
when treating the tumour and considerations regarding the fragility of the 
developing brain. Not only does the location of the tumour differ between 
paediatric and adult patients; with paediatric GBM arising more often 
infratentorally (below the tentorium) and adult GBM supratentorally (above 
the tentorium); Bax, Little, et al., 2009 found differential expression of 93 
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genes between the two patient groups. Paediatric cell lines had an increase 
in genes associated with DNA replication and repair whilst adults had an 
increased expression of genes associated with regulation of the extracellular 
matrix. This study only analysed a small number of samples and still found 
huge differences between the paediatric and adult disease highlighting the 
vital need for paediatric specific research. 
 
Amplification of the epidermal growth factor receptor (EGFR) gene, which 
encodes a tyrosine kinase implicated in cell replication, has been 
consistently reported in adult GBM but is uncommon in the paediatric 
disease (Pollack et al., 2006) (Paugh et al., 2010). Supporting this, 0% 
(Cheng et al., 1999) and 14% (Bax, Gaspar, et al., 2009) of paediatric GBMs 
were found to have EGFR amplification. Not surprisingly there is also 
differences from adults in protein expression, with paediatric’s showing 25% 
(Cheng et al., 1999) and 58% (Liang et al., 2008) expression for the wildtype 
gene but a very low expression for the mutated gene EGFRvIII, 2% (Liang et 
al., 2008) and 5% (Bax, Gaspar, et al., 2009), which is lacking the ligand-
binding domain making it constantly active. This is reinforced again in a 
comparative study which saw EGFR amplification in just 5.5% of paediatric 
GBM but overexpression of the EGFR protein in 39% of cases (Suri et al., 
2009). Bax, Gaspar, et al., 2009 found no correlation between clinical 
outcome and EGFR amplification. 
The gene encoding phosphatase and tensin homolog (PTEN) is often 
deleted in adult GBM, activating the Akt pathway and causing increased 
levels of Akt (Haas-Kogan et al., 1998). However, Cheng et al. (Cheng et al., 
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1999) found PTEN mutations in just 15% of paediatric GBM with an average 
age of 11 and another study including grade III and IV paediatric gliomas 
found PTEN mutations to be rare (Pollack et al., 2010). Interestingly though, 
high levels of Akt were still found in 42 of the 53 tumours and this was 
associated with a poorer prognosis with 1-year event free survival dropping 
to 59% with overexpression of Akt from 91% for those with no expression 
(Pollack et al., 2010). 
Alpha-type platelet-derived growth factor receptor (PDGFRa) amplification 
was identified as a central event in paediatrics compared with a much lower 
expression in adult HGG (Bax et al., 2010) (Paugh et al., 2010). Increased 
expression of PDGFRa was also detected in 7 of 11 DIPG samples 
(Zarghooni et al., 2010). 
IDH1 mutations are frequent in adult secondary GBM but rare in paediatrics 
and interestingly a study noted that all IDH1 mutations that were found in 
patients with HGG were exclusively in children over the age of 14 (Pollack et 
al., 2011) underlining the notion that these tumours are biologically different 
not only in paediatrics compared with adult but also between infants, 
children and teenagers. Interestingly, adults with a GBM who carried IDH1 or 
IDH2 mutations were found to be significantly younger (32 years) than those 
with the wild-type genes (59 years), despite no mutations being found in 
their paediatric GBM cohort (Yan et al., 2009). This finding highlights the 
notion of there being subtypes within aGBM defined by IDH mutations, which 
has recently been defined in the updated WHO guidelines. 
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This same pattern can be found in TP53 mutations which is frequently 
mutated in adult GBM compared with paediatrics and was shown to have a 
significantly higher incidence in older children at 40% compared with 
younger children at 12% (Pollack et al., 2001). 
 
The O6-methylguanine-DNA methyltransferase (MGMT) gene is known to be 
silenced by methylation at the promoter in a subset of adult GBM. The gene 
encodes a DNA repair protein which removes akyl groups from the O6 
position of guanine resulting in DNA alkylating agents, such as 
temozolomide, being largely ineffective. Therefore, silencing of the gene has 
been strongly associated with increased survival in patients (Hegi et al., 
2005). Patients who had MGMT promoter methylation had a 55% decreased 
risk of death irrespective of treatment with radiation alone or with 
temozolomide, resulting in an overall survival of 18.2 months with promoter 
methylation compared to 12.2 months without (Hegi et al., 2005). When 
analysed independent of other prognostic factors the study found MGMT 
promoter methylation to be prognostically significant (Hegi et al., 2005).     
 
In a small study of 10 paediatric GBMs, there was no complete methylation 
of the MGMT promoter but 40% of tumours did have partial methylation 
(Donson et al., 2007). Even this partial methylation translated to a significant 
increase in overall survival from 2.5 months to 13.7 months (Donson et al., 
2007).  
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As discussed there are stark differences between paediatric GBM and adult 
GBM, particularly at the molecular level and is fitting that the two are now 
acknowledged as separate diseases.  
 
1.4 Treatment 
 
When it comes to the ‘gold standard’ of treatment for paediatric GBM, 
surgical resection and radiotherapy are essential. However, radiotherapy is 
not given to those under the age of 3 years because of the damaging effects 
it has on the developing brain (Vanan & Eisenstat, 2014). Unfortunately, it is 
also well known that there is no existing chemotherapeutic agent that 
demonstrates a significant survival advantage for these patients. Often a 
range of chemotherapies will be tried, including any clinical trials the patient 
may be eligible for.  
 
1.5 Clinical Trials 
 
The ‘HIT-GBM’ study was devised to evaluate chemotherapy protocols for 
children with HGG, following surgical resection. The first protocol (HIT-GBM-
A) used trophosphamide and etoposide, the second (HIT-GBM-B), used 
intensive chemotherapy and radiation together, followed by interferon 
gamma maintenance treatment (Wolff et al., 2010). The third and final 
protocol (HIT-GBM-C) used intensive chemotherapy with concomitant 
radiation for a longer period and added Valproic acid, a histone deacetylase 
inhibitor (Wolff et al., 2010). Chemtherapeutic agents given included 
cisplatin, etoposide, vincristine, and ifosfamide in various combinations for 
 23 
30 weeks (Wolff et al., 2010). For patients with pontine tumours and tumours 
outside of the pons with residual tumour following resection, the results were 
similar to previous protocols (Wolff et al., 2010). However, for patients with 
complete surgical resection, overall survival at 6 months and 60 months was 
95% (±5) and 63% (±12) respectively, whereas the control group was 100% 
and 17% (±10), with a similar pattern for event-free survival (Wolff et al., 
2010). Even when compared with respect to other prognostic features, 
gender, metastasis and age, the HIT-GBM-C protocol was still the stronger 
protocol, only tumour location was equally as influential as the treatment 
regimen (Wolff et al., 2010). 
 
Another study compared two chemotherapy regimens, the ‘HIT’ sandwich 
chemotherapy protocol (Protocol S) and the HIT maintenance chemotherapy 
protocol (Protocol M), in paediatric patients with high-grade glioma (Wolff et 
al., 2002). Protocol S, consisting of ifosfamide, etoposide, methotrexate with 
citrovorum factor rescue (reduced folic acid used both as a chemoprotectant 
and to enhance chemosensitivity), cisplatin and cytosine arabinoside across 
four blocks of treatment, was repeated then followed by radiation. Protocol M 
started with radiotherapy and vincristine, then followed every four weeks with 
cycles of lomustine, cisplatin, and vincristine once radiotherapy was 
completed (Wolff et al., 2002). For patients who underwent complete or 
subtotal resection, protocol S gave a significantly increased overall survival 
compared with protocol M, 5.17 years (± 2.18 years) and 1.94 years (± 0.36) 
respectively (Wolff et al., 2002). For increased overall survival, female 
gender, younger age and lower histological grade were all significant 
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parameters, but this was not the case when using event-free survival when 
none of these parameters were significant (Wolff et al., 2002).  
 
Out of 15 paediatric patients with a GBM who took part in a temozolomide 
trial following radiotherapy, the average survival time was just 0.98 years 
with just 1 patient still alive at follow up (Broniscer et al., 2006). The study 
excluded brainstem gliomas. Another study published in 2013 found a 
significant reduction in proliferation (determined by WST-1 cleavage) and 
cell growth when 2-Deoxyglucose (an inhibitor of glycolysis) and metformin 
(1,1 dimethylbiguanide hydrochloride) (an anti-diabetic agent) were used 
together in paediatric GBM cell lines (Levesley, Steele, Taylor, Sinha, & 
Lawler, 2013). Dual treatment decreased ATP levels and increased AMP-
activated protein kinase (AMPK) phosphorylation indicating metabolic cell 
stress but a lack of caspase-3 and PARP cleavage indicated any cell death 
seen was caspase independent  (Levesley et al., 2013).  
 
Valproic acid is a histone deacetylase (HDAC) inhibitor which is used to treat 
epileptic seizures in children. However, over recent years there has been 
trials using the drug at a higher dose to help treat high grade gliomas. One 
study used the HDAC inhibitor (HDACi) in combination with the HIT-GBM-C 
protocol (Wolff, Kramm, et al., 2008). This study found that the biggest 
influence on survival were location of tumour, extent of surgical resection, 
metastatic status and histology rather than treatment with Valproic acid 
(Wolff, Kramm, et al., 2008). The use of Valproic acid to treat brain tumours 
is discussed further in section 2.4.1.  
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New clinical trials are constantly being put forward with the latest novel 
agents including radiosensitizers, anti-angiogenics, growth factor receptor 
inhibitors, immunotherapy, free radical inducers and gene therapy (Reddy & 
Wellons, 2003) but as of yet, there has been no significant impact in the 
treatment of paediatric GBM. More recently, the discovery of oncohistones 
and related mutations have provided a new focus for studies, investigating 
the way that gene expression can be altered via epigenetic modification.  
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2.0 Epigenetics 
 
Epigenetics describes heritable, enzymatic changes in the DNA affecting 
gene expression without altering the sequence of base pairs. Waddington 
first described the concept of the ‘epigenetic landscape’ in 1942 
(Waddington, 2012) (figure 1.2) which depicts how a single genotype can 
lead to multiple phenotypes through modification of gene expression. 
	
	
Figure 1.2: Waddington’s epigenetic landscape.  
Described originally in 1946, it represents how a single genotype can 
lead to multiple phenotypes through epigenetic modification of gene 
expression. Waddington uses the metaphor of a marble placed at the top 
of a valley with multiple paths carved out. At each fork in the pathway, 
the marble will select a route, and each combination of choices will 
result in a different destination (phenotype). 
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Modification comes about via ‘epigenetic marks’ of which there are three 
broad groups: direct modification of DNA, positioning of nucleosomes along 
the DNA and posttranslational modifications of histone proteins (Gray, 
2015). Posttranslational modifications include acetylation, methylation, 
ubiquitylation and phosphorylation, among others, and are controlled 
through various chromatin remodelling enzymes and micro RNAs (miRNAs). 
 
2.1 Histone Deacetylases 
 
Chromatin remodelling enzymes, such as histone acetyltransferases (HATs) 
and histone deacetylases (HDACs) modify the structure of the chromatin by 
the addition (HATs) or removal (HDACs) of acetyl groups at lysine amino 
acids present at the N-termini. Addition of acetyl groups decreases binding 
affinity of the histones to the DNA backbone by neutralising the positive 
charge of amine groups located on the lysine and arginine amino acids. 
Chromatin is able to relax and expand allowing room for transcription 
machinery to bind. Removal of acetyl groups increases the positive charge 
of the histone tails so encouraging binding affinity to the negatively charged 
phosphate groups on the DNA backbone, causing compression of the 
chromatin structure (figure 1.3).  
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Figure 1.3: Histone deacetylases and histone acetyltransferases 
effect the chromatin structure and subsequently effect 
transcription of genes.  
Within the nucleus of a cell, acetyl groups are added to histone tails by 
HATs, allowing the chromatin structure to expand and allow 
transcription machinery to access and bind to DNA, and transcription to 
occur. HDACs remove these acetyl groups, causing the chromatin 
structure to compress, resulting in gene repression. HAT – histone 
acetyltransferase; HDAC – histone deacetylase; TM – transcription 
machinery. 
	
HDACs are grouped in relation to their structure, cellular localization and 
homology with yeast HDAC proteins. There are 4 zinc dependent groups; I, 
IIa, IIb and IV with group III containing nicotinamide-adenine-dinucleotise 
(NAD)-dependent sirtuins. Group I contains HDACs 1, 2, 3 and 8 and are 
homologous to Rpd3 (reduced potassium dependency 3), a yeast 
transcriptional regulator, group IIa, containing HDACs 4, 5, 7, 9a and 9b and 
group IIb containing HDAC6 and 10 are homologous to Hda1 (histone 
HAT
Chromosomes
Chromatin
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deacetylase 1) in yeast (Lucio-Eterovic et al., 2008). Group IV contains 
HDAC11, classed by itself as it is phylogenetically different from groups I 
and II (Lucio-Eterovic et al., 2008) (figure 1.4). Groups I, II and IV share the 
same enzymatic mechanism of action where the acetyl-lysine amide bond is 
hydrolysed when a zinc atom binds to the HDAC (Lucio-Eterovic et al., 
2008). 
	
	
Figure 1.4: Structure, length and cellular localization of Histone 
Deacetylases. 
Image taken from Lucio-Eterovic et al., 2008.  
 
HDAC expression was analysed in normal brain, low-grade and high-grade 
astrocytoma in adults (Lucio-Eterovic et al., 2008). HDACs 1, 2, 3 and 8 
(class I) had no significant differences in expression between normal brain, 
low-grade and high-grade whereas all but 1 of class II and class IV HDACs 
had decreased expression in high-grade compared with low-grade 
astrocytoma (Lucio-Eterovic et al., 2008).  
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Very few of the human HDAC 3D structures have been solved but the first to 
do so was Somoza et al. who published the 3D structure of HDAC8. From 
this they discovered HDAC8 to be quite different to its counterpart class I 
HDACs. HDAC8 does not appear to have a C-terminal domain extending 
from its catalytic domain and its active site has a much wider pocket and 
surface opening compared to HDACs 1, 2 and 3 (Somoza et al., 2004). A 
few others have been revealed since this with the structure of HDAC10 only 
predicted very recently (Sabeena, 2016). There is still a large gap in our 
knowledge regarding the structures of HDACs and subsequently we lack a 
full understanding of these enzymes. Future investigations into solving the 
structures of all the HDAC enzymes are critical and could be incredibly 
beneficial to finding novel agents for therapy, particularly if HDACs 
themselves are to be targeted. 
 
2.2 Function of Histone Deacetylases 
 
2.2.1 Function in the Brain 
HDACs are known to be required in many cellular processes in addition to 
transcriptional regulation and includes apoptosis, DNA damage repair, cell 
cycle control, autophagy, metabolism and senescence (Li & Zhu, 2014). All 
zinc-dependent HDACs are expressed in the normal functioning brain 
(Volmar & Wahlestedt, 2015) at differing levels, dependent on cell type and 
function. It is thought classes I, II and IV are all expressed in neurons 
(Broide et al., 2007) and astrocytes, although at a lower level in the latter. 
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Whereas only HDACs 2, 3, 4, 5 and 11 are expressed in oligodendrocytes 
(Gräff & Tsai, 2013).  
 
Juan et al., 2000 show direct inhibition of p53 by HDACs -1, -2 and -3 in a 
concentration dependent manner. This inhibition is mediated through 
deacetylase activity and is believed to reduce the DNA-binding ability of p53 
therefore decreasing gene transcription (Juan et al., 2000). 
HDAC1 in the hippocampus has been found to regulate fear extinction, a 
specific form of emotional memory known to affect schizophrenic patients 
(Bahari-Javan et al., 2012). Selectively inhibiting HDAC1 prevented the 
extinction of contextual fear in mice, whereas over-expressing HDAC1 
resulted in enhanced extinction of fear memories (Bahari-Javan et al., 2012). 
HDAC1 and HDAC3 have been shown to interact with each other to elicit 
neuronal death in neurodegenerative mouse models whereas knockdown of 
either HDAC1 or HDAC3 suppresses the ability of the other to produce this 
neurotoxic effect (Bardai, Price, Zaayman, Wang, & D'Mello, 2012). 
However, when HDAC1 interacts with the histone deacetylase related 
protein (HDRP); a truncated form of HDAC9; it switches to become 
neuroprotective and prevents neuronal death (Bardai et al., 2012). 
 
HDAC2 has been negatively implicated in memory formation where 
overexpression in mice resulted in associative learning impairments (Guan 
et al., 2009). The study revealed a decrease in hippocampus dependent 
learning such as spatial learning and spatial working memory whereas 
knockout mice displayed enhanced associative learning and spatial working 
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memory (Guan et al., 2009). Interestingly, mice with overexpressed HDAC2 
also showed a decrease in dendritic spines, and therefore synapse 
numbers, along dendrites of hippocampal CA1 pyramidal neurons and 
dentate gyrus granule cells along with impaired synaptic plasticity. Knockout 
mice however, showed a significant increase in dendritic spines and 
enhanced synaptic plasticity (Guan et al., 2009). Since synapses are thought 
to be the cellular basis for learning and memory (Martin, Grimwood, & 
Morris, 2000), this data reinforces the idea that HDAC2 is a negative 
regulator of these two processes (Guan et al., 2009).  HDAC2 is not the only 
HDAC found to be involved in memory regulation, HDAC3 has been found to 
negatively regulate long-term memory (Malvaez et al., 2013). Inhibition of 
HDAC3 in mice found memory processes were enhanced during 
consolidation of extinction. 
 
HDAC4 has been found to also impact upon learning and memory. Knockout 
mice were found to display decreased anxiety-like behaviour compared to 
wild-type mice (Kim et al., 2012). Long-term memory tests showed knockout 
mice to have an impairment during fear conditioning suggesting a deficiency 
in associative and spatial learning and memory (Kim et al., 2012). The study 
also showed loss of HDAC4 may cause alterations in presynaptic function, 
reinforcing the relationship between synapses and learning and memory. 
Increasing HDAC4 in cerebellar granule neurons was found to have 
neuroprotective effects and mice without HDAC4 had cerebellar 
abnormalities and increased activity of cyclin-dependent kinase-1 (CDK1), 
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an important protein with an essential role in control of the cell cycle 
(Majdzadeh et al., 2008). 
Spatial memory has been shown to be impaired in mice lacking HDAC5 
(Agis-Balboa et al., 2013). Although HDAC5 does not seem to be implicated 
in basal anxiety levels, it was shown that tone-dependent fear memory 
consolidation was disturbed in the absence of HDAC5.  
HDAC7 has also been shown to be neuroprotective and suppression of 
HDAC7 was able to induce neuronal death through increased expression of 
c-jun, an essential protein for neuron death (Ma & D'Mello, 2011). 
 
Data demonstrates many HDACs to be essential in healthy brain function 
with a clear relationship with learning and memory shown for HDACs 1, 2, 3, 
4 and 5. However it is clear that further research is needed into the more 
recently identified HDACs as there is understandably a lack of knowledge in 
this area.  
	
2.2.2 Function of HDACs in the Development of the Brain 
 
A 2009 study showed that deletion of HDAC1 or HDAC2 individually did not 
impact upon oligodendrocyte development in mouse brains, but when 
deleted simultaneously, mice developed tremors associated with myelin 
deficiency (Ye et al., 2009). There was complete loss of both 
oligodendrocyte precursor cell markers and mature oligodendrocyte markers 
in the spinal cord and brains of these mice too suggesting HDAC1 and 
HDAC2 are required for oligodendrogenesis and oligodendrocyte 
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differentiation (Agis-Balboa et al., 2013). Ye et al., 2009 observed that the 
loss of HDAC1 and HDAC2 did not impact upon other neural cell types in the 
developing CNS. However, another study using a similar model showed loss 
of HDAC1 and HDAC2 caused mice to have smaller brains with a 
compacted cerebellum (Montgomery et al., 2009). Defects were also found 
in the cortex, hippocampus and cortical laminar organization. Significant 
neuronal abnormalities were observed and Purkinje cells did not migrate 
from the nuclei of the cerebellum which prevented normal cerebellar growth 
(Montgomery et al., 2009). This study suggests HDAC1 and HDAC2 are 
essential in neural development. When over-expressed Guan et al., 2009 
showed that HDAC1 and HDAC2 did not change either the neuro-anatomy 
or the positioning of neurons in mouse brains suggesting it is only the loss of 
these HDACs that causes impaired neural development. This is a critical 
finding given the rise of the use of HDAC inhibitors to aid in the treatment of 
childhood neoplasms (discussed further in section 2.3). 
 
HDAC2 and HDAC3 have been found to bind to genes associated with 
transcription regulation of differentiation and development, such as Cebpb 
(C/EBPb), Hoxd4, Ovol2 and Zfp7 in neural stem cells from rat brains 
(Castelo-Branco et al., 2014). HDAC2 and HDAC3 were found to be 
enriched at promoters of Sox8, and HDAC3 at promoters of Pax6 genes, 
associated with neuronal and oligodendrocyte differentiation (Castelo-
Branco et al., 2014). Concomitant treatment of Valproic acid (VPA) and a 
thyroid hormone (T3) which promotes neural, oligodendrocyte and astrocyte 
differentiation of cortical neural stem cells resulted in an increase in 
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expression of Mbp and Plp compared with either compound alone (Castelo-
Branco et al., 2014). Specifically an increased expression of late markers, 
notably Mbp, of oligodendrocyte differentiation compared to early markers 
was seen (Castelo-Branco et al., 2014). Morphological changes such as 
formation of myelin plaque-like structures and an increase in 
oligodendrocyte radius was also observed following co-treatment. VPA 
treatment alone had no significant effects but was shown to promote 
oligodendrocyte differentiation when in combination with T3 (Castelo-Branco 
et al., 2014). Knockdown of HDAC2 induced an increase in expression of 
oligodendrocyte markers MBP, CNPase and PLP. In one cell line this led to 
a change in morphology suggesting the earlier effects seen with VPA may 
be partially dependent on HDAC2 (Castelo-Branco et al., 2014). SOX10, 
required for terminal oligodendrocyte differentiation, was increased in 
HDAC2 knockdown cells and data showed HDAC2 may be needed for 
SOX10 gene regulation in early oligodendrocyte development (Castelo-
Branco et al., 2014). HDAC3 has also been reported to repress neuronal 
genes and differentiation in embryonic neural stem cells (Castelo-Branco et 
al., 2014) which agrees with a report in the same year finding mislocalization 
of cortical and cerebellar purkinje neurons, a reduction in the number of 
oligodendrocytes and death within 24 hours of birth in mice lacking HDAC3 
(Norwood, Franklin, Sharma, & D'Mello, 2014). However, those with 
conditional knockdown of HDAC3 in neurons in the forebrain did not show 
these cellular organisational abnormalities but instead quickly produced 
paralysis in their back legs and died at around 6 weeks (Norwood et al., 
2014) showing HDAC3 to play multiple critical roles in neural development. 
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Class II HDACs have also been shown to play a role in the development of 
the brain. HDAC6 was found to play a critical role in dendrite development 
through interaction with Cdc20 in neuronal centrosomes (Kim et al., 2009) 
and HDAC9 was shown to translocate from the nucleus to the cytoplasm 
with maturation of cortical neurons (Sugo et al., 2010).  When replaced with 
a mutant HDAC9, total length of dendritic branches was significantly reduced 
suggesting HDAC9 is required for the proper development of these cells 
(Sugo et al., 2010). HDAC10 has been found to interact with the 
transcription factor Pax3, which is needed for normal neural crest 
development, among other processes (Lai et al., 2010). 
Oligodendrocyte differentiation depends on HDAC activity to form 
morphological changes characterised as primary, secondary and tertiary 
branches (Marin-Husstege, Muggironi, Liu, & Casaccia-Bonnefil, 2002). 
Differentiating progenitors treated with HDAC inhibitors were unable to form 
branches. It would be interesting if this research looked further into which 
HDAC(s) specifically were critical for the observed oligodendrocyte 
differentiation. Another study found HDAC inhibitors to induce apoptosis in 
cerebellar granule neurons (Salminen, Tapiola, Korhonen, & Suuronen, 
1998). Conversely, a 2004 study found that the HDAC inhibitor VPA, 
promoted neuronal differentiation in foetal neural stem cell cultures (Laeng 
et al., 2004) showing that potentially HDACs, and consequently HDAC 
inhibitors, can have both positive and negative effects on neural 
development dependent on timing and cell type. This is highlighted again by 
Shakèd’s 2008 study which found HDAC inhibition resulted in an increase in 
neurogenesis in the cortex and a reduction in the gangliolic eminence of 
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mouse embryos and of differentiating neural precursors in vitro (Shakèd et 
al., 2008). A possible reason for the disparity here is the specific HDAC(s) 
being inhibited and the inhibitors themselves being used as it may be that 
different HDACs are responsible for the apparently contradictory results 
obtained. Unfortunately, all these studies are conducted in mouse or rat 
brains, and are all on a small scale. Although the research provides valuable 
insights that would not be ethically possible to obtain in humans, it is 
somewhat limiting in what conclusions can be applied to human brain 
development.  
 
2.2.3 HDACs in Cancer 
Given the essential and critical roles of HDACs already discussed, it is not 
surprising that dysregulation of these proteins are implicated in 
tumourigenesis. Inhibitors of HDACs are in clinical trials for treatment of a 
variety of cancers but since there is rarely a ‘one size fits all’ solution and the 
consequences of incorrect dosages and compounds could arguably 
exacerbate the situation, significant work needs to be done to understand 
the role of HDACs in each tumour type so treatment can be adjusted 
accordingly. A large factor in this work will be understanding the effects of 
hypoxia (reduced oxygen) on the expression and function of HDACs since 
many tumours, particularly pGBM, are under hypoxic stress. This is due to 
the fact that as the tumour mass rapidly grows, large areas become oxygen 
starved as immature, leaky vessels prevent oxygen reaching the central 
regions. Some research has already taken place concerning the effects of 
hypoxia on HDACs, but is currently very limited. 
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In a number of cell lines tested including hepatoblastoma, human Chang 
liver cells (HeLa derivative) and human umbilical vein endothelial cells 
(HUVECs), hypoxia was seen to significantly increase HDAC1 activity at 
both mRNA and protein levels, compared to normoxia reaching a maximum 
after 16 hours (Kim et al., 2001). Hypoxia was found to significantly 
decrease transcription and translation of p53 and VHL tumour suppressors, 
which promote degradation of HIF-1a and help to inhibit angiogenesis. 
Interestingly, in this study the effect was short term for p53 and expression 
increased again after 48 hours in hypoxia (Kim et al., 2001). 
 
Overexpression of HDAC1 suppressed p53 and VHL and significantly 
upregulated HIF-1a and VEGF compared with a mutant HDAC1 which had 
no transcriptional or deacetylating activity and showed no significant 
changes in expression of p53, VHL, HIF-1a or VEGF (Kim et al., 2001). 
Conditioned media from HDAC1 overexpressing cells caused an increase in 
proliferation, migration, viability and capillary formation in HUVECs in 
comparison with conditioned media from either mutant HDAC1, non-
transfected cells or mock transfectant cells (Kim et al., 2001). This increase 
could be blocked by a neutralising antibody against VEGF implicating it in 
HDAC-stimulated angiogenesis (Kim et al., 2001).  
HDAC1 was found to be upregulated along with HIF-1a and VEGF in areas 
of hypoxia in vivo and HDACi TSA was found to cause an inhibitory effect on 
hypoxia-induced angiogenesis in vivo (Kim et al., 2001). 
 
 39 
Increased HDAC1 expression has been found to be significantly associated 
with increased proliferation in human pancreatic adenocarcinoma but the 
same study also revealed Kaplan-Meier survival analysis to show patients 
with high expression had significantly increased survival time in comparison 
with patients with low HDAC1 expression (Giaginis et al., 2015). HDAC2 
expression was not found to positively or negatively significantly impact upon 
patient prognosis however, survival analysis by Kaplain-Meier showed 
significantly increased survival when both HDAC1 and HDAC2 were highly 
expressed (Giaginis et al., 2015).  The study found a significant association 
with high HDAC4 expression and a lack of metastasise, although survival 
analysis found no relationship between HDAC4 expression and patient 
survival (Giaginis et al., 2015). Kaplan-Meier analysis also showed 
increased HDAC6 expression to be associated with increased survival times 
(Giaginis et al., 2015). 
 
HDAC5 and HDAC9 have been found to be highly expressed at the mRNA 
level amongst prognostically unfavourable medulloblastoma patients, 
whereas HDAC4 and HDAC1 were found to be down-regulated (Milde et al., 
2010). Patients with high expression of both HDAC5 and HDAC9 had a 
lower survival probability than those who had high HDAC5 or HDAC9 
expression. Patients with low HDAC5 and HDAC9 expression had a 
significantly higher overall survival probability than either of the other groups 
(Milde et al., 2010). In relation to known prognostic markers, increased 
HDAC5 expression correlated with chromosome 17q gain, another 
unfavourable marker, and increased HDAC9 expression correlated with a 
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gain on chromosome 6, also unfavourable (Milde et al., 2010). These 
expression patterns also correlate with molecular subgroups, with lower 
expression in the WNT and SHH groups and higher expression seen in 
groups C and D (Milde et al., 2010). Tissue microarrays showed mRNA 
expression to correlate with protein expression in primary medulloblastoma 
samples. Knockdown of HDAC5 or HDAC9 led to reduced cell growth and 
viability and an increase in caspase-3-like activity which was associated with 
apoptosis (Milde et al., 2010). 
 
Inhibition of HDAC8 was found to suppress cell growth in vitro in human 
Malignant Peripheral Nerve Sheath Tumours (MPNST) and cause both S-
phase cell cycle arrest and apoptosis with an increase in cleaved caspase-3 
and Annexin V compared to the control (Lopez et al., 2015). HDAC8 was 
also found to be overexpressed in oral squamous cell carcinoma with 
knockdown of HDAC8 inducing apoptosis (Ahn & Yoon, 2017). 
 
In highly aggressive basal breast cancer cell lines, HDAC9 was found to be 
over expressed at both the protein and mRNA levels causing dysregulated 
expression of several genes (Lapierre et al., 2016). This led to increased 
proliferation and a decrease in apoptosis and consequently was associated 
with a poor prognosis for these patients (Lapierre et al., 2016).  
 
High HDAC10 expression was found to significantly correlate with poor 
prognosis and decreased survival probability to 11% in Neuroblastoma 
patients compared to an 80% survival probability with low HDAC10 
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expression (Oehme et al., 2013). They found that HDAC10 plays a critical 
role in regulating autophagy in neuroblastoma cells. Increased levels of this 
HDAC was able to protect cells from chemotherapeutic agents via 
interaction and subsequent deacetylation of heat shock protein family A 
(Hsp70) member 8 (HSPA8), involved in lysosomal functions, whilst 
depletion of HDAC10 blocked autolysosome formation (Oehme et al., 2013).  
In contrast, cervical squamous cell carcinoma tissue in patients with lymph 
node metastasis had significantly lower HDAC10 expression compared to 
those without metastasis (Song, Zhu, Wu, & Kang, 2013). Overexpressing 
HDAC10 was able to significantly decrease cell migration and invasion, 
whilst inhibiting HDAC10 significantly increased migration and invasion 
(Song et al., 2013). It is thought HDAC10 inhibits invasion and metastasis by  
decreasing matrix metalloproteinase (MMP) -2 and -9 expression via an 
increase in TIMP1 and TIMP2 (found previously to inhibit MMP2 (TIMP2) 
and MMP9 (TIMP1) (Vasala, 2008)). A decrease in HDAC10, lead to a 
decrease of TIMP1 and -2 expression, allowing an increase of MMP2 and -9 
and subsequently an increase in invasion and migration (Song et al., 2013). 
However, expression of HDAC10 did not significantly modify proliferation, 
impact upon the cell cycle or have an effect on apoptosis of cervical cancer 
cells (Song et al., 2013). Another study investigated HDAC10 expression in 
gastric cancer patients and found decreased expression in cancer tissues 
compared with closely situated healthy tissue and overall survival was found 
to be significantly decreased in those with low HDAC10 expression 
compared with those with high HDAC10 (Jin et al., 2014). Expression of 
HDAC10 was so crucial it was found to be an independent prognostic factor 
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for these patients (Jin et al., 2014). Similar to gastric cancer cells, HDAC10 
was found to be significantly down-regulated in renal cell carcinoma tissue in 
comparison to healthy tissue and was associated with proliferation and 
invasion in vitro and larger tumour size, metastasis and more advanced 
stage of disease (Fan, Huang, & Xiao, 2015). The study concluded that 
overall survival was significantly different between patients with high, and 
those with low HDAC10 expression and that HDAC10 was an independent 
prognostic factor for renal cell carcinoma with higher levels leading to longer 
survival times (Fan et al., 2015). HDAC10 has been reported to regulate the 
G2/M transition in the cell cycle via regulation of cyclin A2 expression where 
knockdown of HDAC10 leads to decreased cyclin A2 and inhibition of 
mitosis (Li, Peng, & Seto, 2015). HDAC10 depletion was also seen to inhibit 
proliferation of cells both in vitro and in vivo (Li et al., 2015). Reduced 
expression of class II HDACs is associated with poor prognosis in lung 
cancer patients with HDAC10 being the strongest predictor of poor 
prognosis (Osada et al., 2004).  
 
It is interesting that HDAC10 has such differing effects dependent on 
cell/cancer type. It would be beneficial for future research to unravel the 
mechanisms of HDAC10 to fully understand how HDAC10 functions to 
produce these effects.  
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2.3 HDAC Inhibitors 
 
There are multiple types of HDAC inhibitors (HDACi), from specific to pan 
inhibitors, hydroximates to benzamides, cyclic peptides to aliphatic acids 
(Xu, Parmigiani, & Marks, 2007). They have different structural 
characteristics and inhibit different HDAC isoforms. Some target just one 
HDAC, some a whole class of HDACs. HDACis can cause cell cycle arrest, 
differentiation or apoptosis both in vitro and in vivo (Lee et al., 2011). The 
length of time, concentration and type of inhibitor used affects the number of 
genes detected with altered transcription (Xu et al., 2007). It was only 
recently that the crystal structure of the interaction between HDAC8 and 
hydroxamate was solved (Somoza et al., 2004) providing a greater 
understanding of the mechanism of action of HDAC inhibition. In this case, 
the hydroxamic acid inhibitor directly interacts with the zinc ion at the base of 
the catalytic pocket of HDAC8 (Xu et al., 2007). 
 
In Vitro studies 
 
A recent study found twelve out of sixteen DIPG cultures, which were 
insensitive to traditional chemotherapeutic agents carboplatin and 
vincristine, demonstrated decreased viability at 48 hours and had a 
decrease in proliferation associated genes (MK167 and CCND1) following 
treatment with the HDACi panobinostat (Grasso et al., 2015). They show a 
concentration dependent decrease in cell proliferation and increase in cell 
death after panobinostat exposure as well as a decrease in gene expression 
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of the oncogene MYC. Knockdown of HDAC1 or HDAC2 was shown to 
decrease viability of DIPG cells (Grasso et al., 2015) supporting the notion 
that inhibition of certain HDACs can be beneficial in the treatment of DIPG. 	
Proliferation and colony formation of paediatric glioblastoma cell lines 
KNS42 and SF188 were significantly inhibited by PCI-24781, a pan HDAC 
inhibitor of classes I and IIb (de Andrade et al., 2016). Apoptosis was 
induced with just a small dose of PCI-24781 and both cell lines showed 
increased sensitivity to radiation (de Andrade et al., 2016).	
 
Richon et al. (Richon, Sandhoff, Rifkind, & Marks, 2000) showed increased 
numbers of cells arresting in G1 phase of the cell cycle with low 
concentrations of HDACi suberoylanilide hydroxamic acid (SAHA), with 
higher concentrations resulting in cells arresting in both G1 and G2 phase 
and decreased numbers of cells in S phase. This is thought to be due to the 
induction of p21, one of the first genes to be switched on under HDAC 
inhibition, inhibiting cyclin dependent kinases (CDKs) which regulate G1 
progression and G1/S, G2/M transitions (Vidal & Koff, 2000) (cited in (Xu et 
al., 2007)). In a phase 1 trial in paediatric brain tumours, vorinostat, which 
inhibits class I and II HDAC activity by blocking the active site, combined 
with temozolomide were well tolerated but no clear advantage was observed 
at the trialled dose (Hummel et al., 2013).  
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Case Study 
 
Although not used as a standard mode of treatment, there are case reports 
of various HDAC inhibitors successfully treating, or managing, childhood 
brain tumours and this was touched upon earlier in section 1.3. In 2004 
(Witt, Schweigerer, Driever, Wolff, & Pekrun, 2004) it was reported that a ten 
year old with a GBM in the pineal gland showed no evidence of tumour 
response using the German protocol for malignant gliomas in children (HIT-
GBM-C), which included partial surgical resection, radiotherapy and multiple 
chemotherapies. After 30 weeks, no response and an array of severe 
therapy-related side effects, treatment was switched to gradually increasing 
dosages of oral Valproic acid (VPA), an HDACi normally used to treat 
epilepsy in children. After just 14 weeks following treatment with VPA, the 
tumour decreased and the child returned to school. Complete remission was 
seen at 10 months on MRI scans. Unfortunately, the child reduced the 
dosages of VPA due to drowsiness and the tumour relapsed at 16 months 
from the start of HDACi treatment. This case study is unfortunately a rare 
finding though. Masoudi et al., 2008 report that VPA provided no significant 
difference in response or outcome in children with grade III or IV glioma 
compared to those who did not receive VPA, which is in agreement with 
Wolff, Kramm, et al., 2008 discussed in section 1.3. 
 
 
 
 
 46 
Table 1.4: Summary of relevant literature on histone deacetylase inhibitors. 
 
HDAC INHIBITOR 
(HDAC TARGETED) EFFECT REFERENCE 
Trichostatin A and 
Sodium Butyrate Apoptosis induced in neuronal cells (Salminen et al., 1998) 
Trichostatin A 
(HDAC1) 
Decreased the hypoxia-mediated expression and activity of HIF-1a and 
VEGF and increased expression of VHL and p53, repressing angiogenesis 
in human hepatoblastoma cells. Inhibited angiogenesis in chick embryos 
and significantly inhibited hypoxia-stimulated networks including migratory 
and invasive activity in bovine aortic endothelial cells 
(Kim et al., 2001) 
Trichostatin A 
(HDACs 1, 6 and 10) 
Disruption of HDAC-protein phosphatase complexes in transfected 
HEK293T cells (Brush et al., 2004) 
Valproic Acid Regression of paediatric Glioblastoma (1 case study) (Witt et al., 2004) 
Valproic Acid Increased sensitivity to radiation in vitro and in vivo in adult human glioma (Camphausen et al., 2005) 
Sodium Butyrate 
Combined with adenoviral vector carrying wildtype p53 increased necrosis, 
suppressed growth and inhibited vascularization in gastric cancer and 
hepatocellular carcinoma cells 
(Takimoto et al., 2005) 
Valproic Acid Induced changes associated with differentiation, decreased proliferation and led to activation of the Notch signalling cascade 
(Stockhausen et al., 
2005) 
Butyric Acid 
Derivatives 
Pivaloylomethyl 
Increased radio-sensitization, enhanced apoptosis via caspase-8 and 
reduced proliferation in adult glioma cells (Entin-Meer, 2005) 
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Butyrate (An-9) and 
Butyroyloxymethyl 
Butyrate (An-1) 
Depsipeptide 
Despite showing decreased proliferation in cell lines, in childhood cancer 
models in vivo, tumour regression was shown in 8% and stable disease 
shown in 10% of models (including 1 of each of primitive neuroectodermal 
tumour, atypical/teratoid rhabdoid tumour, anaplastic astrocytoma and 2 
Wilms’ tumours). 
(Graham et al., 2006) 
Suberoyl Anilide 
Hydroxamic Acid 
(SAHA), Sodium 
Butyrate and 
Trichostatin A 
Decrease in mitochondrial membrane potential and activation of caspase-3 
and -9 resulting in apoptosis in medulloblastoma cells.  Increased 
sensitivity to irradiation in 1 cell line and SAHA increased sensitivity to 
some chemotherapeutic agents (etoposide) but not others (vincristine). 
(Sonnemann et al., 2006) 
CRA-026440 
(Hydroxamic Acid-
Based Inhibitor) 
(Class I and IIb) 
Inhibited growth and angiogenesis and induced apoptosis and altered gene 
expression in a range of cancer cell lines including human colorectal, 
breast, prostate, ovarian, lung and pancreatic carcinomas. 
(Cao, 2006) 
MS-275 
(Benzamide), 
Suberoyl Anilide 
Hydroxamic Acid, 
Trichostatin A, 
Valproic Acid, and 
M344, M360, D85, 
SW55, SW187 
Inhibited proliferation in a time and concentration dependent manner in and 
induced apoptosis in cells from a range of embryonal tumours of the 
nervous system 
(Furchert et al., 2007) 
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(Novel Compounds 
Developed By The 
Authors) 
Valproic Acid, Vpm, 
Butyrate 
Induced apoptosis and G2 cell cycle arrest and activation of p53 in 
neuroblastoma cells (Condorelli et al., 2008) 
Trichostatin A 
(HDAC1) 
Suppression of matrix-metalloproteinase (MMP) -2 and -9 and inhibition of 
hypoxia-stimulated migration of human breast and human fibrosarcoma cell 
lines. 
(Jeon & Lee, 2010) 
Trichostatin A 
Decreased proliferation and telomerase activity and increased cleaved 
caspase-3 and activation of DNA damage response in the majority of high 
grade paediatric brain tumours tested (CNS PNET, Medulloblastoma and 
GBM) 
(Rahman et al., 2010) 
Curcumin 
(Diferuloylmethane 
– Component of 
Tumeric) 
Induced apoptosis and cell cycle arrest in medulloblastoma cell lines and 
increased survival in a Medulloblastoma mouse model. (Lee et al., 2011) 
Trichostatin A and 
Sodium Butyrate 
By modifying the acetylation of p53 and decreasing DNA-binding and 
transcriptional activation of certain genes, DNA damage-induced 
neurodegeneration was prevented in mouse primary cortical neurons. 
(Brochier et al., 2013) 
Trichostatin A, 
Suberoylanilide 
Hydroxamic Acid 
and Vorinostat 
Increased cytotoxicity of chemotherapeutic agents and apoptosis in rat 
cortical neurons 
(Vashishta & Hetman, 
2014) 
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A summary of relevant literature on HDAC inhibitors is given in table 1.4. 
Intriguingly, despite the many studies investigating the use of HDAC 
inhibitors, there does not appear to be an investigation into the expression of 
HDACs in these neoplasms, or an investigation into how targeting HDACs 
using broad spectrum inhibitors effects the young brain. 
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3.0 Summary 
 
Further research and new therapies are desperately needed for paediatric 
glioblastoma. The field of epigenetics is making promising and intriguing 
discoveries and advancing our understanding and knowledge of pGBM at a 
molecular level. We wanted to investigate further, the expression of HDACs 
in pGBM, to identify specific targets to inhibit and discover the effect of 
inhibition at the cellular level.   
 
Hypotheses: Histone deacetylases (HDAC) will have increased mRNA 
expression in pGBM. HDAC mRNA and protein expression will be increased 
in two established paediatric GBM cell lines when compared to a foetal 
astrocyte control. 
 
Aims: 
Investigate expression levels of histone deacetylases in paediatric 
glioblastoma using the R2: Genomics Analysis and Visualisation Platform 
 
Characterise two paediatric glioblastoma cell lines in terms of HDAC 
expression at the mRNA and protein level. 
 
Determine the impact on viability and function in paediatric glioblastoma of 
targeting dysregulated HDACs in vitro. 
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Chapter 2. Materials and Methods 
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All the work carried out in this thesis is the sole work of the author, Emily 
Pinkstone. This includes (but is not limited to) bioinformatics, cell culture, the 
design, implementation and execution of all experiments and analyses, all 
statistical analysis and graphical representation.  
 
1.0 Bioinformatics 
 
The ‘R2: Genomics Analysis and Visualization Platform’ ((http://r2.amc.nl)) is a 
web-based application allowing users to explore publicly available mRNA 
gene expression data and perform a variety of analyses using single or 
multiple datasets. The database contains more than 50,000 human samples, 
grouped together using characteristics such as tumour type, tissue and cell-
line experiments. The R2 database is hosted by the AMC cancer centre.  
 
1.1 Using the R2 database 
 
Use of the R2 database is summarised by the flowchart in figure 2.1. 
 
 53 
 
Figure 2.1: Use of the R2: Genomics Analysis and Visualisation 
Database.  
The database is a powerful tool which allows visualization of specific 
genes in a range of samples from various tissues, diseases and 
tumours. Once selected, the user is able to further define their exact 
requirements to ensure only genes in the target population is analysed. 
 
1.1.1 Gene Expression Analysis in a Single Dataset 
The main window of R2 guides the user through a number of steps to 
perform and visualise the desired analysis, summarized in figure 2.1. First 
the user must choose the dataset required for analysis. The user then 
identifies the type of analysis they wish to do, for example, ‘view a gene’ or 
‘view multiple genes’ and specifies the gene(s) of interest. In the next 
window, labelled as ‘adjustable settings’, data settings and subsets within 
the chosen dataset, known as tracks, can be defined such as ‘adjuvant 
R2:	Genomics	Analysis	
and	Visualisation
Platform
View	a	Gene	in	a	Single	
Dataset
Specify	gene	of	interest
Define	tracks	(subsets)
Kaplan	Meier	by	Gene	
Expression
Select	dataset
View	a	Gene	in	Multiple	 	
Datasets
Visualise Data	in	Graph	
Format
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therapy’, ‘age’ or ‘WHO grade’. Not all tracks are available for every dataset. 
The database then provides the requested data in graph form. 
 
1.1.2 Kaplan Meier Analysis 
At the home page of the R2 database, there is a list of options on the right, 
with one of the options being “Kaplan Meier’, shown in figure 2.1, which 
assesses survival. When selected, the option will show a tab where dataset, 
analysis and gene of interest can be defined. The final tab to be displayed 
allows the user to select tracks to ensure the analysis represents the correct 
population. The R2 database then presents the Kaplan Meier survival 
analysis with the user-defined settings. 
 
1.1.3 Data Grabber 
The data grabber tool allows users to extract raw expression data for 
specific genes from a specified population, and download the raw data for 
custom analysis outside of the R2 database. In the main menu, the user 
selects ‘tools’ and ‘data grabber’. The dataset is chosen and the user then 
defines tracks and genes they require the data for. Once defined, a link is 
provided to the extracted raw data file. 
 
1.1.4 Statistical Analysis and Graphical Representation 
Raw data from the R2 database was sorted accordingly in Microsoft Excel to 
extrapolate data according to my hypothesis, for sections to be extracted 
and pasted into Graphpad Prism 7 for analysis. Due to the data being non-
parametric and unpaired, a Kruskal-Wallis test (similar to ANOVA) was 
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selected to identify if any of the groups showed a statistically significant 
difference between them. Following analysis with Kruskal-Wallis, a post-hoc 
analysis was performed using Dunn’s multiple comparisons test to compared 
each group individually against each other to detect where the significance 
lay. Significance was found if the p value was less than (<) 0.05. Data were 
represented graphically using scatter-dot plots which showed the minimum 
to maximum range of the data, along with bars showing the median and first 
and third quartile ranges. Data displayed by heat maps represent median 
expression values of the whole dataset. Significance was represented using 
lines connecting the two groups which showed a significant difference and 
the level of significance was represented using the asterisk (*) symbol. * 
p<0.05; ** p<0.01; ***p<0.001; **** p<0.0001. 
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2.0 Cell Culture 
 
The brain tumour research centre at the University of Portsmouth was given 
a favourable ethical opinion by the national research ethics service (NRES) 
committee South Central- Hampshire A (REC reference number 
11/SC/0048) for the study title: The cellular and molecular biology of brain 
tumours: migration, apoptosis, malignancy and therapeutic applications 
(Appendix 13). 
 
2.1 Paediatric Glioblastoma Multiforme Cell Lines 
 
Two paediatric GBM cell lines were cultured, KNS42 and SF188.  
 
2.1.1 KNS42 
KNS42 was derived from a GBM in the right fronto-parietal region of the 
brain of a sixteen-year old male in 1972. The tumour was noted to contain 
small anaplastic cells and areas of necrosis. The patient died one year from 
onset of symptoms (Takeshita et al., 1987).  
 
Morphologically, KNS42 cells were noted to be polygonal and flat (Takeshita 
et al., 1987) (Bax et al., 2009), which can still be seen in the cultures shown 
in figure 2.2 showing a remarkable consistency over time and through 
passages. The cells grow in distinct clusters and do not possess the long 
processes seen in the other pGBM cell line, SF188 (figure 2.3) or the 
astrocytic control cell line, CC2565 (figure 2.4).   
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Doubling times of KNS42, are calculated at 40-48 hours, consistent with 
those originally calculated by (Takeshita et al., 1987) (Bax et al., 2009). In 
the 1987 paper characterising the cell line, KNS42 was found to express 
astroglial (glial fibrillary acidic protein (GFAP)), and neuronal (neuron-
specific enolase (NSE)) markers. A further analysis 22 years later, analysis 
showed the cell line to be positive for GFAP, S100 and synaptophysin (glial 
markers), as well as stem cell markers nestin and CD133 (Bax et al., 2009). 
KNS42 was found to have the epigenetic mutation H3F3A G34V, but no 
K27M or G34R mutation (Bjerke et al., 2013), discussed in Chapter 1. 
 
KNS42 was cultured in DMEM/nutrient mixture F-12 Ham (DMEM-F12) 
(Sigma) with 10% heat inactivated Foetal Bovine Serum (FBS) (Sigma) and 
1% GlutaMAX™ (Gibco™). GlutaMAX™ contains L-alanyl-L-glutamine 
dipeptide, a more stable form of L-glutamine; an essential nutrient for cells; 
that does not degrade into ammonia. This improves proliferation and viability 
of the cells.  
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Figure 2.2: Paediatric glioblastoma multiforme cell line KNS42.  
Image taken using an Olympus IX71 inverted phase contrast microscope 
using Analysis software. Objective: 4x. 
 
2.1.2 SF188 
SF188 has not been as extensively characterised as KNS42. The cell line 
was derived from an eight-year old male and has a doubling time of twenty-
six hours (Bax et al., 2009). Morphologically, SF188 is very different to 
KNS42, displaying bipolar and stellate cells with long processes as shown in 
figure 2.3. 
 
Despite the clear morphological differences, SF188 expresses the same glial 
markers GFAP, S100 and synaptophysin as KNS42 and has a slightly higher 
expression of stem cell markers Nestin and CD133 (Bax et al., 2009). 
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SF188 is maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
(Gibco™) with 10% heat inactivated FBS and 1% GlutaMAX™, minimising 
variables in culture conditions between the cell lines as much as possible. 
 
 
Figure 2.3: Paediatric glioblastoma multiforme cell line SF188. 
Image taken using an Olympus IX71 inverted phase contrast microscope 
using Analysis software. Objective: 4x. 
 
 
2.2 Foetal Astrocyte Cell Line 
 
A foetal astrocyte, CC2565 (Lonza) was deemed to be the best non-
neoplastic control cell line, due to the astrocytic nature of paediatric 
glioblastoma cells. CC2565 was derived from a male foetus at sixteen weeks 
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gestation. The certificate of analysis showed doubling time of this cell line as 
26 hours but up to a maximum of 48 hours.  
 
Astrocyte morphology is heterogenous. CC2565 dispalys bipolar and stellate 
cells, often with long processes. In culture, this cell line appears to extend 
processes to find and connect with other cells (figure 2.4). 
Viral and microbial testing was negative and cells were found to be more 
than 80% positive for GFAP (See appendix 1 for full certificate of analysis).  
 
CC2565 (P1-10) are cultured in astrocyte basal medium (ABM) (Lonza) with 
SingleQuots™ of supplements and growth factors and 3% FBS.  
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Figure 2.4: Foetal astrocyte cell line CC2565.  
Image taken using an Olympus IX71 inverted phase contrast microscope 
using Analysis software. Objective: 4x. 
 
2.3 Culture Conditions 
 
All cells were cultured as a monolayer in their respective mediums in T75 or 
T25 flasks (Greiner-Bio-One). All cell culture was conducted inside a class II 
safety cabinet and all equipment washed with 70% ethanol (ETOH) prior to 
use to protect cells from contamination. Two incubators were used for 
experiments, a normoxic to replicate normal conditions and a hypoxic 
incubator to replicate the environment inside a large tumour. Both incubators 
were humidified and kept at 37°Celsius with 5% carbon dioxide (CO2) and 
either 21% (normoxic), or 1% (hypoxic) oxygen (O2) respectively. 
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2.4 Resurrecting 
 
Cells were batch cultured and stored in liquid nitrogen. When required, a vial 
was taken out of liquid nitrogen and added to a 37°C waterbath until it began 
to defrost. Appropriate warmed media was added drop by drop to the vial to 
thaw the cells. The cell suspension was added to 4ml (T25) or 8ml (T75) 
warmed media. The cell suspension was either added straight to a culture 
flask and incubated in the normoxic incubator or was centrifuged in a 15ml 
centrifuge tube at 170 g for 5 minutes to pellet the cells. Media was poured 
off without disturbing the pellet and 1mL fresh media added to re-suspend 
the pellet. This cell suspension was added to a culture flask and topped up 
to 9mL with media before being incubated in the normoxic incubator. If the 
cells were not centrifuged initially, after 24 hours the media was changed 
and refreshed to ensure no freezing medium remained. 
 
All centrifuge speeds are displayed in terms of relative centrifugal force 
(RCF) expressed in units of gravity (g). Conversion from revolutions per 
minute (RPM) where applicable were calculated as described in Bio files by 
Sigma Aldrich (Vol. 6, No.5) with the following calculation, where r=radius in 
cm and Q=speed of rotation in RPM: 
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2.5 Cryopreservation 
 
Cells were batch cultured and cryopreserved in liquid nitrogen for long term 
storage. When a confluent culture flask of cells was ready to be frozen 
down, Recovery™ Cell Culture Freezing Medium (Gibco), containing high 
glucose DMEM, FBS, bovine serum and 10% dimethyl sulfoxide (DMSO) 
was defrosted (1mL per flask to be frozen) and a Mr Freezy pot containing 
isopropyl alcohol at room temperature was readied. This ensured cells were 
cooled at a rate of 1 degree Celsius (°C) per minute when placed into the -
80°C freezer to maintain cell viability. The confluent culture flask was 
removed from the incubator and the cell monolayer was washed twice with 
warm Hanks Balanced Salt Solution (HBSS) (Gibco) before trypsinizing with 
TrypLE™ Express (Gibco®). Cells were incubated with frequent disruption to 
aid enzymatic digestion of the extracellular matrix (ECM) for 3-6 minutes. 
Once cells had rounded and detached from the surface, warmed media 
containing serum was added to quench the trysinization. The cell 
suspension was transferred to a 15mL centrifuge tube and spun at 170 g for 
5 minutes to pellet the cells. The media/supernatant was poured off without 
disrupting the pellet and 1mL freezing media added to resuspend the pellet. 
The cell suspension was quickly transferred to a cryovial and placed in the 
Mr Freezy pot where it was immediately placed into the -80°C freezer. After 
24 hours, the frozen cells were put into liquid nitrogen where they are kept 
for long term storage. 
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2.6 Culture Methods 
 
2.6.1 Passaging/subculture 
Cells are passaged when they reach around 80% confluency. Initially the 
monolayer of cells was washed twice with warmed HBSS and trypsinised 
with TrypLE™ Express for 3-6 minutes, with frequent disruption to 
encourage cells to detach from the ECM. Once cells had rounded up and in 
suspension, warmed media containing serum was added to quench the 
trypsin action. The cell suspension was split between 1:4 and 1:8 into new 
T75 or T25 culture flasks and topped up with warmed media containing 
serum and growth factors as discussed in section 1.1 and 1.2. Each 
subculture increases the passage number by 1 and was recorded on each 
culture flask. 
 
2.6.2 Cell dissociation/enzymatic digestion 
The cells used were grown on a monolayer, adhered to the culture flasks 
surface by ECM proteins. When cells were ready to be passaged or plated 
for an experiment, the ECM holding the cells in place needs to be 
enzymatically digested. This was done using TrypLE™ Express, a 
recombinant enzyme which cleaved the peptide bonds. Following incubation 
for 3-6 minutes and frequent disruption, a single cell suspension was left and 
warmed media was added to inhibit the trypsin action.   
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2.6.3 Media change/feeding 
Medium on cells was frequently changed to replenish nutrients that had 
been consumed. Old media was removed and cells were washed twice with 
warmed HBSS (to get rid of any remaining dead cells/cell debris) before 
adding fresh warmed media back into the culture flask.  
 
2.7 Cell Counting with the Countess™ II FL Automated Cell Counter 
 
The Countess™ II FL automated cell counter (Invitrogen) uses the trypan 
blue dye exclusion method. The method allows dead cells to be 
differentiated from live ones because trypan blue dye is unable to cross the 
membrane of a viable living cell, but the dye is not excluded from a non-
viable cell. The Countess II FL provides cell count and viability (live, dead, 
total cells) by counting a total volume of 0.4µL in the center of the Countess 
cell counting chamber slide. Parameters could be manipulated to increase or 
decrease the sensitivity, circularity and size of cells for inclusion criteria. The 
countess can count cells as small as 5µm and up to as large as 60µm. A cell 
pellet was re-suspended in 1mL of media and 10µL of the cell suspension 
was added to 10µL trypan blue making a 1:1 dilution. 10µL of the cell 
suspension-trypan blue mix was loaded into a chamber slide, and the slide 
was inserted into the counter. 
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2.8 Plating 
 
Cells were plated for immunocytochemistry and cloning experiments. When 
cells were ~80% confluent in a tissue culture flask, depleted media was 
aspirated and the cell monolayer washed twice with warmed HBSS. Cells 
were trypsinised with cold TrypLE Express and incubated for a few minutes 
with frequent mechanical disruption until cells had rounded and detached 
from the ECM/tissue culture flask. At this point, fresh media containing 
serum was added at a ratio of 2:1 (media: TrypLE Express) to quench the 
trypsin action. The cell suspension was transferred to a 15mL centrifuge 
tube and spun at 170 g for 5 minutes to pellet the cells. Supernatant was 
removed without disrupting the pellet and 1mL fresh media added to re-
suspend the cell pellet. Cells were counted as described in section 2.1.7 to 
enable equal seeding between wells. Required volume of cell suspension 
was added to each well before topping up with fresh warmed media. Cells 
were incubated for at least 24 hours before starting the experiment to allow 
cells to settle, adhere and acclimatize to the new conditions to ensure they 
were not under additional stress when performing the experiment. 
 
2.9 DNA Fingerprinting – Authentication of Cell Lines 
 
All cell lines are DNA fingerprinted on a regular basis to ensure no cross 
contamination has occurred and the cell line is true to it’s origins. Protocol 
was carried out as described by An, Fillmore, Vouri, & Pilkington, 2014.  
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2.10 Mycoplasma Testing 
 
All cell lines were tested on a monthly basis for mycoplasma (a species of 
bacteria resistant to most antibiotics and undetectable via phase contrast 
microscopy) infection using the MycoAlert™ PLUS Mycoplasma Detection 
Kit (Lonza) with the MycoAlert™ Assay Control Set (Lonza). The assay 
detects all common mollicute contaminations by detecting enzymatic activity 
of mycoplasma. Lysis of viable mycoplasma and reaction with the MycoAlert 
substrate converts ADP to ATP, which is then converted into a light signal by 
the luciferase enzyme in the MycoAlert reagent. The ratio obtained by 
measuring the amount of ATP before and after MycoAlert substrate was 
added indicates the presence or absence of infection.  
 
Conditioned media incubated with cells for 24+ hours was centrifuged at 200 
g for 5 minutes in an Eppendorf 5415r microcentrifuge. 100µL of media was 
added into a 96 well, white, flat bottomed plate (Gibco) followed by the same 
quantity of MycoAlert reagent. After a 5 minute incubation at room 
temperature, each well was read on a BMG labtech POLARstar Optima 
plate reader. 100µL MycoAlert substrate was added to each well before 
another incubation for 10 minutes at room temperature. The second read 
was taken immediately after the incubation. Dividing the second reading by 
the first reading gives the ratio. A ratio of >1 was indicative of infection. Any 
cell lines found to be positive after a retesting for the bacterium mycoplasma 
were discarded immediately and all equipment cleaned thoroughly. 
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2.11 Contamination 
 
Cell lines were monitored daily for contamination with fungus or bacterium, 
as cells were routinely cultured without antibiotics. Any cell lines found to be 
contaminated were immediately discarded and all equipment cleaned 
thoroughly.   
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3.0 mRNA Expression 
 
3.1 RNA Isolation 
 
RNA was isolated using RNeasy Mini Plus kit (Qiagen). Cells were 
harvested by trypsinization as in 2.6.1 and transferred to a 2ml Eppendorf. 
Cell suspension was centrifuged at 300 g for 5 minutes and all supernatant 
carefully aspirated to avoid disrupting the pellet. Buffer RLT Plus was added 
(600µl for 5 x106-1 x107 cells) to lyse the cells and mixed by vortexing for 30 
seconds. The cell suspension was passed through a 20-gauge needle at 
least 5 times and transferred to a genomic DNA (gDNA) eliminator spin 
column, then centrifuged for 30 seconds at 8000 g. The column was 
discarded and 1 volume of 70% ETOH mixed with the flow through. The 
flow-through + ETOH mix was transferred to an RNeasy spin column and 
centrifuged at 8000 g for 15 seconds and the flow-through was discarded. 
700µL of buffer RW1 was added to the RNeasy spin column and centrifuged 
at 8000 g for 15 seconds to wash the spin column membrane, discarding the 
flow-through afterwards. A further 2 wash steps were carried out in the same 
way with 500µL buffer RPE. A longer 2 minute spin was done after the final 
wash to dry the membrane and ensure no ETOH was carried over during the 
elution step, since this can interfere with downstream reactions. To ensure 
no carryover of ETOH occurs, the RNeasy spin column was placed in a 
fresh Eppendorf and spun for 1 minute at full speed. Finally, the column was 
placed into a collection tube and 30µL RNase-free water was added directly 
onto the membrane of the spin column, then centrifuged for 1 minute at 8000 
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g to elute the RNA. The final step was repeated if a high RNA yield was 
expected. RNA was stored at -80°C.  
 
3.2 RNA Quantification and Specification 
 
RNA quantification and specification was performed using the Agilent 
Technologies RNA 6000 Nano assay and Bioanalyzer. To prepare the gel, 
550µL gel matrix was centrifuged in a spin filter for 10 minutes at 1500 g and 
1µL of dye concentrate was then added to 65µl of the filtered gel and 
vortexed.  
9µL gel-dye mix was loaded into a new RNA nano chip, into the well labelled 
‘G’, then pressurize for 30 seconds using the chip priming station. 5µL of 
RNA 6000 Nano marker was added to each sample well and the well 
marked ‘ladder’. The ladder was heat denatured at 70°C for 2 minutes to 
avoid the appearance of secondary structures and 1µL was dispensed into 
the ladder well. 1µL of each sample was added to each sample well and the 
chip was vortexed at 2000 rpm for 60 seconds in the IKA vortex mixer. The 
chip was then inserted into the Bioanalyzer and read using the 2100 expert 
software (Chapter 4, figure 4.2).  
 
3.3 cDNA Synthesis 
 
The RT2 First Strand Kit (Qiagen) was used to synthesise cDNA from RNA. 
Reagents were thawed and the genomic DNA elimination mix made from the 
components listed in the table below (Figure 2.5).  
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Component Quantity 
Buffer GE 2µL 
RNA 500ng 
RNase-free water Top up to 10µL 
 
Figure 2.5: Components and quantities to make up the genomic 
DNA elimination mix 
 
The genomic DNA elimination mix was incubated for 5 minutes at 42°C, 
followed immediately by ice for a minimum of 1 minute. The reverse 
transcription mix (Qiagen) was made up of the components listed in the table 
below (Figure 2.6). 
 
Component Quantity 
5 x Buffer BC3 4µL 
Control P2 1µL 
RE3 Reverse Transcriptase Mix 2µL 
RNase-free water 3µL 
 
Figure 2.6: Components and quantities to make up the reverse 
transcriptase mix 
 
10µL of reverse transcription mix was added into each sample containing 
genomic DNA elimination mix. The reaction was incubated at 42°C for 15 
minutes followed by 95°C for 5 minutes to halt the reaction. To this, 91µL 
RNase-free water was added to each reaction and placed on ice to continue 
with the real time PCR protocol. 
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3.4 Custom RT2 Profiler PCR Array 
 
Custom RT2 Profiler PCR Array (Qiagen) was purchased to include all 
histone deacetylase genes as well as a range of tumour suppressor genes 
and oncogenes (shown in Figure 2.7). Full list of genes available, including 
control genes in appendix 2. 
 
 
Figure 2.7: Plate layout for the custom RT2 Profiler PCR Array. 
 
The PCR components mix was prepared as in figure 2.8. 
Component Quantity 
2 x RT2 SYBR Green Mastermix 1350µL 
cDNA synthesis reaction 102µL 
RNase-free water 1248µL 
Total Volume 2700µL 
Figure 2.8: Components and quantities to make up the PCR 
components mix 
 
25µL of the PCR components mix was added to each well of the custom RT2 
Profiler PCR Array plate and the plate was tightly sealed with optical 
adhesive film. The plate was centrifuged at 1000 g for one minute at room 
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temperature and placed into the Bio-Rad CFX96 real time cycler for the 
following cycles (shown in Figure 2.9): 
 
Cycles Duration Temperature 
1 x 10 minutes 95°C 
40 x 15 seconds 95°C 
1 minute 60°C 
Figure 2.9: Cycling conditions for custom RT2 Profiler PCR 
Array using the Bio-Rad CFX96 cycler. 
 
3.5 Custom RT2 Profiler PCR Array Analysis 
 
All values were exported from the real-time cycler and formatted in a 
spreadsheet (appendix 3) to be uploaded to Qiagen’s online Data Analysis 
Center where all analysis, from quality control and statistics, to graphical 
visualization, takes place. 
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4.0 Protein Expression 
 
4.1 Whole Cell Lysis – Protein Isolation 
 
Pierce™ Radioimmunoprecipitation Assay (RIPA) buffer (25mM Tris HCl pH 
7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
(Thermo Scientific) enables proteins to be extracted from the cytoplasm, 
nucleus and membrane of cultured cells. Prior to protein extraction, lysis 
buffer was prepared with a 1:100 ratio of Halt™ Protease and Phosphatase 
inhibitor cocktail (Thermo Scientific) to RIPA buffer, to prevent proteolysis of 
proteins and preserve their phosphorylation status. Once removed from the 
incubator, cells were immediately put on ice and stayed on ice throughout 
lysis to prevent protein degradation. The cell monolayer was washed twice 
with cold Phosphate-Buffered Saline (PBS) before cold lysis buffer was 
added (750µL per 80% confluent T75 flask or 250µL per 80% confluent T25 
flask) and incubated for 5 minutes on ice on a rocker. Cell scraper was used 
to gather the lysate at the bottom of the flask to transfer into an Eppendorf 
tube. The lysate was vortexed for 30 seconds to maximise protein yield and 
centrifuged at 4°C, 14,000 g for 15 minutes to pellet cell debris. The lysate 
was transferred and aliquoted to clean chilled tubes, leaving the pellet 
undisturbed and stored at -20°C. 
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4.2 Bicinchoninic Acid (BCA) Protein Assay 
 
Pierce™ Bicinchoninic Acid (BCA) Protein Assay (Thermo Scientific) uses 
colourimetric detection to quantify total protein in cell lysates. The assay 
involves two reactions: first, the protein reduction of copper(2+)ions (Cu2+) to 
copper(1+)ion (Cu1+), and secondly, the colourimetric detection of Cu1+ by 
bincinchoninic acid. The amount of (Cu2+) reduced to (Cu1+) is directly 
related to the amount of protein in the lysate, therefore increased protein 
leads to a stronger purple colour.  
 
Standards were prepared of known concentrations so that when absorption 
values were plotted on a graph, the protein concentration of any lysate could 
be analysed using a trend line created by the standards.  
The set of standards were prepared in tubes labelled A through to I, from 
bovine serum albumin (BSA) at 2mg/mL and RIPA buffer, as shown in 
Figure 2.10. 
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Vial RIPA Buffer 
(µL) 
BSA 
(µL) 
Final BSA 
Concentration 
(µg/mL) 
A 0 300 stock 2000 
B 125 375 stock 1500 
C 325 325 stock 1000 
D 175 175 from B 750 
E 325 325 from C 500 
F 325 325 from E 250 
G 325 325 from F 125 
H 400 100 from G 25 
I 400 0 0 
 
Figure 2.10: Volumes and reagents for preparing BSA Standards 
 
Working Reagent (WR) was prepared using a 50:1 ratio of BCA reagent A 
(Sodium carbonate, sodium bicarbonate, bicinchoninic acid, sodium tartrate 
in 0.1M sodium hydroxide) to BCA reagent B (copper (II) sulfate solution) 
(Sigma). The volume of WR required was calculated using the following 
formula: 
 
(# standards + # samples) x (# replicated) x (volume of WR per sample)  
 
Using a 96 well microplate, 25µL of each standard and sample was 
dispensed into wells in triplicate, followed by 200µL of WR. The plate was 
covered and incubated at 37°C for 30 minutes before allowing it to cool 
briefly, and then measured the absorbance at 562nm on a plate reader.  
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The replicates of each sample were averaged and normalised and the 
standards plotted as a scatter graph with trendline. Both the R2 value and 
equation were displayed on the graph. The closer the R2 value was to 1 the 
more accurate the assay standards. The equation was used to work out the 
protein concentration of the samples in µg/mL. 
 
4.3 Western Blotting 
 
4.3.1 Casting a gel 
Casting apparatus was set up by placing a short flat plate with a larger plate, 
thicker on either side, leaving a 1.5mm gap between the two to pour the gel 
in to. The plates were set up in a casting frame, blocking the bottom off to 
avoid the gel running through. A 10% gel was made by adding the 
components into a 15mL centrifuge tube in the exact quantities and order as 
in the table below (Figure 2.11). 
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Component Quantity 
Distilled Water (dH2O) 4mL 
30% Acrylamide/Bis-Acrylamide Mix 29:1 3.3mL 
1.5M Trisaminomethane (Tris) (pH 8.8) 2.5mL 
10% Sodium Dodecyl Sulfate (SDS) 100µL 
Ammonium Persulfate (APS) 100µL 
Tetramethylethylenediamine (TEMED) 4µL 
 
Figure 2.11: Components and Quantities to make the Resolving 
Gel 
 
APS and TEMED polymerize the gel so it was important that once added, 
the gel was gently inverted to mix and poured as quickly as possible into the 
casting apparatus followed by 2mL of Isopropanol. This eliminated any 
bubbles and ensured the gel was level. Once set, Isopropanol was poured 
off and rinsed with distilled water several times before soaking up any 
excess with paper towel. The stacking gel was prepared by adding the 
components of Figure 2.12 into a 15mL centrifuge tube in the quantities and 
order specified. 
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Component Quantity 
Distilled Water (dH2O) 1.4mL 
30% Acrylamide/Bis-Acrylamide Mix 29:1 330µL 
1M Trisaminomethane (Tris) (pH 6.8) 250µL 
10% Sodium Dodecyl Sulfate (SDS) 20µL 
Ammonium Persulfate (APS) 20µL 
Tetramethylethylenediamine (TEMED) 2µL 
 
Figure 2.12: Components and Quantities to make the Stacking 
Gel 
 
Again, as soon as the APS and TEMED was added, the tube was gently 
inverted to mix and cast straight away before the gel polymerized and 
avoiding making any bubbles. The comb was inserted and the gel left to set.  
 
4.3.2 Electrophoresis 
Using the results from the BCA assay, samples were prepared so each one 
had 20µg of protein. Samples were kept on ice throughout preparation 
except when otherwise specified. Samples were made up to 40µL (the 
volume of each well) with RIPA buffer and Laemmli Loading Buffer 
(containing SDS; 2-mercaptoethanol; glycerol and bromophenol blue) 
(Amresco). The 2-mercaptoethanol and SDS breaks disulphide bonds, 
denaturing the proteins for SDS to bind, giving all proteins in the sample the 
same negative charge, ensuring electrophoresis separates proteins based 
on their size only. Samples were vortexed and centrifuged briefly to spin 
down before boiling for 5 minutes in a waterbath at 100°C (to help ensure 
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proteins are completely denatured and disulphide bonds are broken – this 
also helps the gel run straight). The Western blotting apparatus was set up 
and 1 litre of running buffer made up with 900mL distilled water (dH2O) and 
100mL of 10 x running buffer stock (0.25M Trizma base; 1.92M glycine and 
1% sodium dodecyl sulfate (SDS); dH2O). Running buffer was poured 
between the gels to the top, covering the wells, and the combs were 
removed. Following boiling, samples were loaded into the gel, with the All 
Blue Precision Plus Protein™ Standards (Bio-Rad) to enable protein of 
interest to be checked against molecular weight. Once all samples were 
loaded, the tank was filled to the appropriate line with running buffer and the 
lid placed on. The gel was run at 100 volts (V) until the dye front approached 
the bottom of the gel and the lower molecular weight markers could be seen 
(about 90 minutes).  
                          
4.3.3 Transfer 
The separated proteins were transferred from the gel onto a polyvinylidene 
difluoride (PVDF) membrane. 
 4.3.3.1 Wet Transfer 
The membrane was cut to size and activated in methanol for 2.5 minutes 
before being washed in dH2O for 30 seconds. The membrane, blotting pads 
and fiber pads were soaked in 1 x transfer buffer made up with 700mL 
dH2O, 100mL 10 x transfer buffer stock (0.25M Trizma base; 1.92M glycine, 
dH2O) and 200mL methanol. The gel was removed from the chamber and 
the comb pockets removed, then placed into the ‘transfer sandwich’ as 
shown in figure 2.13. The sandwich was put into a tank with a flea and 
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icepack to ensure a constant temperature and no overheating and filled with 
1 x transfer buffer. The transfer was run for 90 minutes at 100 V. 
 
 
Figure 2.13: Set-up of wet transfer pack 
 
 4.3.3.2 Semi-Dry Transfer 
The membrane was cut to size and activated in methanol for 15 seconds, 
then soaked in 1-step transfer buffer (Thermo Scientific) for at least 5 
minutes. The gel was removed from the glass case and equilibrated in 
transfer buffer for 15 minutes. Filter paper was soaked in transfer buffer and 
the stack was arranged as in figure 2.14 on the Pierce™ Power System 
semi-dry transfer machine (Thermo Scientific).  
 
Casing 
Fiber	Pads 
Blotting	Pads 
Gel 
PVDF	Membrane 
Anode	(+) Cathode	(-) 
Direction of transfer 
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Figure 2.14: Set-up of semi-dry transfer 
 
The machine was run for 14 minutes at 2.5 volts to pull proteins out of the 
gel and onto the membrane below. 
 
4.3.4 Antibodies for Immunoblotting 
The membrane was immediately blocked for 1 hour at room temperature in 
blocking buffer, made from TBST (900mL dH2O, 100mL 10x TBS stock 
(Trizma Base (0.2M); Sodium Chloride (1.5M); pH to 7.6) plus 0.1% Tween-
20 (Sigma)) and 5% semi-skimmed milk powder. The membrane was 
probed with a primary antibody in blocking buffer (diltutions in figure 2.15) 
either overnight at 4°C or for 1 hour at room temperature.  
 
 
 
 
Anode	(+) 
Cathode	(-) 
Direction 
of transfer 
Blotting pads 
Gel 
PVDF Membrane 
Power Blot Cassette 
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Antibody Concentration 
HDAC1 
(Cell Signalling Technologies) 
1:1000 
HDAC2 
(Cell Signalling Technologies) 
1:1000 
HDAC3 
(Cell Signalling Technologies) 
1:1000 
HDAC4 
(Cell Signalling Technologies) 
1:1000 
HDAC5 
(Abcam) 
1:300 
HDAC6 
(Cell Signalling Technologies) 
1:1000 
HDAC7 
(Abcam) 
1µg/mL 
HDAC8 
(Abcam) 
1:12500 
HDAC9 
(Abcam) 
1:12500 
HDAC10 
(Abcam) 
1:1000 
HDAC11 
(Abcam) 
1:1000 
Figure 2.15: Primary antibody dilutions for Western blotting 
 
It was then washed 5 times for 5 minutes each in TBST and probed with a 
horseradish peroxidase (HRP) conjugated secondary antibody (Promega) 
(Figure 2.16) at a 1:10,000 ratio, in blocking buffer for 1 hour, at room 
temperature. The membrane was washed 5 times for 5 minutes in TBST to 
minimize background signal when imaged. 
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4.3.5 Chemiluminescence Detection 
The membrane was incubated for 2 minutes (or less if the protein of interest 
was abundant in the samples e.g. for loading controls) in Luminata™ Forte 
Western HRP substrate (Millipore) in the dark. Excess was blotted off and 
the membrane was wrapped in cling film, being careful not to introduce 
creases or bubbles, then placed into the G:BOX Chemi XT16 system 
(Syngene). Syngene software allowed images to be taken, first in white light 
(for the visible ladder), and then with no light at varying exposures.  
 
 
 
Figure 2.16: Chemiluminescence detection of proteins 
 
4.3.6 Loading control 
Following imaging, the membrane was washed briefly in TBST. The 
membrane was stripped with 0.2M Sodium Hydroxide (NaOH) for 5 minutes, 
followed by washing with dH2O 3 times, for 5 minutes each and TBST 3 
times for 5 minutes each. Depending on proteins of interest it was not 
always necessary to strip the membrane. The membrane was blocked for an 
HRP conjugate
Chemiluminescence Substrate
Secondary Antibody
(with HRP conjugate)
Primary Antibody
Antigen
Membrane
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hour in 5% blocking buffer as in section 4.4.4 and probed with antibodies for 
the loading control as described in 4.4.4. The membrane was imaged again 
as in 4.4.5 and the loading control was overlaid onto the protein of interest 
blot. This was done using powerpoint. The ladder images were imported and 
lined up identically for both protein of interest blots and appropriate 
cyclophilin blots. This ensured the cyclophilin blot could be cropped and 
overlayed onto the protein of interest blot at the exact molecular weight it 
appeared. 
 
4.4 Immunocytochemistry 
 
Cell were plated in chamber slides (Nunc) and left to incubate overnight to 
adhere and settle before being placed in the experimental conditions 
(hypoxic (1%) or normoxic oxygen concentrations) for 48 hours. Once the 
old media was aspirated, cells were washed with TBST 3 times and fixed in 
4% formaldyehyde (4% formaldehyde in PEM buffer (0.1M PIPES; 5mM 
EGTA; 2mM MgCl2)) for 10 minutes, followed immediately by ice cold 
ethanol (100%) for 10 minutes to permeabilize the cells. Cells were washed 
again in TBST and blocked for 1 hour in blocking buffer (5% semi-skimmed 
milk powder in TBST) at room temperature. The primary antibody was 
prepared on ice in blocking buffer (shown in Figure 2.17) and 100µL added 
to the appropriate wells and left to incubate for 1 hour at room temperature. 
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Antibody Concentration 
HDAC1 
(Abcam) 
1:200 
HDAC2 
(Abcam) 
1:50 
HDAC3 
(Abcam) 
1:1000 
HDAC4 
(Abcam) 
1:100 
HDAC5 
(Abcam) 
1:100 
HDAC6 
(Abcam) 
1:500 
HDAC7 
(Abcam) 
2.1µg/mL 
HDAC8 
(Abcam) 
1:150 
HDAC9 
(Abcam) 
1:100 
HDAC10 
(Abcam) 
1:100 
HDAC11 
(Abcam) 
0.2µg/mL 
 
Figure 2.17: Primary antibody dilutions for 
immunocytochemistry 
 
The cells were washed again 5 times to ensure any excess antibody is 
removed before the secondary antibody, which had a fluorescent conjugate 
(Alexa Fluor488 or 568, Invitrogen), was added at a 1:500 dilution in 
blocking buffer. The fluorescent tag works in the same way as the HRP tag 
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(figure 2.16) but in this case no substrate is needed to visualise the signal. 
The cells were covered with tin foil to prevent photobleaching and incubated 
again for an hour at room temperature. The cells were washed again 5 times 
and 0.1M ammonium chloride was added to each well to quench any 
autofluorescence. The cells were washed again 5 times for 5 minutes before 
being counterstained with Hoechst Blue (Sigma) and mounted with 
Vectashield mounting medium (Vector Labs). Images were taken using the 
Zeiss Axioimager ZI Epifluorescence microscope with Hammamatsu digital 
camera using Volocity software or Zeiss LSM 510 Meta Axioskop2 Confocal 
Microscope equipped with diode, argon and helium-neon lasers. 
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5.0 Cloning 
 
Following analysis of bioinformatic data and cell line data on HDAC 
expression, the decision was made to persue investigation of HDAC10 in 
pGBM cell line KNS42. HDAC10 is a 2.1 kilo base (kb) gene on 
chromosome 22. After two cloning strategies failed (In-Fusion cloning and 
standard ligation) to obtain an HDAC10 expression clone in pIRES2-
ZsGreen1 bicistronic vector, the full length HDAC10 insert (2.1kb) and the 
IRES vector was sent to Eurofins Genomics Services. 
 
5.1 In-Fusion Cloning  
 
5.1.1 PCR Amplification of HDAC10 
 
5.1.1.1 Forward and Reverse Primers 
Forward (HDAC10-F) and reverse (HDAC10-R) primers (Eurofins) were 
designed to have a 15 base pair overlap, complementary or reverse 
complementary to the pIRES2-ZsGreen1 vector (Clontech) that the insert 
would be cloned into and 18 base pairs complementary or reverse 
complementary to the HDAC10 gene to be amplified. Primers arrived 
lyophilized and were reconstituted in sterile water to make a concentration of 
100pmol/µL. Melting temperatures (Tm) were calculated based on molecular 
weight and GC content using OligoCalc for the 18 base pair region that 
would cover the HDAC10 gene.  
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HDAC10-F Tm = 54.9°C  
HDAC10-R Tm = 54.9°C 
 
5.1.1.2 PCR 
The gene of interest was amplified by PCR from a human HDAC10 gene 
cDNA clone plasmid (Sino Biological Inc) (Figure 2.18).  
 
 
 
HDAC10-F: CGA GCT CAA GCT TCG  ATG GGG ACC GCG CTT GTG 
Complementary to pIRES construct                             Complementary to HDAC10 
HDAC10-R: GGA GAG GGG CGG ATC TCA AGC CAC CAG GTG AGG           
Reverse complement to pIRES construct            Reverse complement to HDAC10 
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Figure 2.18 Human HDAC10 gene cDNA clone plasmid  
Purchased from Sino Biological 
 
The plasmid was reconstituted in 1000µL sterile water. 
 
5.1.2 Restriction Endonuclease Double Digest 
 
To linearise the commercial vector, pIRES2-ZsGreen1 (Clontech) (Figure 
2.19), restriction enzymes were used to cleave the DNA in a specific area. 
Two restriction sites were picked from the multiple cloning site (MCS) (figure 
2.20); BamH1 and EcoR1. These two sites were within 40 base pairs of 
each other, which was required for In-Fusion cloning. Restriction enzymes 
BamH1-HF® and EcoR1-HF® (New England Biosciences) cut with sticky 
ends ensuring the gene was inserted into the plasmid in the correct direction 
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and were both high fidelity, meaning rapid digestion, decreased star activity 
and 100% activity in CutSmart® Buffer (New England Biosciences).  
 
 
Figure 2.19: pIRES2-ZsGreen1 vector (Clontech) 
 
 
 
Figure 2.20: Multiple cloning site map of pIRES2-ZsGreen1 
vector 
 
The components listed in figure 2.21 were added to a PCR tube and 
incubated in a thermocycler (BioRad) at 37°C for 1 hour to ensure 
linearization. 
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Component Quantity 
EcoR1-HF 1µL 
BamH1-HF 1µL 
pIRES2-ZsGreen1 Vector 2µL 
CutSmart Buffer 5µL 
Sterile water 41µL 
Total 50µL 
Figure 2.21: Components and quantities for double digest 
 
5.1.3 Agarose Gel Electrophoresis 
 
PCR product and linearized plasmid was run on a 1% agarose gel to verify 
the size of the product/linearization and isolate the DNA from other 
components in the sample. The gel was made by heating 1g of agarose with 
100mL TAE Buffer (20mL TAE, 980mL dH2O), mixing every 20-30 seconds 
until the agarose was completely dissolved. The agarose-TAE solution was 
allowed to cool before 5µL of safeview™ nucleic acid stain was added to the 
100mL of liquid gel. Once equally dispersed in the solution, the liquid gel 
was poured into the casting apparatus, the comb was inserted and the gel 
allowed to set. Once fully set, the comb was taken out and the blocks 
holding the gel in place were removed. 45µL safeview was added into the 
remailing 900mL TAE buffer, which was poured over the gel until 
submerged. 5µL of exACTGene 1kB Plus DNA ladder (Fisher Scienctific) 
was loaded into the first well of the gel to verify the size of the isolated DNA 
when imaged.  
To prepare the samples, 6x loading dye (New England Bioscience) was 
added to each one then carefully loaded into each well. Due to high DNA 
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content, each sample was loaded across 3 wells of the gel. When running 
linearized plasmid, 1µL of non-linearized plasmid was run alongside the 
linearized DNA for direct comparison, to verify the digestion (5.4) was 
successful. The gel was run at 80 Volts for 90 minutes and imaged to ensure 
the DNA fragment was the correct size. Then using a UV light box, the DNA 
fragment was viewed and excised from the gel using a scalpel. 
 
5.1.4 Nucleospin PCR and Gel Clean Up 
 
The Nucleospin PCR and Gel Clean Up kit (Macherey-Nagel) provided all 
the reagents needed to extract and clean up DNA from agarose gels. For 
every 100mg of excised fragment, 200µL of buffer NTI was added to the 
fragment and incubated for 5-10 minutes at 50°C, vortexing briefly every 2 
minutes until the gel was completely solubilised. The sample was passed 
through a column at 11,000 g and the flow through was discarded. The 
membrane was washed twice to minimise the carry-over of chaotropic salt 
by adding buffer NT3 to the column and centrifuging for 30 seconds at 
11,000 g. The membrane was dried by centrifugation for 1 minute to ensure 
any residual ETOH left over from buffer NT3 was removed. Finally, the DNA 
was eluted into a clean Eppendorf by adding 15µL of buffer NE directly onto 
the membrane and incubating at room temperature for 1 minute before the 
column was centrifuged at 11,000 g for 1 minute. This step was repeated to 
provide maximum yield. DNA was stored at -20°C. 
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5.1.5 Quantification of DNA 
 
DNA was quantified using the NanoDrop™ 1000 spectrophotometer 
(Thermo Scientific). Using NanoDrop 1000 software, under the DNA tab, 2µL 
of sterile water was pipetted on the center of the pedal and a ‘clean’ reading 
was taken. Then the same quantity of elution buffer was pipetted onto the 
pedal and a ‘blank’ reading taken. This should come back at 0 ng/µL. Finally, 
the same quantity of DNA was pipetted onto the pedal and read by the 
Nanodrop. Final readings were given as ng/µL, along with 260/280 and 
260/230 ratios and a graph plotting the absorbance and wavelength of the 
sample. The 260/280 ratio of absorbance showed the purity of the DNA with 
~1.8 being ‘pure’. A much lower reading would be indicative of the presence 
of a contaminant that absorbs at 280nm, such as protein. The 260/230 ratio 
of absorbance is also a measure of purity, with a ‘pure’ reading given at 
~2.0-2.2 and much lower values indicative of contaminants which absorb at 
230nm, such as carbohydrates. 
 
5.1.6 Preparation of Luria-Bertani (LB) Agar Plates 
To prepare LB Agar plates for growth of competent E-Coli following 
transformation, 32g LB Agar was dissolved in 1 Litre of dH2O and 
autoclaved. When cooled (but before it set) appropriate antibiotic 
(Kanamycin for the pIRES2-ZsGreen1 vector and Ampicillin for the control 
pUC19 vector) was added to make a concentration of 50µg/mL. The liquid 
LB agar was poured into petri dishes and left to set before being stored 
upside down at 4°C until needed. 
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5.1.7 In-Fusion® Cloning Reaction 
 
The In-Fusion® HD EcoDry™ Cloning kit (Clontech) uses the In-Fusion 
enzyme to fuse together a linearised vector and PCR product with a 15 base 
pair overlap on each side. The enzyme was lyophilised in the reaction tube 
with all the other cloning reaction materials needed so all that needed to be 
added were the vector and PCR product. This minimises variability between 
reactions and users.  
 
Reaction 
Component 
Cloning 
Reaction 
Negative 
Control 
Reaction 
Positive 
Control 
Reaction 
Purified Insert 
(0.5-10kb) 
50-100ng 
HDAC10 
- 
2 µL of control 
insert 
Linearised 
Vector 
(<10kb) 
50-100ng 
pIRES2-
ZsGreen1 vector 
1 µL pIRES2-
ZsGreen1 
vector 
1 µL of pUC19 
control vector 
Deionised 
Water 
Make up to 10µL 9 µL 7 µL 
 
Figure 2.22: Recommended quantities of components for In-
Fusion reactions.  
A range of quantities were trialled for the cloning reaction: from 50ng to 
100ng of insert and vector, to adjusting quantites based on molar ratios, 
to compensate for the relatively large size of the insert (1:6 vector: 
insert). 
 
Using the quantites in Figure 2.22, the linearised vector and purified insert 
were mixed with deionised water to make up a 10µL reaction volume. A 
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negative control with no insert was run to ensure the linearised vector did not 
fuse back together by itself. A positive control (pUC19 vector and insert 
(Clontech) was run to ensure the In-Fusion enzyme was active and working. 
Each 10µL reaction was added to an In-Fusion HD EcoDry pellet and mixed 
well with a pipette to ensure the enzyme pellet was fully reconstituted. Each 
reaction was incubated for 15 minutes at 37°C, followed immediately by 15 
minutes at 50°C and placed on ice, ready for transformation. 
 
 
 
Figure 2.23: The In-Fusion cloning reaction step 
 
15 mins @ 37C
15 mins @ 55C
PCR product (HDAC10 gene)
Linearised pIRES2-ZsGreen1 vector
Lyophilized In-Fusion cloning reaction
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5.2 Trouble shooting - Standard Ligation Cloning 
 
Ligation cloning uses DNA ligase to join DNA fragments together. To do this, 
forward (green) and reverse (purple) primers (Eurofins) were re-designed 
without a 15 base pair overlap (needed for In-Fusion cloning) and instead, 
had complementary ends to the unique restriction sites BamH1 and EcoR1 
(blue and pink), and a GC Clamp (red) to aid binding. Primers arrived 
lyophilized and were reconstituted in sterile water to make a concentration of 
100pmol/µL. 
 
Forward Primer GCG GAA TTC ATG GGG ACC GCG CTT GTG 
HDAC10-F Tm = 71°C  
 
Reverse Primer GCG GGA TCC TCA AGC CAC CAG GTG AGG 
HDAC10-R Tm = 72.6°C 
 
The HDAC10 gene was amplified as described in 5.1.1.1 and 5.1.1.2. 
Linearisation, agarose gel electrophoresis, Nucleospin PCR and gel clean 
up and quantification of DNA was performed as in 5.1.2, 5.1.3, 5.1.4 and 
5.1.5 respectively. 
 
Ligation reactions were set up for HDAC10 and for the empty vector control. 
DNA insert and vector were added in a 3:1 molar ratio, and 1.5µL ligase 
buffer was added, followed by the same quantity of T4 DNA ligase, and 
gently pipetted. The reactions were incubated at 16˚C overnight and heat 
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inactivated at 65˚C for 10 minutes, before transformation, as described in 
2.5. 
 
5.3 Eurofins Cloning 
 
Due to time constraints, and troubleshooting many aspects of the cloning 
process with no successful outcome, the decision was taken to pay for the 
cloning. The pIRES2-ZsGreen1 vector (5µL at 100ng/µL) was sent to 
Eurofins Geneomics Services along with the PCR product (5µL at 10ng/µL) 
to insert. When returned, the construct had passed all quality control 
parameters (appendix 4) and had been sequenced (appendix 5). 
 
5.4 Sequencing 
 
For independent analysis, the construct was sent to Source Bioscience 
Sequencing and found to be homologous with the reference HDAC10 
sequence.  
 
5.5 Transformation 
 
Stellar Competent E.Coli (Clontech) were gently thawed on ice and 2.5µL of 
the In-Fusion cloning reaction/cloned construct (pIRES2-ZsGreen1 + 
HDAC10) was added to 50µL of Stellar Competent E.Coli. The tube was 
gently flicked to mix and placed back on ice. This was repeated for each 
control listed in figure 2.24. 
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Control Components to add to 50µL Stellar 
Competent E.Coli 
In-Fusion negative 
control 
2.5µL pIRES2-ZsGreen1 vector  
In-Fusion positive control 2.5µL pUC19 control vector plus control insert 
Transformation negative 
control 
2.5µL deionised water 
Transformation positive 
control 
1µL pUC19 control vector (non-linearised) 
 
Figure 2.24: Components of controls for transformation 
 
The cloning reaction-E.Coli mix was incubated on ice for 30 minutes. Using 
a heat block, the mix was heat shocked for 50 seconds at 42°C and 
immediately placed back on ice for at least 5 minutes. 950µL of room 
temperature SOC medium was added to each tube and incubated in a 
shaker at 250rpm for 1 hour at 37°C. 100µL of each transformation was 
spread onto LB Agar plates containing appropriate antibiotic (Ampicillin for 
pUC19 reactions; Kanamycin for pIRES2-ZsGreen1 reactions) (see section 
5.8). After a 5 minutes, plates were incubated upside down at 37°C for 
around 16 hours to produce colonies. This process is summarised in figure 
2.25. 
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Figure 2.25: The transformation procedure using stellar 
competent E.Coli. 
E.coli was heat shocked, allowing the plasmid to enter into it. Once the 
plasmid is incorporated into the E.Coli, the transformation was plated 
onto agar containing antibiotic overnight, allowing colonies to grow and 
expanding the plasmid yield. 
 
5.6 Overnight Cultures – small scale 
 
To prepare overnight cultures, one colony was scraped onto the end of a 
pipette tip and used to inoculate 6mL of LB medium containing kanamycin at 
50µg/mL in a universal tube. The lid was not tightened to allow for gas 
exchange. The tube was put into a shaking incubator at 250rpm for 12-16 
hours at 37°C.  
 
5.7 Miniprep 
 
The PureYield™ Plasmid Miniprep System (Promega) isolates high-quality 
plasmid DNA suitable for eukaryotic transfection using a silica-membrane 
column. The protocol was carried out as per the manufacturer’s instructions. 
Prior to starting, a volume of 95% ETOH was added to the Column Wash 
Solution (CWS). To process as large a volume as possible, 1.5mL of the 
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culture was spun in a microcentrifuge at maximum speed for 30 seconds, 
the supernatant was discarded and another 1.5 mL of culture was added to 
the tube and the process repeated. To the tube, 600µL of sterile, 
microbiology grade water was added to resuspend the pellet completely and 
100µL of Cell Lysis Buffer (CLB) was added. The contents was mixed by 
inverting 6 times. Within 2 minutes of the addition of the cell lysis buffer, 
350µL of cold Neutralization Solution (NSC) was added to avoid excessive 
lysis and subsequent damage of the plasmid DNA. This was again mixed by 
inversion and centrifuged for 3 minutes at maximum speed. The supernatant 
was transferred to a PureYield™ Minicolumn, sat in a PureYield™ Collection 
Tube and centrifuged for 15 seconds at maximum speed. The flow through 
was discarded and 200µL of Endotoxin Removal Wash (ERB) was added to 
the minicolumn. Again this was centrifuged at maximum speed for 15 
seconds and 400µL of CWC was added to the minicolumn, followed by a 30 
second spin at maximum speed. The minicolumn was transferred to a clean 
Eppendorf and 30µL of Elution Buffer (EBB) was added directly onto the 
minicolumn matrix and incubated at room temperature for 1 minute. This 
was spun at maximum speed for 15 seconds, eluting the plasmid DNA. 
 
5.8 Overnight cultures – large scale 
 
For larger quantities of DNA, a megaprep was required and therefore a large 
scale overnight was needed. LB Broth (25g/L in dH2O) was autoclaved and 
once cooled, Kanamycin was added to a concentration of 50µg/mL. To this, 
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6mL of bacterial culture (see section 5.14) was added and incubated in a 
shaking incubator at 250rpm for 16 hours at 37°C. 
 
5.9 Megaprep 
 
The Plasmid Plus Mega Kit (Qiagen®) isolates high-quality, ultrapure plasmid 
DNA from large quantites of bacterial culture (up to 500mL) for use in 
eukaryotic transfection. The protocol was carried out as per the 
manufacturers instructions. 
 
Prior to starting, RNase A solution and LyseBlue reagent were added to 
Buffer P1 and ETOH was added to buffer PE. Bacterial culture from large 
scale overnight cultures (5.16) was centrifuged at 6000 g for 15 minutes at 
4°C. The pellet was resuspended thoroughly in 25mL of Buffer P1 followed 
by 25mL of Buffer P2 which was mixed by inversion and incubated at room 
temperature for 5 minutes to lyse the cells. To this, 25mL of Buffer S3 was 
added to the suspension and mixed by inversion and then the whole 
suspension was transferred to the QIAfilter cartridge and incubated for 10 
minutes at room temperature. Without disrupting the cartridge, the vacuum 
was turned on until all the liquid was drawn through the filter into the bottle 
below. 25mL of Buffer BB was added to the lysate in the bottle and mixed by 
inversion before being transferred to spin columns attached to the QIAvac 
24 Plus. The vacuum was switched on again and -300 mbar of pressure was 
applied to draw through the liquid at a constant pressure. The DNA was 
washed by adding 80mL of Buffer ETR and again switching on the vacuum. 
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A second wash was carried out with 50mL of Buffer PE, again switching on 
the vacuum to draw through the liquid. The spin columns were taken off the 
vacuum source and placed in a 50mL collection tube and centrifuged at 
5000 g for 10 minutes at room temperature. To elute the DNA, the spin 
column was transferred to a clean tube and 1mL of Buffer EB was added 
directly onto the membrane and incubated for 1 minute. The column was 
then centrifuged for 5 minutes at 5000 g at room temperature. 
 
5.10 Transfection 
 
Cells were plated in 6-well plates with 2mL of normal growth media. They 
were transfected when they reached 60-80% confluency with jetPRIME® 
transfection reagent (Polyplus transfection) as per the manufacturers 
protocol.  
 
5.10.1 Stable Transfection 
To produce both the clones containing the gene of interest (KNS42-pIRES-
HDAC10) and the clones containing the empty vector control (KNS42-
pIRES), 2µg of each DNA was added to 200µL of jetPRIME® buffer and 
vortexed briefly to mix. To this, 4µL of jetPRIME® reagent was added and 
vortexed for 10 seconds to mix thoroughly. When scaling up to larger 
quantities of cells, a 1:2 ratio of DNA to jetPRIME® reagent was adhered to. 
The transfection mix was incubated at room temperature for 10 minutes 
before being added drop wise onto the cells, whilst gently moving the plate 
in a figure of 8 motion to ensure even distribution over the entire well. The 
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cells were placed back in the incubator for 4 hours, at which point the media 
was replaced to avoid toxicity to the cells from prolonged exposure to the 
jetPRIME®. When cells became confluent, they were trypsinised as 
previously described in section 2.6.2, and transferred into large petri dishes 
containing selection media (Growth media as previously described in section 
2.1, plus 400µg/mL of G418 selection antibiotic as determined by kill curves 
appendix 6). The petri dishes were incubated for the cells to form individual 
colonies and were maintained in selection media going forward, which was 
changed every 4 days due to degradation of the antibiotic. 
 
5.10.2 Transient Transfection 
For transient transfection, T75 flasks of around 70-80% confluency were 
transfected using jetPRIME® as per the protocol in 5.16.1 and FuGENE® HD 
(Promega) as per manufacturers protocol. Cells were analysed by In-cell 
western and viability measurements using the Countess™ II FL Automated 
Cell Counter (as described in 2.7), at 24, 48 and 72 hours after transfection 
(example results shown in appendix 7).  
 
5.11 Picking Colonies 
 
Individual colonies were isolated and transferred into small well plates (96, 
48 or 24 wells). From these wells, colonies could start to expand. 
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5.11.1 Cloning Rings 
Location of the colonies were marked by drawing circles on the bottom of the 
petri dish around each colony to be picked. The media was removed and 
cells were washed twice with HBSS. Small sterile plastic cloning rings were 
dipped in silicone cloning grease using sterile tweezers and placed around 
the marked colony(/ies). TryplExpress was dropped into the ring and 
incubated for a few minutes. Once cell had detached, each individual colony 
was transferred into a well plate containing 1mL of selection media. The 
plate was incubated for colonies to start expanding. 
 
5.11.2 Single Cell Isolation 
Old media was discarded and the cells washed with HBSS twice. 
TryplExpress was added to cover the entire petri dish and was incubated at 
37°C for several minutes. Once cells had detached, media was added and 
the suspension transferred to a centrifuge tube and spun at 170 g for 5 
minutes to pellet the cells. The supernatant was discarded and 1mL of fresh 
media added to resuspend the pellet. The cells were counted as previously 
described in section 2.7.3. Cells were then plated into a 96 well plate in 
100µL of selection media at 1 cell per well. The plate was incubated to allow 
cells to proliferate. This method produces very pure clones but takes a long 
time and loses a lot of cells due to being plated so sparsely.  
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5.12 Expansion of Colonies 
 
Colonies were maintained in selection medium with 400µg/mL of G418 
antibiotic. Once colonies were around 80% confluent, each one was 
transferred into a larger well. This was repeated until each colony occupies a 
T75 flask, at which point the cells were passaged according to the protocol 
described in section 2.6.1. As soon as possible, clones were frozen down for 
stocks as described in section 2.5. 
 
5.13 Testing for HDAC10 and ZsGreen1 Expression 
 
One confluent flask from each colony was lysed and protein isolated as 
described in section 4.1. To assess whether clones were expressing the 
gene of interest, Western Blots were run with the clone lysates as described 
in section 4.4. Both HDAC10 (Abcam) (1:1000) and ZsGreen1 (Clontech) 
(1:1000) antibodies were used to probe for expression. ZsGreen1 should 
have been present in both clones (KNS42-pIRES-HDAC10 and KNS42-
pIRES) at similar levels where as HDAC10 should have shown increased 
expression in KNS42-pIRES-HDAC10 clones compared with the control.  
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Chapter 3.  Evaluation of the Histone Deacetylase Family 
mRNA Expression In Paediatric Brain Tumours Using a 
Bioinformatics Approach 
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1.0 Introduction 
 
Little is known about HDAC expression in pGBM so we wanted to evaluate 
the mRNA expression of a large number of paediatric glioblastoma (pGBM) 
tissue samples. The R2: Genomics Analysis and Visualization Platform 
(http://r2.amc.nl) provides a valuable tool allowing us access to a wider 
population than we would otherwise be able to obtain, using publicly 
available datasets.  
 
The R2 database is a tool which allows users to access mRNA data from 
over 50,000 human samples. Datasets are available from a wide range of 
cell lines, tumours, and tissues from all over the body from both diseased 
and healthy participants. To our knowledge, no one has systematically 
assessed HDAC family expression in paediatric glioblastomas, yet multiple 
studies and clinical trials are researching the use of broad spectrum HDAC 
inhibitors as a means to help treat these neoplasms (de Andrade et al., 
2016; Grasso et al., 2015; Hummel et al., 2013; Masoudi et al., 2008; Witt et 
al., 2004; Wolff et al., 2008), without evaluating the potential negative 
implications on the paediatric brain.  
 
Our aim was to evaluate histone deacetylases 1-11 and compare mRNA 
expression between the following groups: 1. H3F3A subgroups, 2. Paediatric 
and adult GBM, and 3. Paediatric brain tumours. We hypothesised that 
mRNA expression of HDACs would be overexpressed in paediatric 
glioblastoma and that HDACs would be dysregulated amongst H3F3A 
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subtypes. We anticipated that HDAC expression would differ between 
paediatric and adult GBM, but that there may be patterns of HDAC 
dysregulation between paediatric high grade brain tumours.    
 
Using the R2 database, a number of datasets were identified which could 
contain histone deacetylase data from pGBMs. ‘Paediatric’ was defined as 
being 18 years old and under. After choosing the dataset, tracks (subsets), 
such as ‘age’, ‘diagnosis’ and ‘WHO grade’ were chosen where applicable 
(shown in Chapter 2) to ensure the data received was only from paediatric 
gliomas of WHO grade IV. When datasets were unable to provide the tracks 
needed to ensure only the target data were received, the dataset was 
discarded as it was not possible to verify the data were from the required 
patients or samples. 
 
All dataset names detail first the type of dataset (e.g. tumour glioma 
paediatric), followed by the name of the author. The name also details the 
probe set. To minimise variation anomalies, we ensured all datasets used for 
our analysis used the same chip type – the Affymetrix Human Genome U133 
Plus 2.0 Array. 
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2.0 Results 
 
2.1 The Datasets 
 
Our search identified six datasets as having histone deacetylase expression 
data originating from paediatric, WHO grade IV glioma patients. The 
datasets used were: Tumour Glioma DIPG - Paugh; Tumour Glioma - 
French; Mixed Paediatric Brain (Normal-Tumour) – Donson; Cell line Glioma 
Paediatric – Grigoriadi; Tumour Glioma Paediatric – Paugh; Tumour 
Glioblastoma – Pfister. Using the ‘data grabber’ tool in the R2 database, the 
specified raw data were extracted and sorted in an Excel spreadsheet. 
French’s ‘tumour glioma’ dataset was discarded after selecting tracks for 
‘age at diagnosis’ and ‘histology’, as only two samples were returned for the 
dataset. The decision was made to exclude Paugh’s DIPG dataset from this 
analysis as although the tumour does exist in the same category as pGBM, 
they are biologically distinct tumours and would introduce new uncontrollable 
variables. We also excluded Grigoriadi’s paediatric glioma cell line dataset 
(appendix 8) from this analysis as it was the only dataset using cell line data, 
rather than tissue data, introducing potential variables because of the 
heterogenous nature of the tissue samples. The raw data for the remaining 
three datasets did not follow a Gaussian (normal) distribution so we used 
median and interquartile ranges to visualise the data extracted from each of 
the three datasets described below (Figure 3.1).
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Figure 3.1: mRNA expression of histone deacetylases in paediatric glioblastoma, using data obtained using 
the R2 database.  
All datasets reveal HDAC2 to be the highest expressing HDAC and HDAC10, the lowest. (A) Donson’s mixed paediatric brain 
dataset returned 34 samples after selecting for glioblastoma under ‘sample source’. (B) Paugh’s glioma dataset returned 37 
samples after selecting for ‘WHO grade IV’. (C) Pfister’s glioblastoma dataset returned 22 samples after selecting for ‘age 
at diagnosis’ to be under 18 years. Individual data points represented as circles. Median and interquartile ranges 
represented with black bars. (Datasets: A: Mixed Paediatric Brain (Normal-Tumour) – Donson; B: Tumour Glioma Paediatric 
– Paugh; C: Tumour Glioblastoma – Pfister) 
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The following datasets were used for analysis: Mixed Paediatric Brain 
(Normal-Tumour) – Donson; Tumour Glioma Paediatric – Paugh; and 
Tumour Glioblastoma – Pfister. As mentioned above data were filtered for 
age (under 18 years), WHO grade (grade IV) and tumour type (glioblastoma) 
to ensure we only received data for the target population. In general, across 
the three datasets the expression of individual HDACs were consistent with 
HDAC2 showing the highest expression, (medians of 511.35, 624.2 and 
1011.65, Donson, Paugh and Pfister respectively), and HDAC10 showing 
the lowest expression, (medians of 38.76, 38.3 and 19.85 respectively) 
(figure 3.1).  
 
Although data is compared using the same microarrays, there are bound to 
be variations in results due to differences in sample handling, tumour 
location, age of patient, and treatment received. Therefore, we compared 
each HDAC family member expression between datasets (figure 3.2).  
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Figure 3.2: Comparison of expression of individual histone 
deacetylases at the mRNA level, across paediatric glioblastoma 
datasets, using the R2 database. 
Expression data extracted from the R2 database after selecting for age 
at diagnosis (<18 years), WHO grade (IV only) and tumour type 
(glioblastoma only). Data analysed in excel to compare expression of 
each gene at the mRNA level between datasets. Large overlap is 
displayed across datasets for each individual HDAC. HDAC2 shows the 
largest discrepancies between datasets. Box and whisker plots show 
median and interquartile ranges whilst error bards display the lower and 
upper ranges. (Datasets: Mixed Paediatric Brain (Normal-Tumour) – 
Donson; Tumour Glioma Paediatric – Paugh; Tumour Glioblastoma – 
Pfister) 
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Given the differences in the datasets themselves, such as patient age, 
location of tumour, stage of disease progression, treatment received and so 
on, as well as lab-to-lab variation in protocols and sample handling, we 
would anticipate a certain amount of variation. Notably HDAC2 shows the 
most discrepancies between datasets, but is still the highest expressing 
HDAC in all datasets (figure 3.2). We performed a Kruskal-Wallis test to 
assess the differences between our datasets, followed by a Dunn’s multiple 
comparisons post-hoc test (appendix 9). Although there were statistically 
significant differences in HDAC expression between datasets, we see that 
the datasets show a continuity in the pattern of expression across HDACs.  
 
We next wanted to compare HDAC expression in paediatric GBM to a non-
neoplastic control. We hypothesised that HDACs would be overexpressed in 
pGBMs compared to non-neoplastic brain. To assess this we used the R2 
database to search for paediatric non-neoplastic brain tissue. We found two 
datasets which matched this search criteria: Normal cerebellum – Roth; and 
Normal-Tumour – Donson. The cerebellum however, is very different 
developmentally and not comparable to areas of the brain in which pGBM 
tumours regularly grow. Therefore, Roth’s dataset is inappropriate as a 
control. Once selecting for age (< 18 years) and excluding the cerebellum in 
Donson’s dataset, insufficient samples remained to use this dataset as a 
control. Unfortunately, to our knowledge at this time, there is no appropriate 
dataset to be used as a non-neoplastic control for paediatric GBM. 
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We wanted to investigate whether there were any differences in HDAC 
expression between paediatric and adult GBM. We searched the R2 
database to find adult GBM (aGBM) datasets to use in our analysis. All 
datasets used the same gene profiling array, u133p2, for continuity and to 
minimize variables between datasets. ‘Adult’ was defined as being over 18 
years of age. Four datasets returned the specified search criteria: Tumour 
Glioblastoma – Pfister; Tumour – Glioma – French; Tumour Glioblastoma – 
Hegi; and Tumour Glioma – Kawaguchi. Again, we use median and 
interquartile ranges to visualise the data extracted from each dataset (figure 
3.3). 
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Figure 3.3: Expression of histone deacetylases at the mRNA level in adult glioblastoma.  
Two datasets (A and B) reveal HDAC2 as the highest expressing HDAC and two (C and D) show HDAC1 as the highest 
expressed HDAC. HDAC10 is shown to be the lowest (A) Pfister’s glioblastoma dataset returned 22 samples after selecting 
for selecting ‘age at diagnosis’ to be over 18 years (B) French’s glioma dataset returned 157 samples after selecting for 
‘histology’ to be GBM (C) Hegi’s glioblastoma dataset returned 80 samples after selecting ‘disease status’ to be GBM (D) 
Kawaguchi’s glioma dataset returned 32 samples once ‘pathological diagnosis’ was selected for GBM. Data obtained from 
the R2 database. Individual data points represented as circles. Median and interquartile ranges represented by black bars
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Four datasets were used for analysis: Tumour Glioblastoma – Pfister; 
Tumour Glioma – French; Tumour Glioblastoma – Hegi; and Tumour Glioma 
- Kawaguchi. Data were filtered by selecting for age at diagnosis (>18 
years), disease status, histology and pathological diagnosis (glioblastoma). 
Pfister and French reveal HDAC2 to have the highest median expression 
(1108.9 and 489.8 respectively) but Hegi and Kawaguchi show HDAC1 to 
have the higher median expression (489.65 and 482.15 respectively), with 
HDAC2 expression levels close behind. All datasets show similar patterns of 
expression across HDACs and show HDAC10 to have the lowest median 
expression (13.6; 26.1; 43.5; and 23.65 respectively) (figure 3.3). 
 
Again, all data were gathered using the same chiptype However, we wanted 
to assess the impact of uncontrollable variables on HDAC expression 
between datasets (figure 3.4). 
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Figure 3.4: Comparison of expression of individual histone 
deacetylases at the mRNA level, across adult glioblastoma 
datasets, using the R2 database. 
Expression data extracted from the R2 database after selecting for age 
at diagnosis (>18 years), disease status, histology and pathological 
diagnosis (glioblastoma). Data analysed in excel to compare expression 
of each gene at the mRNA level between datasets. Large overlap is 
displayed across datasets for each individual HDAC. Again, HDAC2 
shows the largest discrepancies between datasets. Box and whisker 
plots show median and interquartile ranges whilst error bards display 
the lower and upper ranges. (Tumour Glioblastoma – Pfister; Tumour 
Glioma – French; Tumour Glioblastoma – Hegi; and Tumour Glioma - 
Kawaguchi) 
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Comparison of individual HDACs across adult GBM datasets shows a 
consistency in expression between datasets. HDAC2, as with pGBM, shows 
the most discrepancies with a wide range of expression values. It is 
expected that there would be a certain amount of variation between datasets 
due to factors discussed earlier, such as differences in tumour location, 
treatment received and sample handling. Statistical analysis with Kruskal 
Wallis, followed by Dunn’s multiple comparisons post-hoc test shows 
significant differences between aGBM datasets in HDAC expression 
(appendix 10). However, as with the pGBM datasets, we see a continuity in 
the pattern of HDAC expression in each dataset. 
 
Information on each dataset used in our analysis is detailed in table 3.1. 
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Table 3.1: Details of datasets used for bioinformatics analysis. 
Datasets extracted from the R2: Genomics and Visualization 
Platform.
Dataset Number of Samples Microarray Chip type 
Mixed Paediatric Brain - Donson 34 U133 Plus 2.0 
Tumour Glioma Paediatric - Paugh 37 U133 Plus 2.0 
Tumour Glioblastoma - Pfister 22 U133 Plus 2.0 
Tumour Glioblastoma - Pfister 22 U133 Plus 2.0 
Tumour Glioma - French 157 U133 Plus 2.0 
Tumour Glioblastoma - Hegi 80 U133 Plus 2.0 
Tumour Glioma - Kawaguchi 32 U133 Plus 2.0 
Paediatric Glioma DIPG - Paugh 37 U133 Plus 2.0 
Normal Cerebellum -Roth 9 U133 Plus 2.0 
Tumour AT/RT - Birks 18 U133 Plus 2.0 
Tumour AT/RT - Kool 49 U133 Plus 2.0 
Tumour CNS PNET - Grundy 24 U133 Plus 2.0 
Tumour CNS PNET - Kool 182 U133 Plus 2.0 
Tumour Medulloblastoma - Gilbertson 76 U133 Plus 2.0 
Tumour Medulloblastoma - Pfister 223 U133 Plus 2.0 
Tumour Ependymoma - Gilbertson 76 U133 Plus 2.0 
Tumour Ependymoma - Pfister 209 U133 Plus 2.0 
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2.2 HDAC Expression in pGBM Molecular Subgroups 
   
As described in Chapter 1, the recent update to the WHO classification 
(Louis et al., 2016) represents for the first time, molecularly defined 
subgroups of mutations in the histone H3 gene H3F3A existing amongst 
paediatric diffuse gliomas (Schwartzentruber et al., 2012). Three mutations 
are found in the gene; K27M, G34R and G34V; all of which are located in 
the amino terminal tail (C-terminus) at, or near, sites of post-translational 
modifications such as acetylation and deacetylation. With this in mind we 
wanted to explore whether mutations at sites which interact with HDACs, 
could impact upon their expression levels in pGBMs. We hypothesised that 
tumours with the H3F3A mutations could cause dysregulation of HDAC 
expression compared to the wildtype. We used the R2: Genomics Analysis 
and Visualization Platform to search for and extract HDAC expression data 
from these subgroups. Due to this subgrouping being a recent advancement 
in the field, many of the datasets in the R2 database do not hold this 
information. However, we identified one dataset by Pfister (Tumour 
Glioblastoma) used throughout this chapter, which also held molecular 
subgrouping data. In tracks, we first selected ‘age at diagnosis’ to extract the 
paediatric samples, and then selected tracks for ‘H3F3A status’. We were 
then able to individually extract data for samples from ‘wildtype’, ‘K27M’, 
‘G34R’ and ‘G34V’ mutations with the ‘data grabber’ tool. The G34V 
subgroup only contained 1 sample so was discarded from analysis.  
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Figure 3.5: Scatter-dot plot comparing Class I HDAC expression 
at the mRNA level in H3F3A molecular subgroups of paediatric 
GBM. 
Data extracted from Pfister’s tumour glioblastoma dataset after 
selecting for age (<18 years) and H3F3A subgroup status (wildtype; 
K27M; G34R) from the R2 database. HDAC3 mRNA expression was 
found to be significantly decreased in the K27M mutant compared with 
the G34R mutant subtype (p=0.0448). No statistically significant 
difference in HDAC1 (p=0.7826); HDAC2 (p=0.9924); or HDAC8 
(p=0.6666) mRNA expression was found between the subtypes. Data 
analysed by a Kruskal-Wallis test followed by a Dunn’s multiple 
comparisons post-hoc test using Graphpad Prism 7 software. Circles 
represent individual samples showing the range, with median and 
interquartile ranges depicted by the black bars. Statistical significance 
shown by * : * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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Figure 3.6: Scatter-dot plot comparing class IIa HDAC 
expression at the mRNA level in H3F3A molecular subgroups of 
paediatric GBM. 
Data extracted from Pfister’s tumour glioblastoma dataset after 
selecting for age (<18 years) and H3F3A subgroup status (wildtype 
K27M; G34R) from the R2 database. No statistically significant 
difference in HDAC4 (p=0.7225); HDAC5 (p=0.9222); HDAC7 (p=0.8061); 
or HDAC9 (p=0.3687) mRNA expression found between the subtypes. 
Data analysed by a Kruskal-Wallis test followed by a Dunn’s multiple 
comparisons post-hoc test using GraphPad Prism 7 software. Circles 
represent individual samples showing the range, with median and 
interquartile ranges depicted by the black bars.  
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Figure 3.7: Scatter-dot plot comparing class IIb HDAC 
expression at the mRNA level in H3F3A molecular subgroups of 
paediatric GBM. 
Data extracted from Pfister’s tumour glioblastoma dataset after 
selecting for age (<18 years) and H3F3A subgroup status (wildtype 
K27M; G34R) from the R2 database. No statistically significant 
difference in HDAC6 (p=0.1756); or HDAC10 (p=0.9525) mRNA 
expression was found between the subtypes. Data analysed using a 
Kruskal-Wallis test followed by a Dunn’s multiple comparisons post-hoc 
test using GraphPad Prism 7 software. Circles represent individual 
samples showing the range, with median and interquartile ranges 
depicted by the black bars. 
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Figure 3.8: Scatter-dot plot comparing class IV HDAC 
expression at the mRNA level in H3F3A molecular subgroups of 
paediatric GBM. 
Data extracted from Pfister’s tumour glioblastoma dataset after 
selecting for age (<18 years) and H3F3A subgroup status (wildtype; 
K27M; G34R) from the R2 database. No statistically significant 
differences in HDAC11 mRNA expression were found between the 
subtypes (p=0.9685). Data analysed by a Kruskal-Wallis test followed by 
a Dunn’s multiple comparisons post-hoc test using GraphPad Prism 7 
software. Circles represent individual samples showing the range, with 
median and interquartile ranges depicted by the black bars.  
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We analysed three subgroups of H3F3A gene mutations at the mRNA level 
within paediatric glioblastoma, including the wildtype gene, using a 
bioinformatics approach to assess whether different mutations impacted 
upon HDAC expression. We extracted data from the R2 database, 
individually selecting for age (<18 years) and H3F3A subgroup status. Just 
one dataset contained this information: Pfister’s ‘tumour glioblastoma’ 
dataset (wildtype, n=30; K27M, n=7; G34R, n=46). The G34V subgroup was 
excluded due to lack of sample numbers. Data were analysed using 
GraphPad Prism 7 software. A Kruskal-Wallis test was performed for each 
HDAC, followed by a Dunn’s multiple comparisons post-hoc test. HDAC3 
was the only HDAC to show a significant difference between subgroups, with 
the K27M mutant showing a significant decrease in mRNA expression in 
comparison to the G34R mutant (p=0.0448) (figure 3.5). There was no 
statistically significant difference between H3F3A subgroups in paediatric 
glioblastoma for Class I HDACs: HDAC1 (p=0.7826); HDAC2 (p=0.9924); 
and HDAC8 (p=0.6666); Class IIa HDACs: HDAC4 (p=0.7225); HDAC5 
(p=0.9222); HDAC7 (p=0.8061); and HDAC9 (p=0.3687); Class IIb HDACs: 
HDAC6 (p=0.1756); HDAC10 (p=0.9525) and Class IV HDAC: HDAC11 
(p=0.9685) (figure 3.5 -3.8).  
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2.3 HDAC Expression in Adult vs. Paediatric GBM 
As discussed in chapter 1, GBMs are biologically and molecularly distinct in 
paediatrics, harbouring different mutations and gene expression levels to 
their adult counterpart. We hypothesised that HDAC expression would be 
significantly different at the mRNA level in pGBM compared to aGBM. We 
searched the R2 database to find adult GBM (aGBM) datasets, to compare 
mRNA expression of histone deacetylases with our pGBM datasets to 
ascertain if there was any significant differences in HDAC expression 
between them.  
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Figure 3.9: Scatter-dot plot comparing class I HDAC expression 
at the mRNA level in paediatric GBM and adult GBM. 
Data extracted from the R2 database after selecting for age (paediatric 
<18 years; adult >18 years), tumour type (glioblastoma) and WHO grade 
(IV). No statistically significant difference in HDAC1 mRNA expression 
was found between paediatric and adult GBM. Data were analysed by a 
Kruskal-Wallis test (which initially showed an estimated p value of 
0.0423, indicating significance), but the subsequent Dunn’s multiple 
comparisons post-hoc test revealed no significance (p>0.05). HDAC2 
(p<0.0001), HDAC3 (p<0.0001) and HDAC8 (p<0.0001), were found to be 
significant by Kruskal-Wallis tests and post-hoc analysis with Dunn’s 
multiple comparisons test revealed multiple significant differences 
between pGBM and aGBM. Analysis performed using GraphPad Prism 7 
software. Circles represent individual samples showing the range, with 
median and interquartile ranges depicted by the black bars. Statistical 
significance shown by * : * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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Figure 3.10: Scatter-dot plot comparing class IIa HDAC expression at 
the mRNA level in paediatric GBM and adult GBM. 
Data extracted from the R2 database after selecting for age (paediatric <18 years; 
adult >18 years), tumour type (glioblastoma) and WHO grade (IV). Data were 
analysed by a Kruskal-Wallis test p<0.0001 (HDAC4), p<0.0001 (HDAC5), p<0.0001 
(HDAC7) and p<0.0001 (HDAC9) followed by a Dunn’s multiple comparisons post-
hoc test. Multiple significant differences were identified, at the mRNA level, 
between pGBM and aGBM. Analysis performed using GraphPad Prism 7 software. 
Circles represent individual samples showing the range, with median and 
interquartile ranges depicted by the black bars. Statistical significance shown by * 
: * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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Figure 3.11: Scatter-dot plot comparing HDAC6 expression at 
the mRNA level in paediatric GBM and adult GBM. 
Data extracted from the R2 database after selecting for age (paediatric 
<18 years; adult >18 years), tumour type (glioblastoma) and WHO grade 
(IV). Data were analysed by a Kruskal-Wallis test p<0.0001 (HDAC6) and 
p<0.0001 (HDAC10), followed by a Dunn’s multiple comparisons post-
hoc test. Multiple groups were significantly different in HDAC6 and 10 
expression, at the mRNA level, between pGBM and aGBM. Analysis 
performed using GraphPad Prism 7 software. Circles represent 
individual samples showing the range, with median and interquartile 
ranges depicted by the black bars. Statistical significance shown by * : 
* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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Figure 3.12: Scatter-dot plot comparing HDAC11 expression at 
the mRNA level in paediatric GBM and adult GBM. 
Data extracted from the R2 database after selecting for age (paediatric 
<18 years; adult >18 years), tumour type (glioblastoma) and WHO grade 
(IV). Data were analysed by a Kruskal-Wallis test (p<0.0001), followed by 
a Dunn’s multiple comparisons post-hoc test. Six groups were 
significantly different in HDAC11 expression, at the mRNA level, 
between pGBM and aGBM. Analysis performed using Graphpad Prism 7 
software. Circles represent individual samples showing the range, with 
median and interquartile ranges depicted by the black bars. Statistical 
significance shown by * : * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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We used a bioinformatics approach to analyse HDAC expression at the 
mRNA level in adult GBM compared to paediatric GBM. We obtained data 
from 4 adult GBM datasets and 3 paediatric GBM datasets matching our 
criteria, from the R2 database. Adult datasets: Tumour Glioblastoma – 
Pfister; Tumour – Glioma – French; Tumour Glioblastoma – Hegi; and 
Tumour Glioma – Kawaguchi. Paediatric datasets: Mixed Paediatric Brain 
(Normal-Tumour) – Donson; Tumour Glioma Paediatric – Paugh; and 
Tumour Glioblastoma – Pfister. Statistical analysis revealed all HDACs, with 
the exception of HDAC1 (figure 3.9), had significant differences in mRNA 
expression between pGBM and aGBM (figures 3.9-3.12). Interestingly 
HDACs 3, 9 and 11 all appear to be decreased in pGBM compared to aGBM 
and HDACs 4, 5 and 7 are shown to be increased in pGBM compared to 
aGBM. All statistically significant comparisons are summarised in Table 3.2. 
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Table 3.2: Comparisons with statistically significant differences 
between paediatric GBM and adult GBM of HDAC expression at 
the mRNA level, using a bioinformatics approach. 
 
 
Dunn's Multiple 
Comparisons  
Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC2 
pGBM - Donson vs. aGBM - 
Pfister ⬇ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Pfister ⬇ 0.0172 * 
pGBM - Paugh vs. aGBM - 
French ⬆ 0.0229 * 
pGBM - Paugh vs. aGBM - 
Hegi ⬆ 0.0003 *** 
pGBM - Paugh vs. aGBM - 
Kawaguchi ⬆ 0.0035 ** 
pGBM - Pfister vs. aGBM - 
French ⬆ <0.0001 **** 
pGBM - Pfister vs. aGBM - 
Hegi ⬆ <0.0001 **** 
pGBM - Pfister vs. aGBM - 
Kawaguchi ⬆ <0.0001 **** 
 
Dunn's Multiple 
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC3 
pGBM - Paugh vs. aGBM – 
French ⬇ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Hegi ⬇ 0.0068 ** 
 
Dunn's Multiple 
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC8 
pGBM - Donson vs. aGBM – 
French ⬇ 0.0013 ** 
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pGBM - Paugh vs. aGBM - 
Hegi ⬆ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Kawaguchi ⬆ <0.0001 **** 
pGBM - Pfister vs. aGBM - 
Hegi ⬆ 0.0123 * 
 
Dunn's Multiple  
Comparisons Test 
Increased/Decreased   
Expression 
P Value Significance 
HDAC4 
pGBM - Donson vs. aGBM –               
French ⬆ 0.0007 *** 
pGBM - Paugh vs. aGBM - 
French ⬆ 0.048 * 
pGBM - Pfister vs. aGBM - 
French ⬆ 0.0214 * 
 
Dunn's Multiple  
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC5 
pGBM - Donson vs. aGBM - 
Pfister ⬆ 0.0002 *** 
pGBM - Donson vs. aGBM - 
French ⬆ <0.0001 **** 
pGBM - Donson vs. aGBM - 
Hegi ⬆ <0.0001 **** 
pGBM - Donson vs. aGBM - 
Kawaguchi ⬆ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
French ⬆ 0.0008 *** 
 
Dunn's Multiple 
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC7 
pGBM - Donson vs. aGBM - 
Kawaguchi ⬆ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Pfister ⬆ 0.0175 * 
pGBM - Paugh vs. aGBM - 
French ⬆ 0.0035 ** 
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pGBM - Paugh vs. aGBM - 
Kawaguchi ⬆ <0.0001 **** 
 
 
 
 
 
	   
 
Dunn's Multiple 
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC9 
pGBM - Paugh vs. aGBM - 
Pfister ⬇ 0.0031 ** 
pGBM - Paugh vs. aGBM - 
Hegi ⬇ <0.0001 **** 
pGBM - Pfister vs. aGBM - 
Hegi ⬇ 0.0067 ** 
 
 
Dunn's Multiple 
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC6 
pGBM - Donson vs. aGBM - 
Pfister ⬆ <0.0001 **** 
pGBM - Donson vs. aGBM - 
French ⬆ 0.0007 *** 
pGBM - Donson vs. aGBM - 
Kawaguchi ⬆ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Pfister ⬆ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Kawaguchi ⬆ <0.0001 **** 
pGBM - Pfister vs. aGBM - 
French ⬇ <0.0001 **** 
pGBM - Pfister vs. aGBM - 
Hegi ⬇ <0.0001 **** 
 
 
Dunn's Multiple 
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC10 
pGBM - Donson vs. aGBM - 
Pfister ⬆ <0.0001 **** 
pGBM - Donson vs. aGBM - 
French ⬆ 0.0443 * 
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pGBM - Donson vs. aGBM - 
Hegi ⬇ 0.03 * 
pGBM - Paugh vs. aGBM - 
Pfister ⬆ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
French ⬆ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Kawaguchi ⬆ 0.0006 *** 
pGBM - Pfister vs. aGBM - 
Hegi ⬇ <0.0001 **** 
 
 
Dunn's Multiple 
Comparisons Test 
Increased/Decreased 
Expression 
P Value Significance 
HDAC11 
pGBM - Donson vs. aGBM - 
Hegi ⬇ 0.0006 *** 
pGBM - Donson vs. aGBM - 
Kawaguchi ⬇ 0.0243 * 
pGBM - Paugh vs. aGBM - 
Hegi ⬇ <0.0001 **** 
pGBM - Paugh vs. aGBM - 
Kawaguchi ⬇ 0.0068 ** 
pGBM - Pfister vs. aGBM - 
Hegi ⬇ <0.0001 **** 
pGBM - Pfister vs. aGBM - 
Kawaguchi ⬇ <0.0001 **** 
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Statistical analysis has proven a huge variability exists between paediatric 
GBM and adult GBM mRNA expression of histone deacetylases, despite the 
variability within the paediatric and adult groups themselves (figures 3.9-
3.12, Table 3.2). It is likely at least some of the variability seen between the 
paediatric GBM datasets and the variability seen between adult GBM 
datasets comes from uncontrollable factors such as lab-to-lab variability and 
sample handling, patient age, disease progression, previous treatment, 
location of tumour and so on. Further factors which we were unable to define 
are the various mutations known in these tumours, mutations within each 
individual HDAC and individual known sub-groups of GBM; mesenchymal, 
proneural, neural and classical for adult GBM; and H3F3A status for 
paediatric GBM.  
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2.4 Paediatric Brain Tumours 
 
We were interested in finding out if other paediatric brain tumours showed a 
dysregulation of HDACs at the mRNA level and whether the same HDACs 
were shown to be dysregulated as seen in pGBM. We hypothesised that all 
high grade paediatric brain tumours would show HDAC dysregulation. We 
went back to the R2 database and searched for all paediatric brain tumour 
datasets available to analyse. In addition to the three pGBM datasets 
(Donson; Paugh; and Pfister), we extracted data from one DIPG dataset 
(Paugh), originally excluded from the pGBM analysis (figures 3.1 and 3.2), 
two atypical teratoid/rhabdoid tumour (AT/RT) datasets (Birks; Kool), two 
central nervous system primitive neuroectodermal tumour (CNS PNET) 
datasets (Grundy; Kool), two medulloblastoma datasets (Gilbertson; Pfister) 
and two ependymoma datasets (Gilbertson; Pfister). AT/RT, CNS PNET and 
medulloblastomas are all classified now under embryonal tumours and 
ependymomas have been split into several new classifications under the 
new WHO guidelines (Louis et al., 2016). We used the normal cerebellum 
dataset by Roth as a means of control for the Medulloblastoma, AT/RT and 
CNS PNET data. As before, all datasets used the same gene profiling array, 
U133P2. Data were extracted as previously described (Chapter 2 section 
1.1.1) and tracks were set for ‘age at diagnosis’ for all necessary datasets to 
ensure only paediatric data were extracted.  
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Figure 3.13:  Heat map comparison of mRNA expression of 
HDACs from paediatric brain tumour datasets, using a 
bioinformatics approach. 
Data extracted from the R2 database after selecting for age (paediatric 
<18 years) and WHO grade (IV). Analysis and heat map performed using 
GraphPad Prism 7 software. Median expression values from each 
dataset represented by gradient scale. Data were analysed by a Kruskal-
Wallis test, followed by a Dunn’s multiple comparisons post-hoc test. 
Multiple groups were significantly different in HDAC expression, at the 
mRNA level, between paediatric brain tumours (shown in appendix 11 
with p values).  
Datasets: Mixed Paediatric Brain (Normal-Tumour) – Donson; Tumour 
Glioma Paediatric – Paugh; and Tumour Glioblastoma – Pfister; 
Paediatric glioma DIPG –Paugh; Normal cerebellum – Roth; Tumour 
AT/RT – Birks; Tumour AT/RT – Kool; Tumour CNS PNET – Grundy; 
Tumour CNS PNET – Kool; Tumour Medulloblastoma – Gilbertson; 
Tumour Medulloblastoma – Pfister; Tumour Ependymoma – Gilbertson; 
Tumour Ependymoma – Pfister.  
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We wanted to explore HDAC expression at the mRNA level from paediatric 
brain tumour datasets from the R2 database. We analysed three paediatric 
GBM datasets, Paediatric Brain (Normal-Tumour) – Donson; Tumour Glioma 
Paediatric – Paugh; and Tumour Glioblastoma – Pfister; with one DIPG 
dataset, Paediatric glioma DIPG –Paugh; two AT/RT datasets, Tumour 
AT/RT – Birks; Tumour AT/RT – Kool; two CNS PNET datasets, Tumour 
CNS PNET – Grundy; Tumour CNS PNET – Kool; two medulloblastoma 
datasets, Tumour Medulloblastoma – Gilbertson; Tumour Medulloblastoma – 
Pfister; and two ependymoma datasets,  Tumour Ependymoma – Gilbertson; 
Tumour Ependymoma – Pfister. We used a non-neoplastic cerebellum 
dataset, Normal cerebellum – Roth, as a control for comparison with the 
embryonal tumours. Data were analysed in GraphPad Prism 7 software and 
medians of each dataset represented using a heat map (figure 3.13) for 
comparison of paediatric brain tumours within each gene. A Kruskal-Wallis 
test was performed comparing all groups, which was significant (p<0.0001) 
for all HDAC’s, and a Dunn’s multiple comparisons post-hoc test was carried 
out to identify exactly which groups had significantly different HDAC 
expression.  
 
HDAC1 was found to be differentially expressed between 20 groups of 
paediatric brain tumours (detailed in appendix 11). Notably, the non-
neoplastic cerebellum dataset (Roth) was significantly down regulated 
compared to both AT/RT datasets (Birks and Kool), the CNS PNET dataset 
(Kool), and the Medulloblastoma dataset (Pfister). HDAC2 was differentially 
expressed between 34 paediatric brain tumour datasets and the embryonal 
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brain tumour datasets AT/RT (Kool), CNS PNET (Grundy; Kool), and 
Medulloblastoma (Gilbertson; Pfister) were significantly upregulated 
compared to the normal cerebellum dataset (appendix 11). HDAC3 was 
differentially expressed between 23 paediatric brain tumour datasets 
(appendix 11). All pGBM datasets had lower HDAC3 expression compared 
to the embryonal brain tumours. HDAC8 was found to have a low expression 
across all datasets, with just the Medulloblastoma dataset (Gilbertson) 
having a noticeably higher expression. However, even within the low 
expression range, 17 paediatric brain tumour datasets still had significantly 
different expression to each other (appendix 11). 
 
HDAC4 was dysregulated between 20 paediatric brain tumour datasets 
(appendix 11). The medulloblastoma dataset (Gilbertson) had an increase in 
HDAC4 expression compared to all other datasets. HDAC5 showed 
differential expression between 30 paediatric brain tumour datasets with 
normal cerebellum, AT/RT (Birks) and medulloblastoma (Gilbertson) 
datasets showing increased expression compared to other datasets 
(appendix 11). HDAC7 was differentially expressed between 24 paediatric 
brain tumour datasets with normal cerebellum and the medulloblastoma 
(Gilbertson) datasets being increased above the rest (appendix 11). HDAC9 
expression was similar amongst the datasets with 14 having significantly 
different expression. Both datasets by Kool (AT/RT and CNS PNET) had 
very wide ranges within each dataset (appendix 11).  
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HDAC6 was dysregulated between 36 paediatric brain tumour datasets 
(appendix 11). All datasets showed a wide range of expression. HDAC10 
expression was significantly different between 25 paediatric brain tumour 
datasets, with normal cerebellum and medulloblastoma (Gilbertson) datasets 
showing particularly increased expression (appendix 11). HDAC11 
expression appeared to be very similar across all datasets but still had 27 
profiles with significantly different expression (appendix 11). 
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2.5 Survival Analysis with Kaplan Meier 
 
Lastly, we wanted to investigate whether differences in HDAC expression 
had any impact upon survival in paediatric patients with a GBM, using a 
bioinformatics approach. We used the R2 database’s Kaplan Meier tool and 
used search criteria to include paediatric, diffuse gliomas with both histone 
deacetylase expression data and ‘overall survival’ data. Just one dataset 
met the requirements: Tumour Glioma Paediatric – Paugh. Tracks were 
used to ensure only WHO grade IV data were included in the survival 
analysis and this left 37 samples, 6 of these did not have survival data so the 
analysis was carried out on 31 samples. Using the ‘Kaplan Scanner’, ‘Kaplan 
Meier by Gene Expression’ was selected which allows the database to sort 
samples into two groups based on the mRNA expression of the gene of 
interest. This method also allows the database to choose the optimal 
survival cut-off based on statistical testing. In order, the database uses each 
increasing expression value as the cut-off and uses a log rank test to 
calculate the p-value. The highest expression value is reported and the 
survival curve is plotted. This way the most significant expression cut-off for 
survival analysis is identified. We hypothesised that changing HDAC 
expression would have a significant impact upon survival in paediatric GBM. 
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Figure 3.14: Kaplan-Meier survival curves showing overall 
survival probability in paediatric GBM with high and low mRNA 
expression of histone deacetylases. 
Survival data from the’ Tumour glioma paediatric’ dataset by Paugh was 
extracted from the R2 database using the Kaplan Meier by gene 
expression tool and ‘Kaplan Scanner’ option. p-values are calculated in 
R2 using a log-rank test. HDACs 3, 10 and 11 expression were found to 
significantly impact upon survival of paediatric patients with GBM 
(p=0.017, p=0.013, p=0.0055 respectively) with all three cases revealing 
lower HDAC expression to have a poorer prognosis and shorter survival 
time. Blue line: high expression; red line: low expression. N=31 
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We analysed survival of paediatric patients with high and low expression of 
HDACs, at the mRNA level, using Kaplan Meier survival curves in the R2 
database. Just one dataset (Paugh Tumour Glioma Paediatric) matched the 
search criteria. Log rank tests were used to calculate the p-value and 
showed that HDACs 3, 10 and 11 had a significant impact on length of 
survival in this cohort (p=0.017, p=0.013, p=0.0055 respectively) (figure 
3.14). All three genes showed a significantly decreased survival time with 
lower mRNA expression compared to survival time with higher expression. 
 
Higher HDAC1 expression appears to be worse but the log-rank test returns 
a p-value of 0.292, showing that in this dataset, there is no significant 
difference in survival probability between patients who have high or low 
HDAC1 expression. The graph shows high HDAC2 expression to have a 
worse survival probability, however, the log-rank test shows a non-significant 
result of p=0.190 for the difference in survival probability between having 
high and low HDAC2 expression. Graphically, it appears that from just 
before 36 months, patients in this dataset with low HDAC8 expression have 
a clear survival advantage over those with high HDAC8 expression. 
However, the log-rank test shows there to be no significant difference in 
survival probability between high and low HDAC8 expression in these 
patients. The survival curve shows that up to just past 72 months, low 
HDAC4 expression have a slight advantage in survival probability but this 
switches, and lower HDAC4 expression has the poorer survival probability. 
The log-rank test shows there to be no significant difference (p=0.375) in 
survival probability between the two groups in this dataset. The survival 
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curves for high and low HDAC5 expression follow each other closely and the 
log-rank test confirms there is no significant difference (p=0.236) in survival 
probability between the two groups. From around 24 months, patients with 
low HDAC7 expression appear to have a survival advantage. The log-rank 
test reveals there is no statistically significant difference (p=0.140) in survival 
probability between those with high HDAC7 expression and those with low 
HDAC7 expression. Similarly to HDAC8, low HDAC9 expression appears to 
show a survival advantage in this dataset compared to high HDAC9 
expression. However, the log-rank test shows there is no significant 
difference (p=0.418) in survival probability for patients, between the two 
groups in this dataset. The graph shows high HDAC6 expression in the first 
24 months to have a better survival probability but after this time point there 
is little difference, with lower HDAC6 expression having the slight advantage. 
The log-rank test shows there to be no significant difference (p=0.361) in 
survival probability for patients in this dataset with high or low HDAC6 
expression. 
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3.0 Discussion 
 
We used a bioinformatics approach to systematically analyse histone 
deacetylases in paediatric glioblastoma. We wanted to evaluate expression 
of HDACs in tissue from a larger number of pGBM samples than we would 
otherwise be able to obtain. We used the R2 Database to collect large 
quantities of expression data to increase the validity of our results and to 
ensure to the best of our ability that any results we obtained were 
representative. To minimise variation, we ensured all datasets we used were 
from the same microarray chiptype, Affymetrix Gene Profiling Array U133 
P2. Using the R2 database, we were able to identify three datasets (Donson, 
Paugh and Pfister) that matched the search criteria for pGBM. Despite the 
unavoidable variation between datasets and patients, we found a 
consistency in HDAC expression across pGBM datasets, with HDAC2 
showing the greatest variation and range of expression values. Class I 
HDACs generally showed higher levels of expression with class II and IV 
showing lower levels. HDAC2 was also found to be the most abundantly 
expressed in pGBM, with HDAC10 showing the lowest expression. These 
findings are in contrast to the findings of (Lucio-Eterovic et al., 2008) who 
looked at HDAC expression in a range of adult astrocytomas and found 
class I HDACs to have lower expression levels to Class II. They also found 
HDAC9 to show the highest expression across all grades of astrocytoma, 
with the lowest expression in HDAC 7 (grade IV), HDAC3 (grade III), HDAC2 
(grade II) and HDAC7 (normal brain). We wanted to use a non-neoplastic 
brain dataset as a control and means for comparison between the pGBM 
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datasets, however, we were unable to find one which would be appropriate 
considering the location of the brain in which these tumours grow.  
 
Due to the novel mutations in the histone H3 gene H3F3A amongst pGBMs 
found in 2012 (Schwartzentruber et al., 2012) and incorporated into the 
latest World Health Organisations guidelines for tumours of the central 
nervous system in 2016 (Louis et al., 2016), we hypothesised that these 
mutations may play a role in HDAC dysregulation. We searched the R2 
database for pGBM datasets containing information on H3F3A subgroups 
and found one dataset (Pfister) that matched our criteria. We analysed 
whether there was any statistically significant difference in HDACs between 
tumours with wildtype H3F3A, K27M mutant and G34R mutant. Surprisingly, 
only HDAC3 showed a significant difference in mRNA expression between 
the two H3F3A mutations, with the K27M mutant showing a lower 
expression to that of the G34R mutant. All other HDACs were found to not 
be significantly dysregulated between H3F3A subgroups in our pGBM 
dataset. However, due to lack of samples, we were unable to evaluate the 
G34V mutation, found in the KNS42 cell line. 
 
It is now accepted that pGBM is molecularly and biologically distinct from 
adult GBM, with many mutations and genes being differentially expressed. 
With this in mind, we wanted to explore whether HDAC expression differed 
between them too so we searched the R2 database for adult GBM datasets. 
Four were found which complied with our criteria (Pfister, French, Hegi and 
Kawaguchi) and we compared these with our three pGBM datasets. We 
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hypothesised that HDACs would be significantly differentially expressed 
between the two groups. HDAC1 showed no significant difference in 
expression between the 2 tumours, but all other HDACs showed significant 
differences. HDAC3, HDAC9 and HDAC11 was decreased in paediatrics 
compared to adults, and HDAC4 HDAC 5 and HDAC7 were increased in 
paediatrics compared to adults. HDACs 2, 6, 8 and 10 had significant 
differences but were not consistently up or down regulated in one cohort 
compared to the other.  
 
We wanted to discover whether HDAC expression was dysregulated in other 
paediatric brain tumours so we increased our search criteria in the R2 
database to include other types of brain tumour. We located 8 other datasets 
in 5 types of paediatric brain tumour (Paugh, Birks, Kool, Grundy, Gilbertson 
and Pfister). We found that there was a significant amount of differential 
expression of HDACs between paediatric brain tumours, although a small 
proportion of this variation may be due to external factors such as treatment 
received, location of tumours, age of patients, laboratory protocols and 
sample handling. We were interested to find that HDAC10 and HDAC11 
were both expressed at very low levels across all tumour datasets, and 
tumours which we had relevant controls for (AT/RT; CNS PNET; and 
medulloblastoma), showed significant down regulation of these HDACs 
compared to controls (normal cerebellum). 
 
We wanted to analyse what effect this dysregulation of HDACs might have 
for these patients in terms of survival probability. We used the R2 database 
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to draw Kaplan Meier survival curves so that we could assess whether 
HDAC expression impacted survival. After finding HDAC10 and 11 
expression to be decreased in expression in our paediatric brain tumour 
datasets, we were intrigued to find that lower expression of HDAC 3, 10 and 
11 all showed a significant decrease in survival times for paediatric patients 
with GBM. 
 
To our knowledge, this is the first time a systematic analysis of HDAC 
expression in paediatric GBM has been carried out despite the frequent 
studies and clinical trials attempting to utilise HDAC inhibitors for the 
treatment of this neoplasm. Our analysis suggests that inhibiting HDACs, 
particularly with broad spectrum inhibitors as are currently being used, could 
be causing off-target effects that are not yet understood. Not only are some 
HDACs already expressed at a lower level in these patients, but survival 
analysis suggests that a low level of expression of some HDAC’s 
significantly decreases length of survival in paediatric patients with 
glioblastoma.  
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Chapter 4. Characterisation of Histone Deacetylases in 
Paediatric GBM Cell Lines 
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1.0 Introduction 
 
The limited literature surrounding histone deacetylases in paediatric 
glioblastoma suggests there may be a beneficial effect from using histone 
deacetylase inhibitors to help treat and potentially sensitize cancer cells to 
chemotherapeutic agents and radiation (detailed in Chapter 1, section 2.3). 
However, many of these studies have not fully assessed the expression 
levels of HDACs in paediatric gliomas and therefore, some inhibitors may 
not be effective. Some HDAC family members, in fact, may be 
downregulated already, as seen in Chapter 3, and further inhibiting their 
expression could lead to further problems. As discussed in Chapter 1, 
section 2.2, HDACs are crucially implicated in a range of functions in the 
brain and during neural development, so targeting these enzymes, 
particularly in children, could result in damaging vital functions within the 
brain. 
 
To complement the information gained from analyses of patient data using 
the R2 Genomics and Visualization Platform (Chapter 3), the expression 
level of HDACs at both the mRNA and protein level in two pGBM cell lines 
(SF188 and KNS42) and a foetal astrocyte cell line was examined. We 
predicted that the expression of HDACs would significantly differ in the 
pGBM cell lines compared to the foetal astrocyte control. Prior to 
bioinformatics analyses, on account of the literature, we initially anticipated 
that HDAC expression in both pGBM cell lines would be overexpressed, 
compared with the foetal astrocyte control cell line.  Due to their rapid 
 158 
proliferation and size, many pGBM’s have large areas of hypoxia; therefore 
experiments to determine if HDAC expression is regulated by hypoxia were 
performed. (Pluemsampant, Safronova, Nakahama, & Morita, 2007) showed 
hypoxia lead to an increase in HDAC expression. Our hypothesis is that 
HDAC expression in pGBM cells would be higher when cultured in hypoxia 
compared to normoxia.  
 
To characterise cell lines at the mRNA level, a custom focused RT2 PCR 
Profiler Array consisting of HDAC genes 1-11, and a range of tumour 
suppressor genes and oncogenes were included (Appendix 2) . RNA from 
foetal astrocyte cell line CC2565, and paediatric GBM cell lines KNS42 and 
SF188, was isolated following treatment of normoxic or hypoxic (1%) 
environments for a period of 48 hours. RNA was analysed to ensure purity 
and integrity and reliable results from downstream assays. Equal quantities 
of RNA was used to synthesis cDNA, which was then loaded in equal 
volumes onto RT2 PCR profiler arrays (Qiagen). Data were analysed using 
the Qiagen Data Analysis Centre available on the Qiagen website. All data 
were normalised with the same housekeeping genes. In the first round, 
seven comparisons were performed (Table 4.1).  
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Table 4.1: Table showing the various analyses carried out from RT2 PCR 
Profiler Array data, using Qiagen’s Data Analysis Center. 
 
Comparisons  
CC2565 normoxic vs. hypoxic 
SF188 normoxic vs. hypoxic 
KNS42 normoxic vs. hypoxic 
CC2565 normoxic vs. SF188 normoxic 
CC2565 hypoxic vs. SF188 hypoxic 
CC2565 normoxic vs. KNS42 normoxic 
CC2565 hypoxic vs. KNS42 hypoxic 
 
 
In the second round of arrays, we concentrated on one cell line (pGBM - 
KNS42) to ascertain whether hypoxic (1%) environments had any influence 
on HDAC gene expression compared to the normoxic environment. Due to 
the limited number and expense of RT2 profiler arrays, round one was done 
as a preliminary study to inform and guide us as to which HDACs to 
investigate further, so n=1. This allowed round 2 to focus in on the normoxic-
hypoxic influence and we could perform the experiment in triplicate. 
 
The same cell lines detailed in table 4.1 were exposed to identical 
environmental conditions for the same length of time before being either 
fixed and stained for immunocytochemistry, or lysed and equal quantities run 
together on a polyacrylamide gel electrophoresis. All western blots used 
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Cyclophilin A as a loading control and used chemiluminescence detection. 
Representative western blots shown with graphs for densitometry analysis of 
triplicates. 
 
All experiments were performed in triplicate unless otherwise stated. 
 
Raw data from the PCR Profiler Arrays was uploaded to the Qiagen Data 
Center for analysis where fold regulation change was calculated using the 
delta delta CT method. Relative expression was calculated using the Delta 
CT method using a reference gene, as described by BioRad’s Real-Time 
PCR Apllications Guide. Densitometry analysis of western blots was 
conducted in Image J and relative graphs plotted in GraphPad Prism 7 
software.  
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2.0 Results 
 
2.1 RNA Quality and Quantification 
 
 
RNA was isolated from our paediatric GBM and foetal astrocyte cell lines 
following incubation in normoxic and hypoxic conditions using the RNeasy 
mini plus kit. RNA was quantified using the Agilent Technologies RNA 6000 
Nano assay and Bioanalyzer. This allows total RNA quantification and 
provides the RNA Integrity Number (RIN) which represents the integrity of 
the RNA determined by the entire electrophoretic trace. The RIN 
classification uses numbers 1-10, with 1 indicating the most degraded profile 
and 10, the most intact. A high quality electropherogram should show a 
small marker peak first, followed by 2 ribosomal peaks, as shown in the 
example, representative electropherogram in figure 4.1. 
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Figure 4.1: Representative electropherogram of RNA isolated 
from pGBM and foetal astrocyte cell lines, for RT2 PCR Profiler 
Arrays. 
Paediatric cell lines was incubated for 48 hours under normoxic or 
hypoxic conditions. RNA was isolated using RNeasy Plus mini kit and 
quantified using the Agilent Technologies RNA 6000 Nano Assay and 
Bioanalyzer. RNA was used for analysis of HDAC expression.
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RNA integrity is critical when performing PCR.  We used Agilent RNA 6000 
Nano chips in conjunction with the Bioanalyzer to analyse RNA 
concentration and quality. All of the RNA shows a high integrity, with almost 
all samples having a RIN of 9 or above, indicative of high quality RNA with 
little degradation shown in figure 4.1. All samples are of a high quality and 
can be used for the RT2 PCR Profiler Arrays.
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2.2 HDAC mRNA Expression in cell lines 
 
The first round of arrays were used to determine if there were any 
differences in HDAC expression between the two paediatric cell lines 
(KNS42 and SF188) and the foetal astrocyte control cell line (CC2565). One 
plate per cell line, per condition was used. Fold change of mRNA expression 
is shown in figure 4.2. The manufacturer advises a more than 2-fold change 
to be substantial.  
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Figure 4.2: Fold change of mRNA expression of HDACs in pGBM 
cell lines (KNS42; SF188) compared to foetal astrocyte cell line 
(CC2565) under normoxic conditions. 
Custom real time RT2 PCR arrays were performed and data analysed in 
Qiagen’s Data Analysis Center. Horizontal lines indicate the threshold 
for a 2 fold difference. N=1 
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Fold change has been shown as a more meaningful way to represent the 
data considering we do not have the replicate data to be able to do statistical 
analysis. There is clearly variation between the two pGBM cell lines in their 
HDAC expression when compared to the foetal astrocyte cell line. In class I, 
HDACs 3 and 8 are shown to have a more than 2-fold decrease in 
expression (KNS42) and HDAC1 a more than 2-fold increase in expression 
(SF188) compared to CC2565. Class IIa noticeably shows HDAC4 to have a 
more than 2-fold decrease in mRNA expression in both pGBM cell lines 
compared with the foetal astrocyte control. Interestingly, HDAC9 expression 
in both cell lines reached the 2-fold cut off point compared to control, but 
KNS42 expression was increased and SF188 expression was decreased. It 
appears that HDAC11 expression is greater than 2-fold lower in the two 
pGBM cell lines compared with controls. Within Class IIb, there is a 10-fold 
decrease in HDAC10 expression in KNS42 cells compared to CC2565 but 
SF188 failed to reach the 2-fold threshold.  
 
Under hypoxic conditions in the KNS42 cell line compared to controls treated 
the same way, HDACs 4, 6, 10 and 11 had further decreased in expression, 
whilst HDAC9 had further increased. In SF188 cells under hypoxia, HDAC1 
increased expression again, compared to controls, and HDAC11 further 
decreased in expression. Appendix 12 shows all fold changes of HDACs in 
pGBM cells in hypoxia (1%). While these are interesting observations, 
validation of individual HDAC expression is needed.  
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After obtaining a general survey of HDAC expression in pGBM cell lines and 
normal astrocytes, the next step was to investigate more thoroughly the 
influence of hypoxia on HDAC mRNA expression in the pGBM cell line, 
KNS42. As discussed earlier, a previous study (Pluemsampant et al., 2007) 
reported hypoxia to influence HDACs and initial analysis suggests hypoxia 
may play a role in influencing HDAC expression in our cell lines. Cells were 
either cultured in normoxic or hypoxic conditions for 48 hours, as before. 
 
Although small differences are seen between normoxic and hypoxic relative 
expression in all classes of HDACs, there was no statistically significant 
differences shown in figure 4.3 (Mann Whitney tests show p values of >0.05 
for all HDACs). 
 
 168 
 
Normoxic Hypoxic
0.7
0.8
0.9
1.0
1.1
1.2
1.3
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC1
Normoxic Hypoxic
2.5
3.0
3.5
4.0
4.5
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC2
Normoxic Hypoxic
0.30
0.35
0.40
0.45
0.50
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC3
Normoxic Hypoxic
0.20
0.25
0.30
0.35
0.40
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC8
Normoxic Hypoxic
0
1
2
3
4
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC4
Normoxic Hypoxic
0.0
0.5
1.0
1.5
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC5
Normoxic Hypoxic
0.15
0.20
0.25
0.30
0.35
0.40
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC7
Normoxic Hypoxic
2.5
3.0
3.5
4.0
4.5
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC9
Normoxic Hypoxic
0.15
0.20
0.25
0.30
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC6
Normoxic Hypoxic
0.00
0.05
0.10
0.15
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC10
Normoxic Hypoxic
0.00
0.05
0.10
0.15
R
el
at
iv
e 
Ex
pr
es
si
on
HDAC11
Class I Class IIa
Class IIb Class IV
 169 
Figure 4.3: Relative mRNA Expression of HDACs in pGBM cell 
line KNS42, comparison between normoxic and hypoxic (1%) 
conditions.   
Custom real time RT2 PCR arrays were used to examine HDAC mRNA 
expression from KNS42 cells incubated under hypoxic or normoxic 
conditions for 48 hours.  Data were analysed using Qiagen’s Data 
Analysis Center and graphs were plotted using GraphPad Prism 7 
software. No statistically significant difference in HDAC expression was 
found between normoxic and hypoxic conditions in our cell line 
(determined by Mann Whitney test, p>0.05). Plot shows lowest and 
highest values and the median expression. N=3 
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2.3 HDAC Protein Expression in Cell Lines 
 
While gaining information in HDAC gene expression is important, because 
these are deacetylases, it would be just as important to examine HDAC 
expression at the protein level. To explore HDAC protein expression in both 
normoxic and hypoxic (1%) conditions, we conducted semi-quantitative and 
qualitative analysis in cell lines CC2565, KNS42 and SF188.  
 
2.3.1 Class I Histone Deacetylases 
 
We analysed protein expression in our pGBM and foetal astrocyte cell lines 
using western blots and immunocytochemistry. Representative western blots 
and of class I HDACs (HDACs 1, 2, 3 and 8), in all cell lines are shown in 
figure 4.4. Densitometry analysis using Image J software is shown, 
representing n of 3. Immunocytochemistry images of HDAC1 (figure 4.5), 
HDAC2 (figure 4.6), HDAC3 (figure 4.7) and HDAC8 (figure 4.8) are shown 
in all cell lines, (CC2565, KNS42 and SF188) under normoxic or hypoxic 
conditions, for 48 hours. 
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Figure 4.4: Western blot analysis of Class I HDACs.  
Left - representative western blots of class I HDACs in foetal astrocyte 
(CC2565) and paediatric GBM (KNS42; SF188) cell lines exposed to 48 
hours of normoxic (N) or hypoxic (1%) (H) conditions. 
To access for equal protein loading, antibody to Cyclophilin A (18 kDa) 
was used. Densitometry analysis of western blots performed in ImageJ. 
Graph shows median expression values. Error bars show the range of 
densitometry values from all experiments analysed. N=3 
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Figure 4.5: Immunocytochemistry images of HDAC1 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188.  
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions.  
HDAC1 (green) seen throughout the nucleus, and seen more abundantly 
in the pGBM cell lines compared to the foetal astrocyte cell line in both 
normoxic and hypoxic conditions (shown by the arrows). Images taken 
using a Zeiss Axioimager ZI epifluorescence microscope equipped with 
a Hamamatsu digital camera and Volocity imaging software (Perkin 
Elmer). Objective: 40 x. Scale bar: 60µm. n=3. HDAC1 – green; Hoechst 
- blue 
 175 
 
 176 
Figure 4.6: Immunocytochemistry images of HDAC2 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188.  
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC2 (green) seen throughout the nucleus across the 
pGBM cell line and the foetal astrocyte cell line. Arrows point to ‘holes’ 
in the HDAC2 staining, thought to be nucleoli. Images taken using a 
Zeiss Axioimager ZI epifluorescence microscope equipped with a 
Hamamatsu digital camera and Volocity imaging software.	Objective: 40 
x. Scale bar: 60µm. n=3. HDAC2 – green; Hoechst - blue
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Figure 4.7: Immunocytochemistry images of HDAC3 expression in 
foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 and 
SF188.  
Cells fixed following incubation for 48 hours of normoxic or hypoxic (1%) 
conditions. HDAC3 (green) seen in the nucleus with small amounts shown in 
the cytoplasm in the pGBM KNS42 cell line and the foetal astrocyte cell line, 
shown by arrows. Images taken using a Zeiss Axioimager ZI epifluorescence 
microscope equipped with a Hamamatsu digital camera and Volocity imaging 
software.	Objective: 40 x. Scale bar: 60µm. n=3. HDAC3 – green; Hoechst - blue 
 
 
 
 
 
 
 179 
 
 
 
 180 
Figure 4.8: Immunocytochemistry images of HDAC8 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188.  
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC8 (green) seen in the nucleus and cytoplasm in 
all cell lines at varying intensities, shown by arrows, but more 
abundantly in KNS42. Images taken using a Zeiss Axioimager ZI 
epifluorescence microscope equipped with a Hamamatsu digital camera 
and Volocity imaging software. Objective: 40 x. Scale bar: 60µm. n=3. 
HDAC8 – green; Hoechst - blue 
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Representative western blots of HDAC1 (62 kDa), HDAC2 (60 kDa), HDAC3 
(49 kDa) and HDAC8 (42 kDa) in CC2565, KNS42 and SF188 under 
normoxic and hypoxic (1%) conditions are shown in figure 4.4. HDAC1 
protein expression is clearly higher in the pGBM cell lines compared to the 
foetal astrocyte cell line shown in the western blot and the densitometry 
analysis. Although no obvious difference can be seen between conditions in 
the single western blot, analysis of replicates shows KNS42 to have a 
slightly increased expression of HDAC1 in the normoxic condition compared 
to the hypoxic one. KNS42 looks to have a slightly higher expression of 
HDAC2 compared to the other cell lines. The protein expression of HDAC2 
is in agreement with mRNA expression shown in figure 4.3, showing little 
difference in expression between the normoxic and hypoxic environments. 
The HDAC3 western blot (figure 4.4) shows bands at 2 molecular weights. 
The lower, more intense band is thought to represent HDAC3 at around 
49kDa. Stronger expression is shown in the pGBM cell lines compared to 
the non-neoplastic foetal astrocyte cell line but each hypoxic band shows 
similar expression to it’s normoxic counterpart, as shown in the densitometry 
analysis and in agreement with mRNA expression shown in figure 4.3. 
HDAC8 is shown to be expressed across all cell lines and all conditions, with 
little difference between them, as shown by the densitometry (figure 4.4). 
 
Immunocytochemistry images in figure 4.5 shows HDAC1 expression is 
abundantly and exclusively in the nucleus throughout all cell lines and 
conditions, at varying intensities. Expression is stronger in pGBM cell lines 
compared to the foetal astrocyte cell line, in both conditions, indicated by 
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arrows. Comparable to HDAC1, HDAC2 shows nuclear expression across 
all cell lines (CC2465, KNS42 and SF188) with no cytoplasmic staining 
apparent in figure 4.6. It appears staining is localized to the nucleoplasm as 
‘holes’, likely to be nucleoli, nuclear bodies and/or nuclear speckles 
(indicated by arrows), in the staining are clearly visible. ICC in figure 4.7 
appears to show stronger staining for HDAC3 in SF188 under both 
conditions compared to the other cell lines. Nucleoplasm HDAC3 expression 
can be seen mostly in the SF188 cell lines. There appears to be a small 
amount of HDAC3 expression outside of the nucleus in CC2565 and KNS42 
cell lines, shown by arrows, potentially representing the golgi apparatus, as 
HDAC3 has been reported to express here. HDAC8 is abundantly expressed 
across the cell lines but appears to be higher in KNS42 cells, shown in figure 
4.8. Expression can be seen in the nucleus as well as in the cytoplasm at 
varying intensities, indicated by arrows. 
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2.3.2 Class IIa Histone Deacetylases 
 
Class II HDACs are split into 2 groups, consisting of HDACs 4, 5, 7 and 9 
(group IIa) and HDACs 6 and 10 (group IIb). 
 
We assessed protein expression of class IIa HDACs in our pGBM and foetal 
astrocyte cell lines under normoxic and hypoxic conditions. Representative 
western blots, with densitometry analysis conducted using Image J software, 
are shown in figures 4.9 (HDAC4, 5, 7 and 9). Immunocytochemistry images 
of HDAC4 (figures 4.10), HDAC5 (figures 4.11), HDAC7 (figures 4.12) and 
HDAC9 (figures 4.13) in CC2565, KNS42 and SF188 are shown, under 
normoxic and hypoxic conditions. 
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Figure 4.9: Western blot analysis of Class IIa HDACs.  
Left - representative western blots of class IIa HDACs in foetal astrocyte 
(CC2565) and paediatric GBM (KNS42; SF188) cell lines exposed to 48 
hours of normoxic (N) or hypoxic (1%) (H) conditions. 
To access for equal protein loading, antibody to Cyclophilin A (18 kDa) 
was used. Densitometry analysis of western blots performed in ImageJ. 
Graph shows median expression values. Error bars show the range of 
densitometry values from all experiments analysed. N=3 
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Figure 4.10: Immunocytochemistry images of HDAC4 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188. 
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC4 (green) seen abundantly in the cytoplasm, 
particularly in KNS42 (under hypoxia compared to normoxia) and SF188 
(under normoxia compared to hypoxia), indicated by arrows. Images 
taken using a Zeiss Axioimager ZI epifluorescence microscope 
equipped with a Hamamatsu digital camera and Volocity imaging 
software. Objective: 40 x. Scale bar: 60µm. n=3. HDAC4 – green; Hoechst 
- blue 
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Figure 4.11: Immunocytochemistry images of HDAC5 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188. 
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC5 (green) seen at varying intensities in the 
cytoplasm and nucleus indicated by arrows. HDAC5 is not visable in 
KNS42 under normoxia. Images taken using a Zeiss Axioimager ZI 
epifluorescence microscope equipped with a Hamamatsu digital camera 
and Volocity imaging software. Objective: 40 x. Scale bar: 60µm. n=3. 
HDAC5 – green; Hoechst - blue 
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Figure 4.12: Immunocytochemistry images of HDAC7 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188.  
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC7 (green) seen in very small quantities mainly 
visible in pGBM cell lines, shown by arrows. Images taken using a Zeiss 
Axioimager ZI epifluorescence microscope equipped with a Hamamatsu 
digital camera and Volocity imaging software. Objective: 40 x. Scale bar: 
60µm. n=3. HDAC7 – green; Hoechst - blue 
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Figure 4.13: Immunocytochemistry images of HDAC9 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188.  
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC9 (green) seen abundantly in the nuclei 
throughout all cell lines, indicated by the arrows. Images taken using a 
Zeiss Axioimager ZI epifluorescence microscope equipped with a 
Hamamatsu digital camera and Volocity imaging software. Objective: 40 
x. Scale bar: 60µm. n=3. HDAC9 – green; Hoechst - blue 
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HDAC4 protein expression (note in this blot the 2 pGBM cell lines are in a 
different position to the other blots) is shown to have a higher expression in 
SF188, with CC2565 and KNS42 having much smaller and less intense 
bands shown in figure 4.9. This contradicts the mRNA expression seen in 
figure 4.2, which shows SF188 to be decreased in expression compared to 
CC2565. However, in agreement with mRNA expression in figures 4.3, there 
is no obvious difference in expression between the normoxic and hypoxic 
conditions in any of the cell lines. KNS42 is shown to have stronger bands 
for HDAC5, compared to CC2565, (contradicting the mRNA expression seen 
in figure 4.2) and SF188 (figure 4.9). Again there is little difference to be 
seen between the normoxic and hypoxic conditions in all 3 cell lines, as 
reflected in the mRNA expression shown in figure 4.3. Using the methods 
and antibodies as described in Chapter 2 section 4, no visible band was 
shown for HDAC7 in figure 4.9 for any cell line under either of the conditions, 
showing that this protein is not detectable in these cell lines. Although 
HDAC9 has a predicted molecular weight of 66kDa, the antibody actually 
detects the protein at around 50kDa (as recorded on the data sheet) and can 
be seen at this weight in our cell lines in figure 4.9. A second strong band is 
also seen at around 180-200kDa in all cell lines under all conditions but it is 
thought this is a non-specific band. HDAC9 is seen as an intense band for 
both CC2565 and SF188 cell lines in normoxia and hypoxia but cannot be 
detected at all in KNS42 under either condition. This contradicts the mRNA 
expression seen in figure 4.2 which shows HDAC9 expression in KNS42 to 
be increased more than 2-fold compared to CC2565. 
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Immunocytochemistry shows HDAC4 expression in figure 4.10 to be 
predominantly cytoplasmic in all cell lines, but nuclear expression is also 
seen. SF188 appears to show a decrease in HDAC4 expression under 
hypoxia compared to the normoxic condition, whereas the opposite is true in 
KNS42 cells (shown by the arrows), but this is not reflected in the western 
blotting shown in figure 4.9. HDAC5, in figure 4.11 is shown speckled 
throughout both the nucleus, and cytoplasm in varying intensities, shown by 
arrows. Staining is intense in KNS42 cells under hypoxia, but no visible 
staining is seen under normoxia. The images in figure 4.12 show very weak 
expression of HDAC7, appearing to be mainly localized to the cytosol where 
visible (indicated by arrows). In contradiction to the western blot (figure 4.9), 
but in agreement with mRNA expression (figure 4.2) HDAC9 can be seen in 
abundance in the nucleoplasm across all cell lines, shown by arrows in 
figure 4.13, with pGBM cell lines appearing to have stronger expression than 
the non-neoplastic cell line.  
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2.3.3 Class IIb Histone Deacetylases 
 
Class IIb HDACs consist of HDACs 6 and 10. Representative western blots 
and relative densities of HDAC6 and 10 protein expression, in CC2565, 
KNS42, and SF188 under normoxic and hypoxic (1%) conditions are shown 
in figure 4.14. Immunocytochemistry images of HDAC6 (figures 4.15) and 
HDAC10 (figures 4.16) in CC2565, KNS42 and SF188 are shown, under 
normoxic and hypoxic conditions. 
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Figure 4.14: Western blot analysis of Class IIb HDACs.  
Left - representative western blots of class I HDACs in foetal astrocyte 
(CC2565) and paediatric GBM (KNS42; SF188) cell lines exposed to 48 
hours of normoxic (N) or hypoxic (1%) (H) conditions. 
To access for equal protein loading, antibody to Cyclophilin A (18 kDa) 
was used. Densitometry analysis of western blots performed in ImageJ. 
Graph shows median expression values. Error bars show the range of 
densitometry values from all experiments analysed. N=3 
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Figure 4.15: Immunocytochemistry images of HDAC6 expression 
in foetal astrocyte cell line CC2565, and pGBM cell lines KNS42 
and SF188. 
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC6 (green) seen abundantly in the nuclei in both 
pGBM cell lines, indicated by arrows. Images taken using a Zeiss 
Axioimager ZI epifluorescence microscope equipped with a Hamamatsu 
digital camera and Volocity imaging software. Objective: 40 x. Scale bar: 
60µm. n=3. HDAC6 – green; Hoechst - blue 
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Figure 4.16: Immunocytochemistry images of HDAC10 
expression in foetal astrocyte cell line CC2565, and pGBM cell 
lines KNS42 and SF188. 
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC10 (green) visible at low levels in SF188 under 
normoxia (shown by arrows). Images taken using a Zeiss Axioimager ZI 
epifluorescence microscope equipped with a Hamamatsu digital camera 
and Volocity imaging software. Objective: 40 x. Scale bar: 60µm. n=3. 
HDAC10 – green; Hoechst - blue 
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KNS42 appears to have a higher expression of HDAC6, (note that cell lines 
KNS42 and SF188 are switched in their positions compared to other blots 
shown) seen in figure 4.14, shown by darker bands, compared to CC2565 
and SF188 under both the normoxic and hypoxic conditions. There is 
potentially a slight increase in the normoxic band compared to the hypoxic 
band. For HDAC10 expression, CC2565 is shown to have the strongest 
bands under both conditions compared to KNS42 and SF188, with both 
pGBM cell lines showing faint bands, consistent with mRNA expression seen 
in figures 4.2 and 4.3. 
 
Immunocytochemistry images of KNS42 and SF188 are shown to have an 
increase in HDAC6 expression compared to the non-neoplastic cell line, 
under both normoxic and hypoxic conditions, shown in figure 4.15. 
Expression is shown as both nuclear and cytoplasmic in varying intensities 
in the neoplastic cell lines but appears as more nuclear in the non-neoplastic 
cell line, indicated by arrows. HDAC10 expression is shown in figure 4.16, to 
be nuclear and cytosolic but at very low intensities and is only visible in 
SF188 under normoxic conditions (shown by the arrows). This is consistant 
with the mRNA expression. 
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2.3.4 Class IV Histone Deacetylases 
 
Class IV HDACs currently contain just 1 member – HDAC11. A 
representative western blot of attempts to probe for HDAC11 protein 
expression in CC2565, KNS42 and SF188 under normoxic and hypoxic 
conditions is shown in figure 4.17 with densitometry analysis of replicates.  
This is followed by immunocytochemistry images of HDAC11 (figure 4.18) in 
CC2565, KNS42 and SF188, under normoxic and hypoxic conditions. 
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Figure 4.17: Western blot analysis of Class IV HDACs. 
Left - representative western blots of class I HDACs in foetal astrocyte 
(CC2565) and paediatric GBM (KNS42; SF188) cell lines exposed to 48 
hours of normoxic (N) or hypoxic (1%) (H) conditions. 
To access for equal protein loading, antibody to Cyclophilin A (18 kDa) 
was used. Densitometry analysis of western blots performed in ImageJ. 
Graph shows median expression values. Error bars show the range of 
densitometry values from all experiments analysed. N=3 
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Figure 4.18: Immunocytochemistry images of HDAC11 
expression in foetal astrocyte cell line CC2565, and pGBM cell 
lines KNS42 and SF188. 
Cells fixed following incubation for 48 hours of normoxic or hypoxic 
(1%) conditions. HDAC11 (green) seen at low levels in foetal astrocyte 
cell line, as indicated by arrows, but not visible in pGBM cell lines under 
either condition. Images taken using a Zeiss Axioimager ZI 
epifluorescence microscope equipped with a Hamamatsu digital camera 
and Volocity imaging software. Objective: 40 x. Scale bar: 60µm. n=3. 
HDAC11 – green; Hoechst - blue 
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There are many non-specific bands seen in figure 4.17 and no band seen 
across all cell lines and conditions at the 39kDa weight expected for 
HDAC11. However, a lower band at around 33kDa can be seen in all cell 
lines and conditions and is thought to be a spliced isoform of HDAC11. 
 
Immunocytochemistry images in figure 4.18 show the non-neoplastic cell line 
to have a higher expression of HDAC11 (indicated by arrows) compared to 
the 2 neoplastic cell lines, where HDAC11 expression is not visible, showing 
continuity with the mRNA expression seen in figure 4.2. Expression looks to 
be nuclear, with a small amount of cytoplasmic expression. 
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3.0 Discussion 
 
There have been a number of research studies and clinical trials aimed at 
utilising various HDAC inhibitors to help in the treatment of paediatric brain 
tumours (Chapter 1 section 2.3). As discussed in Chapter 1 section 1.4, 
there is currently no treatment option for those diagnosed with pGBM that 
offers a significant survival advantage. Therefore research is constantly 
looking for ways to sensitise cancer cells to the current treatment options, 
which would also allow lower doses of chemotherapeutic agents and/or 
radiation to be given, improving the quality of life for the patient.  
 
This research aimed at discovering the individual expression levels of class 
I, II and IV of the histone deacetylase family, at both the mRNA and protein 
level, in paediatric GBM. To our knowledge, this is the first study to 
systematically analyse HDAC expression in this tumour in children. We 
anticipated discovering HDAC enzymes that were over/under expressed in 
this tumour compared to a ‘healthy’ control, to be able to target individual 
dysregulated HDACs.  Our initial observation was that HDAC expression 
was not consistent between our 2 pGBM cell lines; KNS42 and SF188. 
Although this research needs to be carried out on a wider range of pGBM 
cell lines to be applicable to the wider population and to be able to draw solid 
conclusions, it is perhaps a first glimpse at the heterogeneous nature of 
these tumours. In terms of mRNA expression, it appears that the majority of 
HDACs, are in fact hypo-expressed rather than hyper-expressed in pGBM 
compared to the foetal astrocyte control (figure 4.2), in agreement with the 
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one other study which looked at HDAC mRNA expression in both high and 
low grade adult astrocytomas (Lucio-Eterovic et al., 2008). Noticeably, 
HDACs 10 and 11 are shown to have a large decrease (10- and 6-fold 
respectively) in the KNS42 cell line compared to CC2565, which is a much 
larger difference in expression than the other HDACs. Unfortunately, due to 
the expense of the arrays, this particular experiment was only performed as 
n=1, preventing us from making any solid conclusions from this data, but 
indicating that further investigations should be conducted.  
 
Due to the aggressive nature of pGBMs, they often grow rapidly, creating 
areas of hypoxia in the central areas of the tumour as blood vessels are 
leaky and cannot form quickly enough, preventing oxygen from penetrating 
through the outer regions of the tumour. Hypoxia has been found to cause 
changes in gene expression, including HDACs, which were found to 
increase under hypoxic conditions (Pluemsampant et al., 2007). However, 
although we found slight changes in expression of HDACs under hypoxia at 
1% oxygen, we show that there was no statistically significant difference, 
using a Mann Whitney test, in mRNA expression between normoxic and 
hypoxic conditions for any of the HDACs in our pGBM cell line KNS42 (figure 
4.3). In hindsight, we should have used a hypoxia control such as hypoxia 
inducible factor (HIF)-1 for our PCR arrays to verify that we had achieved a 
state of hypoxia within our cells. We attempted to probe for HIF-1a on our 
immunoblots but were unsuccessful with the antibodies used. 
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Protein expression in class I HDACs shown by western blotting and ICC 
largely agree with each other, although we have to be cautious with 
comparing expression amongst ICC images. HDAC1 appears to show quite 
a difference in expression between the foetal astrocyte and pGBM cell lines 
with an increase for the latter, which we see again with HDAC3 although the 
contrast is not as vast. HDAC2 and 8 show consistent expression across all 
cell lines and conditions and as the mRNA data showed, there appears to be 
little difference between normoxic and hypoxic conditions in class I of the 
histone deacetylases. Similar to Lucio-Eterovic et al., 2008, we found all our 
cell lines to show nuclear expression of class I HDACs, however, we found 
HDAC8 to also show strong perinuclear and cytoplasmic expression, 
differing from the adult astrocytomas Lucio-Eterovic described. 
 
We see some interesting patterns of protein expression of class IIa HDACs 
in our cell lines. SF188 shows to have a much higher expression of HDAC4 
than KNS42 and CC2565 looking at the western blot but ICC images do not 
agree and show SF188 to lose HDAC4 expression under hypoxic conditions. 
Expression is shown to be strongly cytoplasmic, with perhaps a weaker 
expression within the nucleus. HDAC5 shows nuclear and cytoplasmic 
expression at varying intensities throughout the cell lines and conditions. 
With the antibodies and methods we used, we could not detect HDAC7 
protein in our cell lines via western blotting. In hindsight we should have 
used a positive control for HDAC7, such as a recombinant protein, to ensure 
our antibody was working, and specific for HDAC7.  We were able to detect 
small amounts of HDAC7 in the nucleus and cytoplasm with 
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immunocytochemistry, but this protein is shown to only be weakly expressed 
in our cell lines. HDAC9 shows an interesting pattern in our western blots as 
we were unable to detect any of the protein in our KNS42 cell line but 
detected strong expression in our other cell lines. We also detected a larger 
band in all our cell lines, at around 150-170kDa, which appears to be 
stronger in KNS42. We are unsure if this is a non-specific band or if we are 
potentially seeing a dimer of HDAC9. HDAC9 ICC suggests there is an 
abundance of HDAC9 protein in our cell lines, including the KNS42 cell line, 
so we should have been able to see something on our western blot. 
 
HDAC6, in class IIb of the HDAC family, was detected at 160kDa, instead of 
the 131kDa weight it is predicted to be. However, the datasheet confirms the 
antibody to detect HDAC6 at 160kDa and we find it to be both nuclear and 
cytoplasmic. HDAC10 protein is detected at much stronger levels in our 
foetal astrocyte cell line compared to both our pGBM cell lines in western 
blots. This is also seen at the mRNA level in the KNS42 cell line but not in 
the SF188 cell line. HDAC10 is seen at very low levels in ICC, both in the 
nucleus and cytoplasm. We were unable to detect class IV HDAC11 in our 
immunoblots, although we did detect a smaller band at 33kDa which may be 
an isoform of HDAC11 and we did detect the protein with ICC, in the 
nucleus, with small amounts in the cytoplasm, particularly in the foetal 
astrocyte cell line. However, in hindsight we could have used a recombinant 
HDAC11 protein as a positive control for our western blots, as with HDAC7. 
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Evaluating the overall picture, it is HDACs 10 and 11 that particularly stand 
out, and not because they are over-expressed in pGBM, but because they 
are under-expressed in pGBM compared to our control. Although we show 
that there was no significant difference between normoxia and hypoxia on 
HDAC expression, there is a significant difference in expression between 
neoplastic and non-neoplastic cell lines. These results beg the question, why 
are non-specific HDAC inhibitors being used to try to help treat pGBM when 
many HDACs are already down regulated? Especially when put together 
with our bioinformatics data we then questioned whether, in fact, we should 
be doing the opposite. Due to the trouble we had detecting HDAC11 protein 
in our cell lines, we decided to further investigate HDAC10, and discover 
whether there was any therapeutic value in increasing HDAC10 expression. 
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Chapter 5.  Targeting Histone Deacetylase 10
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1.0 Introduction 
 
Following the bioinformatic analysis and in vitro studies characterising 
mRNA and protein expression of HDACs, together with the available data in 
the literature, we wanted to explore further, the role of HDAC10 in paediatric 
GBM. We were surprised to observe that high expression of a few of the 
HDACs (3, 10 and 11) seemed to be significantly associated with an 
increase in survival (p=0.017, p=0.013, p=0.0055 respectively) (Figure 3.14, 
Chapter 3). Based on this information and with our in vitro studies (described 
below) we were interested in whether the overexpression of HDAC10 would 
provide any therapeutic advantage in pGBM. Due to survival analysis 
suggesting a significant increase in survival probability with high HDAC10 
expression, coupled with our finding that pGBM appeared to have a 
decrease in expression of HDAC10, we hypothesised that overexpression of 
HDAC10 may cause a decrease in proliferation, viability and invasiveness of 
pGBM cells.  
 
HDACs function to modulate chromatin structure and are known to be 
involved in development, transcription and cell cycle progression (Li & Zhu, 
2014). HDAC10 deacetylates lysine residues located on the N-terminus of 
Histones, H2A, H2B, H3 and H4. And by doing so, function to repress 
transcription.  
 
In chapter 4, we showed that HDAC10 mRNA expression was 
downregulated 10-fold in the pGBM cell line KNS42, compared to the foetal 
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astrocyte control cell line CC2565 under normoxia (figure 4.2). Preliminary 
mRNA analysis also showed HDAC10 expression to drop further, to a 15-
fold decrease in expression in KNS42 cells compared to CC2565 cells when 
under hypoxic conditions (figure 5.1a). Additionally, protein analysis was 
shown to support the decrease in HDAC10 expression seen in KNS42 cells 
compared to CC2565 control cells under both normoxic and hypoxic 
conditions (figure 5.1b), although there was little difference to be noted 
between normoxic and hypoxic conditions within the same cell line (figure 
5.1c). Observationally, although the level of expression may not be 
significantly different between the two conditions, it appears that HDAC10 is 
more concentrated within the nucleus under hypoxia, compared to normoxia 
where HDAC10 appears to be more evenly distributed throughout the 
nucleus and cytoplasm (figure 5.1c). As mentioned above, survival analysis 
with Kaplan Meier curves of data from the R2 database, show paediatric 
GBM patients with higher HDAC10 expression have a statistically significant 
survival advantage (p=0.013) compared to those with lower HDAC10 
expression (figure 5.1d). 
 
 
 216 
 
Normoxic Hypoxic
High Expression
Low Expression
A
B
C
D
HDAC10 75kDa
25	kDa
37	kDa
50	kDa
75	kDa
100	kDa
150	kDa
250	kDa
15 kDa
All
-Bl
ue
Pre
cis
ion
	Pl
us	
Pro
tei
n	L
ad
de
r	
20 kDa
Cyclophilin	 A	(18	kDa)
CC
25
65
 N
CC
25
65
 H
KN
S4
2 N
KN
S4
2 H
SF
18
8 N
SF
18
8 H
Foetal 
Astrocyte Paediatric GBM
N N NH H H
HDAC10 75kDa
25	kDa
37	kDa
50	kDa
75	kDa
100	kDa
150	kDa
250	kDa
15 kDa
All-
Blu
e
Pre
cisi
on	
Plu
s	
Pro
tein
	La
dde
r	
20 kDa
Cyclophilin	 A	(18	kDa)
CC
25
65
 N
CC
25
65
 H
KN
S4
2 N
KN
S4
2 H
SF
18
8 N
SF
18
8 H
Cyclophilin A
HDAC10
Paediatric GBM
N
or
m
ox
ic
H
yp
ox
ic
16µm
16µm 16µm
16µm
 217 
Figure 5.1: Histone Deacetylase 10 in paediatric glioblastoma  
(A) mRNA expression of HDAC10 in pGBM cell line KNS42 compared to 
foetal astrocyte cell line CC2565 was decreased 10-fold and 15-fold 
following 48 hours incubation in normoxic (21% O2) or hypoxic (1% O2) 
conditions respectively, n=1. (B) HDAC10 was decreased at the protein 
level in paediatric glioblastoma cell lines compared to our foetal 
astrocyte cell line, under both normoxic (N) and hypoxic (H) conditions 
for 48 hours, shown by western blot. No significant difference was 
observed between normoxic and hypoxic conditions, n=3. (C) 
Immunocytochemistry images of HDAC10 (red) protein expression in 
pGBM cell line KNS42, following incubation in normoxic and hypoxic 
conditions for 48 hours. HDAC10 can be seen in both the nucleus and 
cytoplasm in both images, appearing less cytoplasmic under hypoxia, 
and more evenly distributed through the nucleus and cytoplasm under 
normoxia, n=3. HDAC10 – red; Hoechst – blue; Cyclophilin – green. 
Images taken with a 64 X objective (oil immersion) on a Zeiss LSM 510 
Meta Axioskop2 confocal microscope using Zeiss Zen software. Scale 
bar: 16µm (D) Kaplan Meier survival curve in paediatric patients with 
glioblastoma showing those with high HDAC10 expression have a 
significant survival advantage compared to those with low HDAC10 
expression. Data extracted from the R2 database using Paugh’s 
paediatric glioma dataset and selecting for WHO grade IV. 
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The literature on HDAC10 is still in its infancy in terms of our understanding 
of HDAC10’s interactions and the processes it is involved in. Moreover, to 
our knowledge, there is currently no published literature on the role of 
HDAC10 in paediatric GBM. Although HDAC10 has been reported to 
correlate with poor prognosis in neuroblastoma cells (Oehme et al., 2013), 
lower expression was indicative of poor prognosis in lung cancer patients 
(Osada et al., 2004) and increased HDAC10 expression was found to inhibit 
invasion and metastasis in patients with cervical squamous cell carcinoma 
(Song et al., 2013). HDAC10 expression was found to be decreased in 
gastric cancer and renal cell carcinoma (RCC) tissues compared to matched 
healthy tissue with gastric cancer patients having a significant decrease in 
survival (Jin et al., 2014) and lower expression having an association with 
proliferation, invasion and more advanced stage of disease in RCC patients 
(Fan et al., 2015).  
 
Despite the data discussed, and the evidence that HDACs are essential in 
brain development and for healthy brain function (discussed in chapter 1), 
clinical trials still take place using non-specific HDAC inhibitors, to aim at 
treating paediatric high grade brain tumours.  
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2.0 Methods  
 
Full length HDAC10 in pMD18-T vector was purchased from Sino Biological.  
Using a ligase independent cloning method (In-Fusion, Clontech), attempts 
to insert a PCR amplified HDAC10 into the cloning vector pIRES2-ZsGreen1 
failed.   
 
The pIRES2-ZsGreen1 vector was purchased from Clontech and contains a 
CMV promoter, multiple cloning site region, internal ribosome entry site 
(IRES) allowing two proteins to be simultaneously expressed from a single 
RNA transcript and the Zoanthus sp. Green fluorescent protein (ZsGreen). 
This vector also contains a neomycin-resistance region for selection of 
stable clones in culture. Vector maps are shown in figure 2.26 and 2.27. 
After multiple attempts using the In-Fusion method and due to time 
constraints, an EcoR1 and BamH1 flanking HDAC10 PCR fragment and the 
pIRES2-ZsGreen1 were sent to Eurofins Genomics Services for cloning (QC 
and sequence in appendix 4 and 5).  
 
Following independent sequencing of the pIRES2-ZsGreen1-HDAC10 
vector, both transient and stable transfections were initiated in KNS42 cells. 
Prior to stable transfections, kill curves using G418 were conducted to 
optimise concentration needed to select (appendix 6). Observations from 
multiple transient transfections include poor transfection efficiency and 
viability of transfected KNS42 cells (appendix 7).  
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In stable transfection experiments of KNS42 cells with pIRES2-ZsGreen1-
HDAC10 and vector control with 400 µg/ml G418, colonies formed only after 
many days. Several attempts were made to grow individual colonies after 
selection however, after weeks of feeding, few of the colonies survived. It is 
only after months of feeding that we may have KNS42/HDAC10 and 
KNS42/Vector Control clones, although expression is yet to be analysed. It 
may be that an inducible system would have been a better choice of a 
method to test the effects of up-regulation of HDAC10 in pGBM cell lines 
allowing the gene to be switched on when required which would be a useful 
method to discover whether the upregulation of the gene is proving to be 
toxic to the cells. One explanation for the difficulty could be due to the size of 
HDAC10 (2.1kb) combined with the available means to transfect our cells. 
Tong et al. (Tong, 2002) tried to up-regulate HDAC10 expression in HEK293 
and HEK293T cells but reported that for unknown reasons, they were unable 
to express full length HDAC10. Instead they were forced to use a viral 
vector, which we are not able to facilitate.  
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Figure 5.2: Brightfield images taken 1 month after transfection 
of attempts to produce stable clones with paediatric 
glioblastoma cell line, KNS42.  
(A) pIRES2-ZsGreen1-Ctrl cells were transfected with the control vector 
using jetPRIME® transfection reagent and selected for in 400µg/mL G418 
antibiotic. Cells are ~80% confluent and ready to be passaged indicating 
growth and proliferation. (B) pIRES2-ZsGreen1-HDAC10 cells were 
transfected using jetPRIME® and selected for in 400µg/mL G418 
antibiotic. In contrast to the vector control cells, we see a single cell at 
a lower confluence than when transfected with what appears to be a 
number of vesicles. Images taken using the FLoid® Cell Imaging Station 
with a 20 X objective, scale bar 100µm. Using Microsoft Powerpoint, both 
images were set to 80% contrast to better show the cell in image B. 
 
A
B
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3.0 Alternative Approaches to examine the role of HDAC10  
 
Due to our unsuccessful attempts to over-express HDAC10 in the KNS42 
cell line, we sought to determine what is known concerning the regulation of 
HDAC10. As expression of some HDACs are influenced by hypoxia, could 
HDAC10 expression be induced by this or some other molecules or by post 
translational modification? For example Pluemsampant et al., reported that 
HDAC 1, 2 and 3 were activated following hypoxia induced protein kinase 2 
(CK2) phosphorylation (Pluemsampant et al., 2007). CK2 is implicated in a 
number of cellular processes such as cell cycle control, transcription and 
apoptosis and may contribute to tumourigenesis (Tsai & Seto, 2002). A 
further PubMed search revealed 3 publications implicating CK2 in HDAC 
activation via phosphorylation, regardless of hypoxia (Tsai & Seto, 2002); 
(Pflum, Tong, Lane, & Schreiber, 2001); (Eom et al., 2011). It is currently 
unknown whether there is an interaction between HDAC10 and CK2, 
however, HDAC10 was found to interact with and bind with protein 
phosphastase 1 (PP1) (Brush et al., 2004) suggesting HDAC10 can be 
phosphorylated. A number of protein kinases, receptors, transcriptional 
regulators and other activators of phosphorylation have been found for the 
class II histone deacetylase family member HDAC5 (Chang, 
Bezprozvannaya, Li, & Olson, 2005), which may be worth exploring for 
HDAC10. It has been proposed that the calcium/calmodulin-dependent 
kinase (CaMK) signalling pathway may be activated by these stimuli and 
play a role in phosphorylation of HDACs creating a 14-3-3 docking site. 
Binding of the chaperone protein 14-3-3 can mask the nuclear localization 
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sequence which leads to the nuclear export of the HDAC complex 
(McKinsey, Zhang, & Olson, 2000). Along with CK2, these activators may 
also be worth investigating whether any of them also phosphorylate 
HDAC10, with a means to increasing the Class IIb HDAC.  
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4.0 Discussion 
 
There are many possible reasons for our lack of success in establishing 
HDAC10 clones in our pGBM cell line KNS42. It is possible that the increase 
in HDAC10, or the construct, was toxic to our cells, that the cells were 
rejecting the gene and/or construct or that there was an error in the 
sequence. We had the construct sequenced twice by 2 separate companies, 
minimising the possibility of there being an error in the sequence. Our empty 
vector control, using the same construct, minus the HDAC10 sequence, did 
not show the same issues, minimising the risk of the construct itself being 
toxic to our cells. The HDAC10 gene is relatively big at 2.1kb, potentially 
causing issues. We sought advice from experts in cloning, and from the 
companies we purchased the constructs and cloning material from, and the 
majority of the advice was that the gene was likely too large.  
 
It is not yet understood how HDAC10 is regulated or by what, we can only 
postulate alternative targets and mechanisms for future research to 
investigate. There is still much work to be done to increase our knowledge 
and understanding of HDAC10, how it is regulated, and by what, and 
whether HDAC10 is a feasible and promising target in fighting pGBM.  
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Chapter 6. Discussion 
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Paediatric glioblastoma is a devastating and ultimately fatal diagnosis. Whilst 
it is now accepted that the paediatric neoplasm is a separate entity to the 
adult disease, research into pGBM is still far behind where is should be and 
as yet, little therapeutic value has been gained for these patients. The field 
of epigenetics is picking up pace in the area of pGBM with some important 
discoveries being made in the past 5 years, notably the H3F3A mutations 
now included in the World Health Organisation’s classification of tumours of 
the central nervous system (Louis et al., 2016).  
 
The aims of this study were: (1) to investigate expression levels of histone 
deacetylases using the R2: Genomics Analysis and Visualisation Platform; 
(2) characterize two paediatric glioblastoma cell lines in terms of HDAC 
expression at the mRNA and protein level; (3) determine the impact on 
viability and function of targeting dysregulated HDACs in vitro.  
 
Since histone deacetylases have not before been characterised in paediatric 
GBM, our data represents the first systematic analysis of this family of 
proteins in this neoplasm and the first comparison of HDACs in paediatric 
GBM with adult GBM, and with other paediatric brain tumours, as well as 
within the newly identified H3F3A subgroups. We also conducted preliminary 
studies to look at the differences in expression of HDAC’s under hypoxic 
conditions (1% O2) compared with normoxic conditions in this neoplasm, 
which more closely identifies with pGBMs due to their rapid proliferation and 
immature blood vessels. Subsequently, our data may help to identify HDACs 
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worthwhile pursuing for the treatment and maintenance of this childhood 
brain tumour. 
 
Data obtained from bioinformatic analysis demonstrated that, in contrast to 
the only other investigation looking at expression of HDACs in a relevant 
field, adult astrocytomas (Lucio-Eterovic et al., 2008), class I HDACs are 
abundantly expressed at the mRNA level in paediatric GBM, with HDAC2 
showing the highest expression. Class II HDACs are expressed at very low 
levels, again contradicting findings by Lucio Eterovic et al., with HDAC10 
being the lowest HDAC expressed in pGBM. In our analysis, HDAC1 
showed little difference in mRNA expression between paediatric and adult 
GBM, but all other HDACs had significantly different expression between the 
two neoplasms. It was particularly interesting to find that HDAC3, HDAC9 
and HDAC11 were all significantly decreased in pGBM compared to aGBM 
and HDAC4, HDAC5 and HDAC7 were all significantly increased in pGBM 
compared to aGBM. Findings add further proof that the two are different 
tumours at the molecular and biological level. Unfortunately due to the 
availability of the data, there is a disparity between the number of adult GBM 
samples (291) compared to paediatric GBM samples (93). This is a struggle 
reflected in the literature, as adult GBM tissue is much more abundant, 
perhaps partly due to the increased sensitivity surrounding a child and 
because of the accessibility of aGBM in the brain compared to pGBM. In an 
‘ideal’ study, there would not be the range of expression levels seen 
between samples, as shown in figures 3.1-3.4, but it could be argued that 
these results just reflect the true heterogeneity of glioblastomas. It should 
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also be noted that there was no appropriate ‘healthy’ brain control available 
for pGBM in this database, so a vital gap is missing.     
 
The last five years has shown significant advancement in the field of pGBM, 
with the identification of several novel histone mutations (Schwartzentruber 
et al., 2012; Sturm et al., 2012), allowing molecular classification for the first 
time. One dataset in the R2 database contained information on H3F3A 
mutations (Pfister) enabling analysis of HDACs across each subtype: K27M, 
G34R, G34V and wildtype. Unfortunately, due to lack of data, the G34V 
subtype had to be discarded from analysis. Surprisingly, only HDAC3 was 
found to have significantly different expression between the K27M mutation 
and the G34R mutation, shown in figure 3.5. The reason for the surprising 
lack of significantly different expression between H3F3A subgroups may be 
due to the small sample size currently available. It would be interesting to 
conduct the analysis with a larger cohort to see if the results change. 
 
It is perhaps not surprising to find that significant differences lay between 
different paediatric brain tumours in HDAC expression. What was surprising 
was the homogeneous expression of HDACs 10 and 11 throughout the six 
types of paediatric brain tumour analysed. In comparison to HDACs 1-9, 
which show wide ranging expression values across the datasets, HDAC10 
and 11 show a relatively narrow range of expression, with HDAC10 in 
particular showing a very low level of expression at the mRNA level in all 
paediatric brain tumour datasets, shown in figure 3.13. For the paediatric 
tumours where a control was available, HDAC10 and HDAC11 were 
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significantly decreased in the tumour datasets, which included 
medulloblastoma, CNS PNET and AT/RT. 
 
What makes the finding of low HDAC10 throughout the paediatric brain 
tumours analysed more intriguing, is the results from our Kaplan Meier 
survival analysis, shown in figure 3.14, which show a significant decrease in 
survival of pGBM patients with low expression of HDACs 3 (12+ months), 10 
(60+ months) and 11 (72+ months). It is unfortunate that survival data was 
not available for all datasets used. It should also be noted that only one type 
of microarray was used for our analysis, to minimise variation between 
datasets. It would be interesting to validate the results found using a second 
technique. The range of paediatric brain tumours analysed in this study is by 
no means an exhaustive list of all paediatric brain tumours,  since we were 
only able to utilize what was available in the database. It would be 
interesting future work to be able to more thoroughly assess HDAC 
expression across all paediatric brain tumours, with appropriate controls, to 
ascertain whether HDAC10 is under-expressed in all childhood brain 
tumours.    
 
Although this is valuable data, there are always drawbacks when using 
multiple datasets from different laboratories. Differences in protocols, sample 
handling and user ability results in uncontrollable variables between datasets 
themselves. There is also the uncontrollable variables within each dataset 
themselves as tissue is obtained from patients. Tissue may be obtained 
post-mortem, or from a living patient, the biopsy may be from the center of 
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the tumour mass or the outer margins, and so possibly include healthy 
tissue. There are variables between patients in terms of the type and amount 
of treatment they have already received before the surgery has taken place 
– radiotherapy, chemotherapy, clinical trials? Is this the original tumour mass 
or a regrowth of the tumour? Other patient variables to consider are the age 
of the patient and the time since diagnosis. All these factors can impact upon 
the results. As discussed in the introduction, there are many molecular 
subgroups found both within pGBM and aGBM and these are largely 
unaccounted for in our analysis. Where possible variabilities were minimized 
by using data obtained with the same gene chip and selecting ‘tracks’ in the 
database to exclude samples which did not meet the criteria. The raw data 
files were extracted and identical analyses performed to all data. 
 
Despite these issues, these important findings warrant further investigation, 
and it raises the question as to why broad spectrum inhibitors are being 
used in the treatment of these neoplasms.  
 
There have been many studies and clinical trials looking at the use of HDAC 
inhibitors, as detailed in Table 1.4, with the aim of treating or sensitizing 
cancer cells to radiotherapy and/or chemotherapeutic agents, and ultimately 
improving the quality of life of the patient. We wanted to characterise two 
paediatric GBM cell lines in terms of HDAC expression. This meant we could 
also look at expression at the protein level in addition to the mRNA level, 
and compare this against a foetal astrocyte control. Although a foetal 
astrocyte cell line in not an ideal control, due to factors such as the 
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differences in neurodevelopmental stages, the effect this may have on 
expression of HDACs and the unknown situation as to why the foetus was 
terminated (spontaneous miscarriage/fatal illness/disease etc), among 
others, this is the most appropriate control available to us. Paediatric brain 
tissue is very hard to come by, so a perfect control is rarely available. It 
would have been interesting to have been able to also look at tissue in our 
analysis to add strength to our findings but again we were unable to obtain 
any tissue. 
 
The majority of HDACs were found to be hypoexpressed in pGBM compared 
to the control, shown in figure 4.2 which is consistant with Lucio-Eterovic et 
al., 2008 study in adult astrocytoma. In KNS42 paediatric GBM cell line there 
was a large decrease in expression of HDAC10 and HDAC11, by 10- and 6-
fold respectively, at the mRNA level compared to the control. This is 
consistent with the bioinformatic analysis, proving our initial hypothesis; that 
HDAC’s would be over-expressed in pGBM; to be false.  In hindsight, the 
mRNA results should have been validated by a second PCR analysis 
performed in triplicate with all cell lines under both normoxic and hypoxic 
conditions.  
 
As discussed previously, the rapid proliferation coupled with the aggressive 
nature of these tumours causes large areas of hypoxia in the center of these 
tumours. Pluemsampant et al., reported differential expression of HDAC 
genes under hypoxia so we were surprised to find that hypoxic conditions 
(1% O2) had no significant difference in HDAC expression at 48 hours in our 
 232 
cell lines. However, an appropriate hypoxic control, such as HIF1-a should 
also have been included in both mRNA and protein analyses to confirm that 
cells were in fact under hypoxic conditions. It will also be important to 
investigate further, with different time points and hypoxic conditions lower 
than 1% O2. Additionally, we did not look at HDAC activity under hypoxia, 
which may show differences in these conditions and would be vital for further 
study. 
 
Protein expression in class I HDACs is shown in abundance, in agreement 
with bioinformatics analysis, with the exception of HDAC3, and is largely 
nuclear. HDAC8 also shows strong perinuclear and cytoplasmic staining 
throughout the cell lines, contradictory to reports in adult astrocytoma (Lucio-
Eterovic et al., 2008). Class IIa HDACs are shown to be much weaker than 
class I HDACs, which is also a pattern we see from the bioinformatics 
analysis, and in contradiction to Lucio-Eterovic’s study. HDAC7 in particular 
is barely visible in the ICC staining in figure 4.12, and undetected via 
western blotting, shown in figure 4.9. Class IIb expression is shown to be 
very low via both western blotting (figure 4.14) and ICC (figure 4.15-4.16). 
HDAC10 is seen to be decreased in pGBM compared to the foetal astrocyte 
control, as shown in figure 4.14, in agreement with both mRNA expression 
from this study and from bioinformatics analysis. This pattern is also 
observed in class IV HDAC11 (figure 4.17-4.18), although expression was 
undetected via western blotting methods. It is clear not only that pGBM is 
shown again to have very different expression of HDACs compared to 
aGBM, but also that many HDAC’s appear to be hypo-expressed. This is 
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particularly visible with HDACs 10 and 11. It should be noted that controls for 
the protein analysis, particularly HDAC7 and HDAC11, which we were 
unable to detect using the antibodies and protocols described, should have 
been included in the analysis. Even without these controls, it is clear there is 
a huge implication to the clinical setting. The use of HDAC inhibitors should 
be considered very carefully when targeting an already down-regulated 
protein. HDACs have been shown to have a critical role throughout 
development and in the brain, and have even been shown to be beneficial in 
some cancers, as is suggested by the survival analysis in this study and 
numerous reports in the literature. The data suggest individual cases should 
be assessed before treatment with such inhibitors.  
 
We attempted to investigate the role of HDAC10 by using molecular cloning 
and transfections to determine if the over-expression of HDAC10 in KNS42 
cells led to a change in cellular function and viability. We were unable to 
express the full length HDAC10 gene in our cells.  
 
Future studies should use an inducible system to determine if expressing 
HDAC10 is having an effect on cell viability and proliferation of clones. This 
would also enable assessing the role of HDAC10 on cellular function. 
Research could continue to discover whether HDAC10 plays a role in 
autophagy in pGBM as has been highlighted in some other tumour types. It 
would also be interesting to assess the effect HDAC10 has on the cell cycle, 
since there are reports to suggest HDAC10 is able to regulate G2/M 
transition. Further to this, assessing whether this regulation causes a change 
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in HDAC10 localisation would provide vital insight, since it is not currently 
understood why HDAC10 shuttles between the nucleus and cytoplasm. 
It would be interesting to investigate whether increased expression of 
HDAC10 has an effect on the sensitivity of pGBM cells to chemotherapeutic 
agents, such as Vincristine, commonly used against this neoplasm. 
Subsequently, if this was the case, further long term research should 
evaluate how HDAC10 could be used for therapeutic benefits in the clinic. 
Further research could also investigate HDAC activity and the correlation 
between expression and activity.  
 
The finding that HDAC10 particularly, is hypo-expressed in paediatric 
glioblastoma cells warrants further investigation. Our results suggest that we 
should not be giving children with this neoplasm broad spectrum HDAC 
inhibitors before at least assessing individual cases, as whilst it may be 
appropriate for some, it may not be appropriate for all patients, and in fact, 
may be inhibiting a survival advantage. Future experiments should focus on 
increasing our understanding of HDAC10, and what regulates HDAC10, as 
well as identifying whether HDAC10 could be an effective target to exploit in 
the treatment of paediatric glioblastoma.     
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Appendix 1: Certificate of Analysis for Foetal Astrocyte Cell Line 
CC2565. 
 
 
 
 
 
Tissue Acquisition Number *** *** 27541
DONOR CHARACTERISTICS
Age *** *** 16 WG
Sex *** *** MALE
Race *** *** UNKNOWN
VIRUS TESTING
HIV Test *** *** Not Detected
HBV Test *** *** Not Detected
HCV Test *** *** Not Detected
MICROBIAL TESTING
Sterility Test                          *** *** Negative 
Mycoplasma                              *** *** Negative 
CELL PERFORMANCE TESTING
Cell Passage Frozen                     1
Viability                               >= 70% *** 96 %
Cell Count (Cells/ml)                   >=1,000,000 *** 2270000 
Seeding Efficiency                      >=50% *** 57 %
Doubling Time (hours)                   15 48 26 hrs
Glial Fibrillary Acid Protein           >=80% Positive *** Pass 
_____________________________________________________________________________
These cells were isolated from donated human tissue after obtaining permission for their use in research applications by informed consent or legal authorization.
This product is for research use only.  Details concerning the use of our cell and media products can be downloaded from our website at
www.lonza.com/cell-protocols.
In addition to the specifications listed above, the following are guaranteed for all lots of this product using Lonza's Clonetics (TM) and Poietics (TM) Media,
Reagents, and Protocols: Total Population Doublings >=10.
Printed on, 21-Apr-2017 12:24   Page 1 /    1
______________________________________________________________________________
This lot has been reviewed by Quality Assurance in compliance with requirements of Lonza's Quality System.
This document was generated from a validated Part 11-compliant electronic system and thus handwritten signatures are not required.
_______________________________________________________________________
                           For Technical Assistance, call 1-800-521-0390
_____________________________________________________________________________
TEST (Method) SPECIFICATIONS
 Min. Max. Results
_____________________________________________________________________________
Product Code: CC-2565 Lot Number: 0000412568
Product: NHA-Astrocytes Manufacture Date: 25-Apr-2014
AGM, Cryo amp
CERTIFICATE OF ANALYSIS
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Appendix 1: Certificate of Analysis for Foetal Astrocyte Cell Line CC2565. 
Cells were purchased from Lonza. Normal Human Foetal Astrcocyte cell line 
CC2565 was purchased from Lonza to be used as a control in our 
experiments with paediatric glioblastoma cell lines. Each cell line is tested by 
Lonza for a range of markers, growth curves and contaminants. Certificate of 
analysis details all results and indicates gender and gestation of foetus. 
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Appendix 2: Genes on RT2 PCR Profiler Arrays. 
 
  
 
Appendix 2: List of genes on RT2 PCR Profiler Arrays. Custom RT2 PCR 
Profiler Arrays were purchased from Qiagen to assess expression of genes, 
particularly HDACs 1-11, at the mRNA level. In customising the array, we 
could choose groups of genes from a set of ‘off the shelf’ arrays.  We chose 
the 11 HDAC genes, with a pre-defined array of tumour suppressor genes 
and oncogenes. Arrays were used for analysis of mRNA expression in 
pGBM cell lines (KNS42; SF188) and a foetal astrocyte control (CC2565). 
Gene	Symbol Gene	Symbol Gene	Symbol
BCR HDAC1 BAX PML HIC1 ACTB
EGF HDAC2 BCL2L1 PRKCA IGF2R B2M
ERBB2 HDAC3 CASP8 RAF1 MEN1 GAPDH
ESR1 HDAC4 CDK4 RARA MGMT HPRT1
FOS HDAC5 ELK1 REL MLH1 RPLP0
HRAS HDAC6 ETS1 ROS1 NF1 GUSB
JUN HDAC7 HGF RUNX1 NF2 HGDC
KRAS HDAC8 JAK2 SRC RASSF1 RTC
MDM2 HDAC9 JUNB STAT3 RUNX3 PPC
MYC HDAC10 JUND ZHX2 S100A4
MYCN HDAC11 KIT	(CD177) ATM SERPINB5
NFKB1 KITLG BRCA1 SMAD4
PIK3C2A MCL1 BRCA2 STK11
RB1 MET CDH1 TP73
RET MOS CDKN2B TSC1
SH3PXD2A MYB CDKN3 VHL
TGFB1 NFKBIA E2F1 WT1
TNF NRAS FHIT WWOX
TP53 PIK3CA FOXD3 XRCC1
Gene	Symbol
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Appendix 3: Raw CT Values from RT2 PCR Profiler Arrays 
 
	 CC2565 Normoxic CC2565 Hypoxic SF188 Normoxic SF188 Hypoxic KNS42 Normoxic KNS42 Hypoxic 
Gene Symbol Control Group Test Group 1 Test Group 2 Test Group 3 Test Group 4 Test Group 5 
BCR 29.69 30.42 27.64 28.19 30.14 32.51 
EGF 31.35 31.06 31.20 33.06 28.41 29.92 
ERBB2 26.99 28.39 27.49 28.23 31.55 34.23 
ESR1 36.24 37.26 36.89 37.11 37.71  
FOS 29.54 31.38 27.32 28.51 29.16 30.39 
HRAS 26.30 28.13 25.15 25.32 27.16 29.12 
JUN 25.97 27.19 25.25 26.02 29.48 30.13 
KRAS 26.29 27.52 24.27 24.77 26.15 28.38 
MDM2 23.72 24.84 24.56 25.04 26.04 28.48 
MYC 26.90 28.31 20.55 21.34 26.83 27.70 
MYCN 31.21 31.95  37.33 24.85 27.09 
NFKB1 27.52 28.65 26.05 26.56 28.84 31.35 
PIK3C2A 26.73 28.31 24.40 25.01 25.92 28.29 
RB1 25.49 26.80 25.01 25.39 25.30 27.36 
RET 33.20 33.21 35.08 37.40 35.64 37.79 
SH3PXD2A 25.42 26.24 25.91 26.90 37.47 38.37 
TGFB1 24.48 25.52 22.05 22.28 27.12 29.16 
TNF   34.40 35.72 36.40  
TP53 24.73 25.91 21.75 22.34 26.49 29.27 
HDAC1 27.31 28.82 23.63 23.98 26.34 28.91 
HDAC2 24.09 25.31 22.51 23.02 23.51 25.53 
HDAC3 26.73 28.05 24.36 25.19 27.14 29.89 
HDAC4 25.48 26.18 25.11 25.83 25.98 28.78 
HDAC5 27.08 27.63 24.17 24.74 27.48 28.91 
HDAC6 27.80 28.37 24.89 26.07 28.09 30.93 
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HDAC7 26.82 28.05 25.05 26.22 26.90 29.29 
HDAC8 27.54 28.54 24.49 25.30 27.77 29.55 
HDAC9 26.61 27.60 26.14 26.73 24.03 25.74 
HDAC10 30.37 30.78 27.50 29.22 32.65 36.56 
HDAC11 29.31 29.84 28.64 30.39 30.92 34.13 
BAX 24.18 24.98 22.97 23.75 27.30 29.18 
BCL2L1 25.19 26.05 25.65 26.72 28.21 31.01 
CASP8 27.43 28.69 25.01 25.32 28.44 31.49 
CDK4 25.02 25.87 18.20 18.25 25.37 28.09 
ELK1 26.61 27.74 25.15 26.17 31.59 34.73 
ETS1 26.89 27.82 25.37 25.59 31.17 31.92 
HGF 34.58 35.45 28.10 28.30   
JAK2 29.23 30.08 28.03 28.83 28.49 30.70 
JUNB 26.07 27.13 24.64 25.87 29.85 30.65 
JUND 25.13 25.71 24.47 25.41 27.77 29.00 
KIT (CD177) 28.70 29.75 34.25 36.19   
KITLG 26.09 27.07 26.68 27.06 26.65 28.54 
MCL1 23.71 24.40 22.18 22.41 22.17 22.45 
MET 26.29 27.23 23.78 24.08 28.10 30.04 
MOS 39.28  39.01 37.30 38.04 39.01 
MYB 33.36 34.24 27.65 28.48 31.92 35.96 
NFKBIA 25.64 26.70 23.41 24.58 27.33 29.11 
NRAS 25.40 26.25 24.06 24.35 25.16 27.70 
PIK3CA 26.42 27.25 24.72 25.14 25.02 26.49 
PML 25.58 26.26 24.47 25.35 28.93 30.50 
PRKCA 26.26 27.09 24.07 24.31 25.72 27.97 
RAF1 25.04 25.93 24.01 24.63 25.97 28.57 
RARA 26.35 27.18 25.27 25.87 28.79 29.77 
REL 28.18 28.76 25.75 26.49 27.14 29.03 
ROS1 38.15  37.53  37.68  
RUNX1 24.02 24.61 24.44 24.71 26.03 28.30 
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SRC 28.09 28.36 25.47 26.38 34.05  
STAT3 23.82 24.76 22.71 23.26 23.61 25.67 
ZHX2 25.77 26.26 26.80 27.25 27.23 29.82 
ATM 28.50 29.53 26.92 27.60 27.48 29.15 
BRCA1 29.80 31.04 25.23 25.66 27.55 30.63 
BRCA2 30.50 31.14 27.47 27.98 28.54 31.94 
CDH1 33.00 33.75  38.68 35.71 39.43 
CDKN2B 27.42 28.18 27.50 27.29 29.14 30.74 
CDKN3 27.35 28.34 23.49 24.13 25.49 26.22 
E2F1 28.12 29.29 25.10 26.01 28.84 32.73 
FHIT 32.66 33.41 33.75 36.38 30.61 32.63 
FOXD3 37.25  29.01 30.42   
HIC1 27.46 28.08 27.21 28.48 35.79 37.20 
IGF2R 23.15 24.07 22.61 23.23 25.38 28.44 
MEN1 26.91 28.05 24.43 25.24 26.78 30.13 
MGMT 27.83 28.51 26.68 27.89   
MLH1 26.26 27.44 24.64 25.21 26.56 29.50 
NF1 26.22 26.87 27.05 27.64 25.69 27.03 
NF2 25.08 26.16 23.66 24.28 25.40 28.23 
RASSF1 29.10 29.54 28.02 28.92 31.99 33.69 
RUNX3 37.64 37.31 29.13 29.97 35.33 37.61 
S100A4 23.63 24.19 21.00 21.46 26.80 28.35 
SERPINB5    37.16 34.62  
SMAD4 25.83 26.70 24.06 24.59 25.83 28.42 
STK11 26.86 27.28 25.16 26.02 28.39 30.69 
TP73 36.60 38.10 32.70 33.51 35.84  
TSC1 27.08 28.10 25.11 25.76 26.26 28.77 
VHL 26.59 27.61 23.79 24.38 25.25 27.43 
WT1 34.68 33.89 27.57 28.36 37.25 39.38 
WWOX 28.43 29.27 26.13 26.91 27.82 30.94 
XRCC1 27.09 27.92 24.35 25.18 26.94 29.10 
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ACTB 17.42 18.40 15.88 16.46 18.84 21.22 
B2M 18.79 19.54 18.69 19.47 20.99 21.75 
GAPDH 19.74 19.56 18.50 18.61 21.43 22.40 
HPRT1 27.21 27.55 23.22 23.63 26.21 27.77 
RPLP0 19.45 20.37 17.24 17.87 17.95 18.62 
GUSB 26.44 27.14 24.32 24.98 25.41 27.39 
HGDC       
RTC 24.15 24.12 24.25 24.14 24.85 25.66 
PPC 20.57 20.47 20.72 20.53 20.87 21.04 
 
Raw CT values of HDAC expression in all cell lines, exposed to either normoxic or hypoxic conditions for 48 hours. N=1 
 
	 KNS42 N 1 KNS42 N 2 KNS42 N 3 KNS42 H 1 KNS42 H 2 KNS42 H 3 
Gene Symbol Control Group Control Group Control Group Test Group 1 Test Group 1 Test Group 1 
BCR 27.48 27.46 26.99 27.33 26.99 27.64 
EGF 30.30 29.27 28.89 27.90 28.49 29.29 
ERBB2 29.83 30.35 29.33 29.79 29.28 30.46 
ESR1 38.52 35.42 37.28 36.72 36.95 38.39 
FOS 29.52 29.32 29.24 27.16 29.56 30.04 
HRAS 27.68 26.56 26.54 26.82 26.06 27.06 
JUN 28.14 27.66 27.21 27.57 27.02 28.04 
KRAS 27.12 26.27 25.78 25.51 25.64 26.31 
MDM2 26.12 25.52 25.25 25.05 25.08 25.79 
MYC 30.85 30.04 29.74 30.08 29.77 30.23 
MYCN 24.59 24.19 23.68 23.89 23.51 24.39 
NFKB1 29.19 28.58 28.16 28.38 28.09 28.85 
PIK3C2A 28.73 26.91 26.49 26.03 26.22 27.05 
RB1 27.10 25.47 25.40 25.12 25.03 25.82 
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RET 36.33 35.74 35.77 35.52 35.03 35.42 
SH3PXD2A 37.48 37.07 37.43 37.03 36.56 37.26 
TGFB1 25.47 25.19 25.00 25.74 24.76 25.73 
TNF 38.05 35.29 36.98 38.17 35.74 35.93 
TP53 27.58 26.09 25.32 25.66 25.38 26.09 
HDAC1 27.05 25.03 24.76 24.81 24.35 25.28 
HDAC2 24.62 23.42 23.24 23.15 23.01 23.78 
HDAC3 28.28 26.27 26.04 26.11 25.64 26.60 
HDAC4 25.06 24.92 24.40 24.56 24.06 25.06 
HDAC5 26.35 26.68 26.23 26.23 25.82 26.89 
HDAC6 28.58 27.66 27.07 27.03 26.85 27.82 
HDAC7 28.19 27.36 27.04 27.03 26.73 27.68 
HDAC8 28.09 27.03 26.72 26.60 26.46 27.19 
HDAC9 24.67 23.47 23.13 23.14 22.81 23.46 
HDAC10 30.06 30.77 30.35 31.70 30.04 31.50 
HDAC11 29.67 30.01 29.51 30.42 29.22 30.64 
BAX 26.12 25.33 25.06 25.57 24.78 25.67 
BCL2L1 27.24 26.25 25.99 26.86 25.82 26.84 
CASP8 28.97 27.90 27.52 27.67 27.32 28.05 
CDK4 24.54 24.02 23.76 24.15 23.42 24.42 
ELK1 27.37 27.18 26.72 28.37 26.65 27.78 
ETS1 29.86 27.65 27.39 28.68 27.21 28.00 
HGF 36.58 36.39 37.43 36.45 37.29 36.43 
JAK2 30.27 29.12 28.72 28.38 28.43 29.45 
JUNB 26.62 26.35 26.20 26.86 26.12 27.26 
JUND 25.51 25.57 25.09 25.41 24.86 26.17 
KIT (CD177) 0.00 0.00 0.00 0.00 0.00 0.00 
KITLG 27.83 26.68 26.30 26.22 26.34 27.08 
MCL1 23.29 23.05 22.84 22.73 22.55 23.31 
MET 29.03 27.05 26.76 27.05 26.38 27.08 
MOS 0.00 39.89 0.00 39.34 38.26 38.40 
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MYB 31.35 30.14 29.54 29.24 29.41 29.79 
NFKBIA 27.09 26.18 26.02 26.04 25.53 26.39 
NRAS 26.09 24.75 24.42 24.41 24.36 25.11 
PIK3CA 28.47 26.23 25.58 25.30 25.42 26.16 
PML 26.78 26.54 26.17 26.98 26.10 27.07 
PRKCA 26.41 26.25 25.79 25.47 25.65 26.33 
RAF1 26.01 25.32 25.04 24.96 24.66 25.48 
RARA 27.95 27.29 26.99 27.23 26.77 27.80 
REL 27.78 27.03 26.59 26.20 26.51 27.26 
ROS1 37.50 35.29 34.21 35.30 32.52 34.08 
RUNX1 26.71 26.40 25.87 25.82 25.74 26.53 
SRC 30.69 31.43 32.05 31.88 31.22 32.80 
STAT3 24.13 23.33 22.92 22.82 22.70 23.46 
ZHX2 29.72 28.10 27.29 27.12 27.47 28.12 
ATM 31.44 29.21 28.77 27.81 28.41 29.18 
BRCA1 28.58 26.55 26.24 26.10 26.02 26.86 
BRCA2 30.10 28.56 28.09 28.03 27.81 28.84 
CDH1 34.89 33.27 33.59 33.55 32.33 32.56 
CDKN2B 31.33 29.72 29.28 29.17 29.19 30.00 
CDKN3 25.72 24.57 24.48 24.41 24.38 25.06 
E2F1 26.75 26.62 26.17 26.44 26.13 27.15 
FHIT 32.75 32.36 31.61 31.00 31.41 32.09 
FOXD3 0.00 0.00 0.00 0.00 0.00 0.00 
HIC1 34.16 32.43 33.08 33.71 32.50 33.12 
IGF2R 25.36 24.37 23.93 24.04 23.72 24.51 
MEN1 27.30 25.73 25.25 25.54 25.25 26.05 
MGMT 39.70 0.00 0.00 0.00 0.00 0.00 
MLH1 28.35 26.18 26.10 25.88 25.64 26.52 
NF1 27.07 25.76 25.26 25.08 25.09 25.96 
NF2 25.87 23.85 23.38 23.79 23.31 24.08 
RASSF1 31.22 29.90 29.54 30.55 29.03 30.44 
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RUNX3 37.40 36.09 36.27 37.72 36.10 36.12 
S100A4 28.32 26.46 26.16 26.32 25.64 26.41 
SERPINB5 0.00 37.97 37.29 36.72 35.31 37.12 
SMAD4 28.69 26.51 26.03 25.66 26.22 26.56 
STK11 29.41 27.94 27.27 27.83 27.13 28.52 
TP73 35.04 31.97 31.29 32.39 31.52 32.54 
TSC1 27.10 26.58 26.11 26.01 25.83 26.62 
VHL 26.67 26.02 25.54 24.88 25.39 26.10 
WT1 0.00 0.00 0.00 0.00 38.16 38.12 
WWOX 28.88 27.36 26.84 26.83 26.84 27.52 
XRCC1 27.47 26.25 26.01 25.99 25.53 26.38 
ACTB 20.06 17.53 17.40 17.93 17.25 18.00 
B2M 22.29 21.52 21.02 20.87 21.07 21.59 
GAPDH 21.30 19.24 19.06 19.73 18.70 19.62 
HPRT1 27.00 25.24 24.96 25.13 24.81 25.51 
RPLP0 20.52 19.13 19.05 18.82 18.63 19.45 
GUSB 26.67 25.15 24.96 24.66 24.49 25.48 
HGDC 0.00 0.00 0.00 0.00 0.00 0.00 
RTC 25.52 24.22 24.43 24.02 24.79 24.72 
PPC 20.99 20.68 20.59 20.81 20.76 20.91 
 
Raw CT values of pGBM cell line KNS42, exposed to normoxic or hypoxic conditions for 48 hours. N=3 
 
Appendix 3: Raw CT Values from RT2 PCR Profiler Arrays. Custom RT2 PCR Profiler Arrays were performed using the Bio-Rad 
CFX96 Real-Time PCR Detection System. From this, raw CT values were uploaded to Qiagen’s Data Analysis Center. Raw CT 
values are shown. 
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Appendix 4: Quality Control of Construct from Eurofins 
 
 
 
Appendix 4: Quality Control of Construct from Eurofins. After multiple 
attempts at In-fusion and standard ligation cloning, the pIRES2-ZsGreen1 
construct and the 2010bp HDAC10 insert were sent to Eurofins Genomics 
Services to obtain a pIRES2-ZsGreen1-HDAC10 construct. 
Order ID.: UK-160929-CB3177 / Pinkstone
Plasmid Name: pIRES2-ZsGreen1-HDAC10 Internal Name: HDAC10-0-2
Fragment Name: HDAC10 Fragment Size: 2010bp
Vector Backbone: pIRES2-ZsGreen1 Antibiotic Selection: Kana
Plasmid Prep Scale: Mini Quantity: 4,6 µg
Cloning Strategy:
Insert: HDAC10 Restriction Sites: EcoRI / BamHI
Plasmid: pIRES2-ZsGreen1 Restriction Sites: EcoRI / BamHI
Plasmid Map
Please Note:
Verify sequence after each cloning step. 
All material left at Eurofins Genomics will be discarded after 1 month.
Sequence analysis of cloning sites was done via singlestrand DNA sequencing.
Plasmid DNA was isolated from a dam+, dcm+ E. coli strain.
Eurofins Genomics 24.10.2016
Dr. Susanne Ciniawsky Controlled and Released
Project Assistant Molecular Biology
Cloning Quality Assurance Documentation
QR_Cloning MolBiol   V1.0 / 20140703
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10 20 30 40 50 60 70 80 90 100
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCA
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
110 120 130 140 150 160 170 180 190 200
ACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCC
ACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
210 220 230 240 250 260 270 280 290 300 310
CACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATG
CACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
320 330 340 350 360 370 380 390 400 410
GGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCAC
GGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
420 430 440 450 460 470 480 490 500 510 520
GGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACG
GGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
530 540 550 560 570 580 590 600 610 620
CAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAG
CAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
AGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAGHDAC10-0-2_CMVfor.ab1(1>1111)
630 640 650 660 670 680 690 700 710 720
CTTCGAATTCATGGGGACCGCGCTTGTGTACCATGAGGACATGACGGCCACCCGGCTGCTCTGGGACGACCCCGAGTGCGAGATCGAGCGTCCTGAGCGCCTGA
CTTCGAATTCATGGGGACCGCGCTTGTGTACCATGAGGACATGACGGCCACCCGGCTGCTCTGGGACGACCCCGAGTGCGAGATCGAGCGTCCTGAGCGCCTGAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CTTCGAATTCATGGGGACCGCGCTTGTGTACCATGAGGACATGACGGCCACCCGGCTGCTCTGGGACGACCCCGAGTGCGAGATCGAGCGTCCTGAGCGCCTGAHDAC10-0-2_CMVfor.ab1(1>1111)
gaattcATGGGGACCGCGCTTGTGTACCATGAGGACATGACGGCCACCCGGCTGCTCTGGGACGACCCCGAGTGCGAGATCGAGCGTCCTGAGCGCCTGAHDAC10 Insert Sequence.seq(1>2022)
730 740 750 760 770 780 790 800 810 820 830
CCGCAGCCCTGGATCGCCTGCGGCAGCGCGGCCTGGAACAGAGGTGTCTGCGGTTGTCAGCCCGCGAGGCCTCGGAAGAGGAGCTGGGCCTGGTGCACAGCCCA
CCGCAGCCCTGGATCGCCTGCGGCAGCGCGGCCTGGAACAGAGGTGTCTGCGGTTGTCAGCCCGCGAGGCCTCGGAAGAGGAGCTGGGCCTGGTGCACAGCCCAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CCGCAGCCCTGGATCGCCTGCGGCAGCGCGGCCTGGAACAGAGGTGTCTGCGGTTGTCAGCCCGCGAGGCCTCGGAAGAGGAGCTGGGCCTGGTGCACAGCCCAHDAC10-0-2_CMVfor.ab1(1>1111)
CCGCAGCCCTGGATCGCCTGCGGCAGCGCGGCCTGGAACAGAGGTGTCTGCGGTTGTCAGCCCGCGAGGCCTCGGAAGAGGAGCTGGGCCTGGTGCACAGCCCAHDAC10 Insert Sequence.seq(1>2022)
840 850 860 870 880 890 900 910 920 930
GAGTATGTATCCCTGGTCAGGGAGACCCAGGTCCTAGGCAAGGAGGAGCTGCAGGCGCTGTCCGGACAGTTCGACGCCATCTACTTCCACCCGAGTACCTTTCA
GAGTATGTATCCCTGGTCAGGGAGACCCAGGTCCTAGGCAAGGAGGAGCTGCAGGCGCTGTCCGGACAGTTCGACGCCATCTACTTCCACCCGAGTACCTTTCAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
GAGTATGTATCCCTGGTCAGGGAGACCCAGGTCCTAGGCAAGGAGGAGCTGCAGGCGCTGTCCGGACAGTTCGACGCCATCTACTTCCACCCGAGTACCTTTCAHDAC10-0-2_CMVfor.ab1(1>1111)
GAGTATGTATCCCTGGTCAGGGAGACCCAGGTCCTAGGCAAGGAGGAGCTGCAGGCGCTGTCCGGACAGTTCGACGCCATCTACTTCCACCCGAGTACCTTTCAHDAC10 Insert Sequence.seq(1>2022)
940 950 960 970 980 990 1000 1010 1020 1030 1040
CTGCGCGCGGCTGGCCGCAGGGGCTGGACTGCAGCTGGTGGACGCTGTGCTCACTGGAGCTGTGCAAAATGGGCTTGCCCTGGTGAGGCCTCCCGGGCACCATG
CTGCGCGCGGCTGGCCGCAGGGGCTGGACTGCAGCTGGTGGACGCTGTGCTCACTGGAGCTGTGCAAAATGGGCTTGCCCTGGTGAGGCCTCCCGGGCACCATGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CTGCGCGCGGCTGGCCGCAGGGGCTGGACTGCAGCTGGTGGACGCTGTGCTCACTGGAGCTGTGCAAAATGGGCTTGCCCTGGTGAGGCCTCCCGGGCACCATGHDAC10-0-2_CMVfor.ab1(1>1111)
CTGCGCGCGGCTGGCCGCAGGGGCTGGACTGCAGCTGGTGGACGCTGTGCTCACTGGAGCTGTGCAAAATGGGCTTGCCCTGGTGAGGCCTCCCGGGCACCATGHDAC10 Insert Sequence.seq(1>2022)
1050 1060 1070 1080 1090 1100 1110 1120 1130 1140
GCCAGAGGGCGGCTGCCAACGGGTTCTGCGTGTTCAACAACGTGGCCATAGCAGCTGCACATGCCAAGCAGAAACACGGGCTACACAGGATCCTCGTCGTGGAC
GCCAGAGGGCGGCTGCCAACGGGTTCTGCGTGTTCAACAACGTGGCCATAGCAGCTGCACATGCCAAGCAGAAACACGGGCTACACAGGATCCTCGTCGTGGACHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
GCCAGAGGGCGGCTGCCAACGGGTTCTGCGTGTTCAACAACGTGGCCATAGCAGCTGCACATGCCAAGCAGAAACACGGGCTACACAGGATCCTCGTCGTGGACHDAC10-0-2_CMVfor.ab1(1>1111)
GCCAGAGGGCGGCTGCCAACGGGTTCTGCGTGTTCAACAACGTGGCCATAGCAGCTGCACATGCCAAGCAGAAACACGGGCTACACAGGATCCTCGTCGTGGACHDAC10 Insert Sequence.seq(1>2022)
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1150 1160 1170 1180 1190 1200 1210 1220 1230 1240
TGGGATGTGCACCATGGCCAGGGGATCCAGTATCTCTTTGAGGATGACCCCAGCGTCCTTTACTTCTCCTGGCACCGCTATGAGCATGGGCGCTTCTGGCCTTT
TGGGATGTGCACCATGGCCAGGGGATCCAGTATCTCTTTGAGGATGACCCCAGCGTCCTTTACTTCTCCTGGCACCGCTATGAGCATGGGCGCTTCTGGCCTTTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
TGGGATGTGCACCATGGCCAGGGGATCCAGTATCTCTTTGAGGATGACCCCAGCGTCCTTTACTTCTCCTGGCACCGCTATGAGCATGGGCGCTTCTGGCCTTTHDAC10-0-2_CMVfor.ab1(1>1111)
TGGGATGTGCACCATGGCCAGGGGATCCAGTATCTCTTTGAGGATGACCCCAGCGTCCTTTACTTCTCCTGGCACCGCTATGAGCATGGGCGCTTCTGGCCTTTHDAC10 Insert Sequence.seq(1>2022)
1250 1260 1270 1280 1290 1300 1310 1320 1330 1340 1350
CCTGCGAGAGTCAGATGCAGACGCAGTGGGGCGGGGACAGGGCCTCGGCTTCACTGTCAACCTGCCCTGGAACCAGGTTGGGATGGGAAACGCTGACTACGTGG
CCTGCGAGAGTCAGATGCAGACGCAGTGGGGCGGGGACAGGGCCTCGGCTTCACTGTCAACCTGCCCTGGAACCAGGTTGGGATGGGAAACGCTGACTACGTGGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CCTGCGAGAGTCAGATGCAGACGCAGTGGGGCGGGGACAGGGCCTCGGCTTCACTGTCAACCTGCCCTGGAACCAGGTTGGGATGGGAAACGCTGACTACGTGGHDAC10-0-2_CMVfor.ab1(1>1111)
CCTGCGAGAGTCAGATGCAGACGCAGTGGGGCGGGGACAGGGCCTCGGCTTCACTGTCAACCTGCCCTGGAACCAGGTTGGGATGGGAAACGCTGACTACGTGGHDAC10 Insert Sequence.seq(1>2022)
1360 1370 1380 1390 1400 1410 1420 1430 1440 1450
CTGCCTTCCTGCACCTGCTGCTCCCACTGGCCTTTGAGTTTGACCCTGAGCTGGTGCTGGTCTCGGCAGGATTTGACTCAGCCATCGGGGACCCTGAGGGGCAA
CTGCCTTCCTGCACCTGCTGCTCCCACTGGCCTTTGAGTTTGACCCTGAGCTGGTGCTGGTCTCGGCAGGATTTGACTCAGCCATCGGGGACCCTGAGGGGCAAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CTGCCTTCCTGCACCTGCTGCTCCCACTGGCCTTTGAGTTTGACCCTGAGCTGGTGCTGGTCTCGGCAGGATTTGACTCAGCCATCGGGGACCCTGAGGGGCAAHDAC10-0-2_CMVfor.ab1(1>1111)
CTGCCTTCCTGCACCTGCTGCTCCCACTGGCCTTTGAGTTTGACCCTGAGCTGGTGCTGGTCTCGGCAGGATTTGACTCAGCCATCGGGGACCCTGAGGGGCAAHDAC10 Insert Sequence.seq(1>2022)
1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560
ATGCAGGCCACGCCAGAGTGCTTCGCCCACCTCACACAGCTGCTGCAGGTGCTGGCCGGCGGCCGGGTCTGTGCCGTGCTGGAGGGCGGCTACCACCTGGAGTC
ATGCAGGCCACGCCAGAGTGCTTCGCCCACCTCACACAGCTGCTGCAGGTGCTGGCCGGCGGCCGGGTCTGTGCCGTGCTGGAGGGCGGCTACCACCTGGAGTCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
ATGCAGGCCACGCCAGAGTGCTTCGCCCACCTCACACAGCTGCTGCAGGTGCTGGCCGGCGGCCGGGTCHDAC10-0-2_CMVfor.ab1(1>1111)
ATGCAGGCCACGCCAGAGTGCTTCGCCCACCTCACACAGCTGCTGCAGGTGCTGGCCGGCGGCCGGGTCTGTGCCGTGCTGGAGGGCGGCTACCACCTGGAGTCHDAC10 Insert Sequence.seq(1>2022)
1570 1580 1590 1600 1610 1620 1630 1640 1650 1660
ACTGGCGGAGTCAGTGTGCATGACAGTACAGACGCTGCTGGGTGACCCGGCCCCACCCCTGTCAGGGCCAATGGCGCCATGTCAGAGTGCCCTAGAGTCCATCC
ACTGGCGGAGTCAGTGTGCATGACAGTACAGACGCTGCTGGGTGACCCGGCCCCACCCCTGTCAGGGCCAATGGCGCCATGTCAGAGTGCCCTAGAGTCCATCCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
ACTGGCGGAGTCAGTGTGCATGACAGTACAGACGCTGCTGGGTGACCCGGCCCCACCCCTGTCAGGGCCAATGGCGCCATGTCAGAGTGCCCTAGAGTCCATCCHDAC10 Insert Sequence.seq(1>2022)
1670 1680 1690 1700 1710 1720 1730 1740 1750 1760
AGAGTGCCCGTGCTGCCCAGGCCCCGCACTGGAAGAGCCTCCAGCAGCAAGATGTGACCGCTGTGCCGATGAGCCCCAGCAGCCACTCCCCAGAGGGGAGGCCT
AGAGTGCCCGTGCTGCCCAGGCCCCGCACTGGAAGAGCCTCCAGCAGCAAGATGTGACCGCTGTGCCGATGAGCCCCAGCAGCCACTCCCCAGAGGGGAGGCCTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
AGAGTGCCCGTGCTGCCCAGGCCCCGCACTGGAAGAGCCTCCAGCAGCAAGATGTGACCGCTGTGCCGATGAGCCCCAGCAGCCACTCCCCAGAGGGGAGGCCTHDAC10 Insert Sequence.seq(1>2022)
1770 1780 1790 1800 1810 1820 1830 1840 1850 1860 1870
CCACCTCTGCTGCCTGGGGGTCCAGTGTGTAAGGCAGCTGCATCTGCACCGAGCTCCCTCCTGGACCAGCCGTGCCTCTGCCCCGCACCCTCTGTCCGCACCGC
CCACCTCTGCTGCCTGGGGGTCCAGTGTGTAAGGCAGCTGCATCTGCACCGAGCTCCCTCCTGGACCAGCCGTGCCTCTGCCCCGCACCCTCTGTCCGCACCGCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CCACCTCTGCTGCCTGGGGGTCCAGTGTGTAAGGCAGCTGCATCTGCACCGAGCTCCCTCCTGGACCAGCCGTGCCTCTGCCCCGCACCCTCTGTCCGCACCGCHDAC10 Insert Sequence.seq(1>2022)
1880 1890 1900 1910 1920 1930 1940 1950 1960 1970
TGTTGCCCTGACAACGCCGGATATCACATTGGTTCTGCCCCCTGACGTCATCCAACAGGAAGCGTCAGCCCTGAGGGAGGAGACAGAAGCCTGGGCCAGGCCAC
TGTTGCCCTGACAACGCCGGATATCACATTGGTTCTGCCCCCTGACGTCATCCAACAGGAAGCGTCAGCCCTGAGGGAGGAGACAGAAGCCTGGGCCAGGCCACHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
TGTTGCCCTGACAACGCCGGATATCACATTGGTTCTGCCCCCTGACGTCATCCAACAGGAAGCGTCAGCCCTGAGGGAGGAGACAGAAGCCTGGGCCAGGCCACHDAC10 Insert Sequence.seq(1>2022)
1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080
ACGAGTCCCTGGCCCGGGAGGAGGCCCTCACTGCACTTGGGAAGCTCCTGTACCTCTTAGATGGGATGCTGGATGGGCAGGTGAACAGTGGTATAGCAGCCACT
ACGAGTCCCTGGCCCGGGAGGAGGCCCTCACTGCACTTGGGAAGCTCCTGTACCTCTTAGATGGGATGCTGGATGGGCAGGTGAACAGTGGTATAGCAGCCACTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
ACGAGTCCCTGGCCCGGGAGGAGGCCCTCACTGCACTTGGGAAGCTCCTGTACCTCTTAGATGGGATGCTGGATGGGCAGGTGAACAGTGGTATAGCAGCCACTHDAC10 Insert Sequence.seq(1>2022)
2090 2100 2110 2120 2130 2140 2150 2160 2170 2180
CCAGCCTCTGCTGCAGCAGCCACCCTGGATGTGGCTGTTCGGAGAGGCCTGTCCCACGGAGCCCAGAGGCTGCTGTGCGTGGCCCTGGGACAGCTGGACCGGCC
CCAGCCTCTGCTGCAGCAGCCACCCTGGATGTGGCTGTTCGGAGAGGCCTGTCCCACGGAGCCCAGAGGCTGCTGTGCGTGGCCCTGGGACAGCTGGACCGGCCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CCAGCCTCTGCTGCAGCAGCCACCCTGGATGTGGCTGTTCGGAGAGGCCTGTCCCACGGAGCCCAGAGGCTGCTGTGCGTGGCCCTGGGACAGCTGGACCGGCCHDAC10 Insert Sequence.seq(1>2022)
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2190 2200 2210 2220 2230 2240 2250 2260 2270 2280
TCCAGACCTCGCCCATGACGGGAGGAGTCTGTGGCTGAACATCAGGGGCAAGGAGGCGGCTGCCCTATCCATGTTCCATGTCTCCACGCCACTGCCAGTGATGA
TCCAGACCTCGCCCATGACGGGAGGAGTCTGTGGCTGAACATCAGGGGCAAGGAGGCGGCTGCCCTATCCATGTTCCATGTCTCCACGCCACTGCCAGTGATGAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
TCCAGACCTCGCCCATGACGGGAGGAGTCTGTGGCTGAACATCAGGGGCAAGGAGGCGGCTGCCCTATCCATGTTCCATGTCTCCACGCCACTGCCAGTGATGAHDAC10 Insert Sequence.seq(1>2022)
CTCGCCCATGACGGGAGGAGTCTGTGGCTGAACATCAGGGGCAAGGAGGCGGCTGCCCTATCCATGTTCCATGTCTCCACGCCACTGCCAGTGATGAHDAC10-0-2_F3_premix.ab1(20>763)
2290 2300 2310 2320 2330 2340 2350 2360 2370 2380 2390
CCGGTGGTTTCCTGAGCTGCATCTTGGGCTTGGTGCTGCCCCTGGCCTATGGCTTCCAGCCTGACCTGGTGCTGGTGGCGCTGGGGCCTGGCCATGGCCTGCAG
CCGGTGGTTTCCTGAGCTGCATCTTGGGCTTGGTGCTGCCCCTGGCCTATGGCTTCCAGCCTGACCTGGTGCTGGTGGCGCTGGGGCCTGGCCATGGCCTGCAGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CCGGTGGTTTCCTGAGCTGCATCTTGGGCTTGGTGCTGCCCCTGGCCTATGGCTTCCAGCCTGACCTGGTGCTGGTGGCGCTGGGGCCTGGCCATGGCCTGCAGHDAC10 Insert Sequence.seq(1>2022)
CCGGTGGTTTCCTGAGCTGCATCTTGGGCTTGGTGCTGCCCCTGGCCTATGGCTTCCAGCCTGACCTGGTGCTGGTGGCGCTGGGGCCTGGCCATGGCCTGCAGHDAC10-0-2_F3_premix.ab1(20>763)
2400 2410 2420 2430 2440 2450 2460 2470 2480 2490
GGCCCCCACGCTGCACTCCTGGCTGCAATGCTTCGGGGGCTGGCAGGGGGCCGAGTCCTGGCCCTCCTGGAGGAGAACTCCACACCCCAGCTAGCAGGGATCCT
GGCCCCCACGCTGCACTCCTGGCTGCAATGCTTCGGGGGCTGGCAGGGGGCCGAGTCCTGGCCCTCCTGGAGGAGAACTCCACACCCCAGCTAGCAGGGATCCTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
GGCCCCCACGCTGCACTCCTGGCTGCAATGCTTCGGGGGCTGGCAGGGGGCCGAGTCCTGGCCCTCCTGGAGGAGAACTCCACACCCCAGCTAGCAGGGATCCTHDAC10 Insert Sequence.seq(1>2022)
GGCCCCCACGCTGCACTCCTGGCTGCAATGCTTCGGGGGCTGGCAGGGGGCCGAGTCCTGGCCCTCCTGGAGGAGAACTCCACACCCCAGCTAGCAGGGATCCTHDAC10-0-2_F3_premix.ab1(20>763)
2500 2510 2520 2530 2540 2550 2560 2570 2580 2590 2600
GGCCCGGGTGCTGAATGGAGAGGCACCTCCTAGCCTAGGCCCTTCCTCTGTGGCCTCCCCAGAGGACGTCCAGGCCCTGATGTACCTGAGAGGGCAGCTGGAGC
GGCCCGGGTGCTGAATGGAGAGGCACCTCCTAGCCTAGGCCCTTCCTCTGTGGCCTCCCCAGAGGACGTCCAGGCCCTGATGTACCTGAGAGGGCAGCTGGAGCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
GGCCCGGGTGCTGAATGGAGAGGCACCTCCTAGCCTAGGCCCTTCCTCTGTGGCCTCCCCAGAGGACGTCCAGGCCCTGATGTACCTGAGAGGGCAGCTGGAGCHDAC10 Insert Sequence.seq(1>2022)
GGCCCGGGTGCTGAATGGAGAGGCACCTCCTAGCCTAGGCCCTTCCTCTGTGGCCTCCCCAGAGGACGTCCAGGCCCTGATGTACCTGAGAGGGCAGCTGGAGCHDAC10-0-2_F3_premix.ab1(20>763)
2610 2620 2630 2640 2650 2660 2670 2680 2690 2700
CTCAGTGGAAGATGTTGCAGTGCCATCCTCACCTGGTGGCTTGAGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAG
CTCAGTGGAAGATGTTGCAGTGCCATCCTCACCTGGTGGCTTGAGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
CTCAGTGGAAGATGTTGCAGTGCCATCCTCACCTGGTGGCTTGAggatccHDAC10 Insert Sequence.seq(1>2022)
CTCAGTGGAAGATGTTGCAGTGCCATCCTCACCTGGTGGCTTGAGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGHDAC10-0-2_F3_premix.ab1(20>763)
GGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGHDAC10-0-2_R_premix.ab1(28>351)
2710 2720 2730 2740 2750 2760 2770 2780 2790 2800
GCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGG
GCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
GCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGHDAC10-0-2_F3_premix.ab1(20>763)
GCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGHDAC10-0-2_R_premix.ab1(28>351)
2810 2820 2830 2840 2850 2860 2870 2880 2890 2900 2910
GGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCT
GGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
GGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTHDAC10-0-2_F3_premix.ab1(20>763)
GGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTHDAC10-0-2_R_premix.ab1(28>351)
2920 2930 2940 2950 2960 2970 2980 2990 3000 3010
TTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTG
TTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
TTGCAGGCAGCGGAACCCCCCACHDAC10-0-2_F3_premix.ab1(20>763)
TTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGHDAC10-0-2_R_premix.ab1(28>351)
3020 3030 3040 3050 3060 3070 3080 3090 3100 3110 3120
TGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTG
TGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3130 3140 3150 3160 3170 3180 3190 3200 3210 3220
GGGCCTCGGTACACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATA
GGGCCTCGGTACACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
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3230 3240 3250 3260 3270 3280 3290 3300 3310 3320
ATATGGCCACAACCATGGCCCAGTCCAAGCACGGCCTGACCAAGGAGATGACCATGAAGTACCGCATGGAGGGCTGCGTGGACGGCCACAAGTTCGTGATCACC
ATATGGCCACAACCATGGCCCAGTCCAAGCACGGCCTGACCAAGGAGATGACCATGAAGTACCGCATGGAGGGCTGCGTGGACGGCCACAAGTTCGTGATCACCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3330 3340 3350 3360 3370 3380 3390 3400 3410 3420 3430
GGCGAGGGCATCGGCTACCCCTTCAAGGGCAAGCAGGCCATCAACCTGTGCGTGGTGGAGGGCGGCCCCTTGCCCTTCGCCGAGGACATCTTGTCCGCCGCCTT
GGCGAGGGCATCGGCTACCCCTTCAAGGGCAAGCAGGCCATCAACCTGTGCGTGGTGGAGGGCGGCCCCTTGCCCTTCGCCGAGGACATCTTGTCCGCCGCCTTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3440 3450 3460 3470 3480 3490 3500 3510 3520 3530
CATGTACGGCAACCGCGTGTTCACCGAGTACCCCCAGGACATCGTCGACTACTTCAAGAACTCCTGCCCCGCCGGCTACACCTGGGACCGCTCCTTCCTGTTCG
CATGTACGGCAACCGCGTGTTCACCGAGTACCCCCAGGACATCGTCGACTACTTCAAGAACTCCTGCCCCGCCGGCTACACCTGGGACCGCTCCTTCCTGTTCGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3540 3550 3560 3570 3580 3590 3600 3610 3620 3630 3640
AGGACGGCGCCGTGTGCATCTGCAACGCCGACATCACCGTGAGCGTGGAGGAGAACTGCATGTACCACGAGTCCAAGTTCTACGGCGTGAACTTCCCCGCCGAC
AGGACGGCGCCGTGTGCATCTGCAACGCCGACATCACCGTGAGCGTGGAGGAGAACTGCATGTACCACGAGTCCAAGTTCTACGGCGTGAACTTCCCCGCCGACHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3650 3660 3670 3680 3690 3700 3710 3720 3730 3740
GGCCCCGTGATGAAGAAGATGACCGACAACTGGGAGCCCTCCTGCGAGAAGATCATCCCCGTGCCCAAGCAGGGCATCTTGAAGGGCGACGTGAGCATGTACCT
GGCCCCGTGATGAAGAAGATGACCGACAACTGGGAGCCCTCCTGCGAGAAGATCATCCCCGTGCCCAAGCAGGGCATCTTGAAGGGCGACGTGAGCATGTACCTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3750 3760 3770 3780 3790 3800 3810 3820 3830 3840
GCTGCTGAAGGACGGTGGCCGCTTGCGCTGCCAGTTCGACACCGTGTACAAGGCCAAGTCCGTGCCCCGCAAGATGCCCGACTGGCACTTCATCCAGCACAAGC
GCTGCTGAAGGACGGTGGCCGCTTGCGCTGCCAGTTCGACACCGTGTACAAGGCCAAGTCCGTGCCCCGCAAGATGCCCGACTGGCACTTCATCCAGCACAAGCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3850 3860 3870 3880 3890 3900 3910 3920 3930 3940 3950
TGACCCGCGAGGACCGCAGCGACGCCAAGAACCAGAAGTGGCACCTGACCGAGCACGCCATCGCCTCCGGCTCCGCCTTGCCCTGAGCGGCCGCGACTCTAGAT
TGACCCGCGAGGACCGCAGCGACGCCAAGAACCAGAAGTGGCACCTGACCGAGCACGCCATCGCCTCCGGCTCCGCCTTGCCCTGAGCGGCCGCGACTCTAGATHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
3960 3970 3980 3990 4000 4010 4020 4030 4040 4050
CATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTA
CATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4060 4070 4080 4090 4100 4110 4120 4130 4140 4150 4160
ACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAA
ACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4170 4180 4190 4200 4210 4220 4230 4240 4250 4260
CTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAA
CTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4270 4280 4290 4300 4310 4320 4330 4340 4350 4360
TCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTC
TCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4370 4380 4390 4400 4410 4420 4430 4440 4450 4460 4470
AAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCC
AAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4480 4490 4500 4510 4520 4530 4540 4550 4560 4570
TAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTG
TAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
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4580 4590 4600 4610 4620 4630 4640 4650 4660 4670 4680
TAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATT
TAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4690 4700 4710 4720 4730 4740 4750 4760 4770 4780
TGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAG
TGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4790 4800 4810 4820 4830 4840 4850 4860 4870 4880
AACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTG
AACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
4890 4900 4910 4920 4930 4940 4950 4960 4970 4980 4990
TGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAA
TGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5000 5010 5020 5030 5040 5050 5060 5070 5080 5090
CTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGA
CTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5100 5110 5120 5130 5140 5150 5160 5170 5180 5190 5200
GGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGG
GGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5210 5220 5230 5240 5250 5260 5270 5280 5290 5300
CCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTT
CCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5310 5320 5330 5340 5350 5360 5370 5380 5390 5400
TTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGA
TTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5410 5420 5430 5440 5450 5460 5470 5480 5490 5500 5510
CGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGG
CGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5520 5530 5540 5550 5560 5570 5580 5590 5600 5610
CTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGT
CTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5620 5630 5640 5650 5660 5670 5680 5690 5700 5710 5720
CTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGT
CTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5730 5740 5750 5760 5770 5780 5790 5800 5810 5820
GACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACA
GACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
5830 5840 5850 5860 5870 5880 5890 5900 5910 5920
TAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCC
TAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
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5930 5940 5950 5960 5970 5980 5990 6000 6010 6020 6030
TTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCC
TTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6040 6050 6060 6070 6080 6090 6100 6110 6120 6130
GCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGG
GCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6140 6150 6160 6170 6180 6190 6200 6210 6220 6230 6240
GAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATA
GAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6250 6260 6270 6280 6290 6300 6310 6320 6330 6340
AACGCGGGGTTCGGTCCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCCCACCCCACCCCCCA
AACGCGGGGTTCGGTCCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCCCACCCCACCCCCCAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6350 6360 6370 6380 6390 6400 6410 6420 6430 6440
AGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTT
AGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6450 6460 6470 6480 6490 6500 6510 6520 6530 6540 6550
TTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGA
TTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6560 6570 6580 6590 6600 6610 6620 6630 6640 6650
TCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTA
TCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6660 6670 6680 6690 6700 6710 6720 6730 6740 6750 6760
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGC
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6770 6780 6790 6800 6810 6820 6830 6840 6850 6860
ACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATA
ACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6870 6880 6890 6900 6910 6920 6930 6940 6950 6960
AGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGC
AGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
6970 6980 6990 7000 7010 7020 7030 7040 7050 7060 7070
GCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCT
GCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
7080 7090 7100 7110 7120 7130 7140 7150 7160 7170
TTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTT
TTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
7180 7190 7200 7210 7220 7230 7240 7250 7260
TACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT
TACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCATHDAC10 in pIRES2-ZsGreen1 in silico SCI 161005.seq(1>7268)
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Appendix 5: Sequence of pIRES2-ZsGreen1 construct. Homology of the HDAC10 sequence cloned into the pIRES2-ZsGreen1 
construct and the HDAC10 reference sequence of 2010bp.  
 
 
 270 
Appendix 6: Kill Curves of KNS42 in G418 at varying concentrations. 
 
 
Appendix 6: Kill Curves of KNS42 in G418 at varying concentrations between 0µg/mL - 1500µg/mL. Cells incubated with MTS for 2 
hours at 37oC before absorbance was read on a BMG Labtech POLARstar Optima platereader. 
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Appendix 7: Transient Transfections – Example Results  
 
 
 
 
Appendix 7: Transient transfections were performed by In Cell Western and 
Nucleocounter analysis in KNS42 cells as described in Chapter 2 and 
analysed at 24 hours, 48 hours, and 72 hours. In-cell westerns should show 
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green staining for the HDAC10 construct and the Vector control, with nothing 
in the ‘reagent only’ wells. Red staining should be shown in the HDAC10 
construct wells only, to indicate HDAC10. Transfection efficiencies were low 
at all time points for both the HDAC10 construct and empty vector control, at 
less than 10%. 
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Appendix 8: mRNA expression of HDACs in Grigoriadi’s pGBM cell line 
dataset, from the R2 Genomics Analysis and Visualization Platform. 
 
 
 
Appendix 8: mRNA expression of HDACs in Grigoriadi’s pGBM cell line 
dataset, from the R2 Genomics Analysis and Visualization Platform. WHO 
grade IV was selected for to ensure only GBM cell lines were included. 
HDACs 1 and 2 have the highest expression with HDAC10 showing the 
lowest expression showing agreement with the tissue datasets and our 
pGBM cell lines.
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Appendix 9: Table of Significant Differences Between Paediatric GBM 
Dataset 
 
DUNN'S MULTIPLE 
COMPARISONS TEST 
SUMMARY ADJUSTED 
P VALUE 
HDAC1 
DIPG - PAUGH VS. PGBM - 
DONSON 
ns 0.1577 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns 0.2185 
DIPG - PAUGH VS. PGBM - 
PFISTER 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PAUGH 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PFISTER 
ns 0.0776 
PGBM - PAUGH VS. PGBM - 
PFISTER 
ns 0.1061 
HDAC2	
DIPG - PAUGH VS. PGBM - 
DONSON 
ns >0.9999 
DIPG - PAUGH VS. PGBM - 
PAUGH 
* 0.0452 
DIPG - PAUGH VS. PGBM - 
PFISTER 
**** <0.0001 
PGBM - DONSON VS. PGBM - 
PAUGH 
ns 0.4572 
PGBM - DONSON VS. PGBM - 
PFISTER 
**** <0.0001 
PGBM - PAUGH VS. PGBM - 
PFISTER 
** 0.0081 
HDAC3	
DIPG - PAUGH VS. PGBM - 
DONSON 
** 0.0018 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns 0.0828 
DIPG - PAUGH VS. PGBM - 
PFISTER 
** 0.006 
PGBM - DONSON VS. PGBM - 
PAUGH 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PFISTER 
ns >0.9999 
PGBM - PAUGH VS. PGBM - 
PFISTER 
ns >0.9999 
HDAC4	
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DIPG - PAUGH VS. PGBM - 
DONSON 
ns >0.9999 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns >0.9999 
DIPG - PAUGH VS. PGBM - 
PFISTER 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PAUGH 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PFISTER 
ns >0.9999 
PGBM - PAUGH VS. PGBM - 
PFISTER 
ns >0.9999 
HDAC5	
DIPG - PAUGH VS. PGBM - 
DONSON 
* 0.0357 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns >0.9999 
DIPG - PAUGH VS. PGBM - 
PFISTER 
ns 0.1437 
PGBM - DONSON VS. PGBM - 
PAUGH 
** 0.0022 
PGBM - DONSON VS. PGBM - 
PFISTER 
**** <0.0001 
PGBM - PAUGH VS. PGBM - 
PFISTER 
ns 0.7437 
HDAC6	
DIPG - PAUGH VS. PGBM - 
DONSON 
**** <0.0001 
DIPG - PAUGH VS. PGBM - 
PAUGH 
* 0.0289 
DIPG - PAUGH VS. PGBM - 
PFISTER 
ns 0.2147 
PGBM - DONSON VS. PGBM - 
PAUGH 
ns 0.0811 
PGBM - DONSON VS. PGBM - 
PFISTER 
**** <0.0001 
PGBM - PAUGH VS. PGBM - 
PFISTER 
**** <0.0001 
HDAC7	
DIPG - PAUGH VS. PGBM - 
DONSON 
* 0.0112 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns 0.1306 
DIPG - PAUGH VS. PGBM - 
PFISTER 
**** <0.0001 
PGBM - DONSON VS. PGBM - 
PAUGH 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PFISTER 
ns 0.5629 
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PGBM - PAUGH VS. PGBM - 
PFISTER 
ns 0.0818 
HDAC8	
DIPG - PAUGH VS. PGBM - 
DONSON 
**** <0.0001 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns 0.7855 
DIPG - PAUGH VS. PGBM - 
PFISTER 
ns 0.1015 
PGBM - DONSON VS. PGBM - 
PAUGH 
* 0.0107 
PGBM - DONSON VS. PGBM - 
PFISTER 
ns 0.6001 
PGBM - PAUGH VS. PGBM - 
PFISTER 
ns >0.9999 
HDAC9	
DIPG - PAUGH VS. PGBM - 
DONSON 
ns 0.1546 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns 0.9211 
DIPG - PAUGH VS. PGBM - 
PFISTER 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PAUGH 
** 0.0017 
PGBM - DONSON VS. PGBM - 
PFISTER 
ns 0.2599 
PGBM - PAUGH VS. PGBM - 
PFISTER 
ns >0.9999 
HDAC10	
DIPG - PAUGH VS. PGBM - 
DONSON 
ns 0.5809 
DIPG - PAUGH VS. PGBM - 
PAUGH 
* 0.0311 
DIPG - PAUGH VS. PGBM - 
PFISTER 
ns 0.1308 
PGBM - DONSON VS. PGBM - 
PAUGH 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PFISTER 
** 0.0013 
PGBM - PAUGH VS. PGBM - 
PFISTER 
**** <0.0001 
HDAC11	
DIPG - PAUGH VS. PGBM - 
DONSON 
ns 0.2424 
DIPG - PAUGH VS. PGBM - 
PAUGH 
ns 0.0921 
DIPG - PAUGH VS. PGBM - 
PFISTER 
**** <0.0001 
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PGBM - DONSON VS. PGBM - 
PAUGH 
ns >0.9999 
PGBM - DONSON VS. PGBM - 
PFISTER 
ns 0.0771 
PGBM - PAUGH VS. PGBM - 
PFISTER 
ns 0.149 
 
Appendix 9: Table of Differences Between Paediatric GBM Datasets. 
Datasets by Paugh, Donson and Pfister were used for bioinformatics 
analysis. Datasets extracted from the R2: Genomics Analysis and 
Visualisation Platform.  
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Appendix 10: Table of Differences Between Adult GBM Datasets  
 
DUNN'S MULTIPLE COMPARISONS 
TEST 
SUMMARY ADJUSTED 
P VALUE 
HDAC1	
AGBM - PFISTER VS. AGBM - 
FRENCH 
ns >0.9999 
AGBM - PFISTER VS. AGBM - HEGI ns >0.9999 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - FRENCH VS. AGBM - HEGI ns >0.9999 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
HDAC2	
AGBM - PFISTER VS. AGBM - 
FRENCH 
**** <0.0001 
AGBM - PFISTER VS. AGBM - HEGI **** <0.0001 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
AGBM - FRENCH VS. AGBM - HEGI ns 0.2131 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
ns 0.4752 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
HDAC3	
AGBM - PFISTER VS. AGBM - 
FRENCH 
*** 0.0002 
AGBM - PFISTER VS. AGBM - HEGI ** 0.0051 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - FRENCH VS. AGBM - HEGI ns >0.9999 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
** 0.0022 
HDAC4	
AGBM - PFISTER VS. AGBM - 
FRENCH 
**** <0.0001 
AGBM - PFISTER VS. AGBM - HEGI ns 0.1155 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - FRENCH VS. AGBM - HEGI **** <0.0001 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
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AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
* 0.0451 
HDAC5	
AGBM - PFISTER VS. AGBM - 
FRENCH 
ns >0.9999 
AGBM - PFISTER VS. AGBM - HEGI ns >0.9999 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - FRENCH VS. AGBM - HEGI ns >0.9999 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
HDAC6	
AGBM - PFISTER VS. AGBM - 
FRENCH 
**** <0.0001 
AGBM - PFISTER VS. AGBM - HEGI **** <0.0001 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - FRENCH VS. AGBM - HEGI * 0.0372 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
HDAC7	
AGBM - PFISTER VS. AGBM - 
FRENCH 
ns >0.9999 
AGBM - PFISTER VS. AGBM - HEGI * 0.0402 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
ns 0.5561 
AGBM - FRENCH VS. AGBM - HEGI ** 0.0062 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
** 0.0035 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
HDAC8	
AGBM - PFISTER VS. AGBM - 
FRENCH 
ns >0.9999 
AGBM - PFISTER VS. AGBM - HEGI ** 0.0036 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
* 0.0185 
AGBM - FRENCH VS. AGBM - HEGI **** <0.0001 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
HDAC9	
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AGBM - PFISTER VS. AGBM - 
FRENCH 
* 0.0378 
AGBM - PFISTER VS. AGBM - HEGI ns >0.9999 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
ns 0.6396 
AGBM - FRENCH VS. AGBM - HEGI **** <0.0001 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
* 0.0391 
HDAC10	
AGBM - PFISTER VS. AGBM - 
FRENCH 
**** <0.0001 
AGBM - PFISTER VS. AGBM - HEGI **** <0.0001 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
** 0.0076 
AGBM - FRENCH VS. AGBM - HEGI **** <0.0001 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
**** <0.0001 
HDAC11	
AGBM - PFISTER VS. AGBM - 
FRENCH 
ns >0.9999 
AGBM - PFISTER VS. AGBM - HEGI **** <0.0001 
AGBM - PFISTER VS. AGBM - 
KAWAGUCHI 
** 0.0012 
AGBM - FRENCH VS. AGBM - HEGI **** <0.0001 
AGBM - FRENCH VS. AGBM - 
KAWAGUCHI 
*** 0.0001 
AGBM - HEGI VS. AGBM - 
KAWAGUCHI 
ns >0.9999 
 
 
Appendix 10: Table of Differences Between Adult GBM Datasets. Datasets 
by Pfister, French, Hegi and Kawaguchi were used for bioinformatics 
analysis. Datasets extracted from the R2: Genomics Analysis and 
Visualisation Platform.  
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Appendix 11: Tables of Significant Differences in HDAC Expression 
Between Paediatric Brain Tumours 
 
Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. AT/RT - Kool ⬇	 0.0011 ** 
pGBM - Donson vs. Medulloblastoma 
- Gilbertson 
⬆	 0.0002 *** 
pGBM - Paugh vs. AT/RT - Kool ⬇	 0.0017 ** 
pGBM - Paugh vs. Medulloblastoma - 
Gilbertson 
⬆	 <0.0001 **** 
pGBM - Pfister vs. Medulloblastoma - 
Gilbertson 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
AT/RT - Birks 
⬇	 0.0056 ** 
Non-Neoplastic Brain - Roth vs. 
AT/RT - Kool 
⬇	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. CNS 
PNET - Kool 
⬇	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
Medulloblastoma - Pfister 
⬇	 0.0238 * 
AT/RT - Birks vs. Medulloblastoma - 
Gilbertson 
⬆	 0.0102 * 
AT/RT - Kool vs. CNS PNET - Grundy ⬆	 <0.0001 **** 
AT/RT - Kool vs. CNS PNET - Kool ⬆	 0.0004 *** 
AT/RT - Kool vs. Medulloblastoma - 
Gilbertson 
⬆	 <0.0001 **** 
AT/RT - Kool vs. Medulloblastoma - 
Pfister 
⬆	 <0.0001 **** 
AT/RT - Kool vs. Ependymoma - 
Gilbertson 
⬆	 0.0009 *** 
CNS PNET - Kool vs. 
Medulloblastoma - Gilbertson 
⬆	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Medulloblastoma - Pfister 
⬇	 0.0006 *** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Gilbertson 
⬇	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Pfister 
⬇	 <0.0001 **** 
Medulloblastoma - Pfister vs. 
Ependymoma - Pfister 
⬇	 0.0004 *** 
 
HDAC1 
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Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson Vs. pGBM - Pfister ⬇	 0.0397 * 
pGBM - Donson Vs. AT/RT - Kool ⬇	 <0.0001 **** 
pGBM - Donson Vs. CNS PNET - 
Grundy 
⬇	 0.0131 * 
pGBM - Donson Vs. CNS PNET - Kool ⬇	 <0.0001 **** 
pGBM - Donson Vs. Medulloblastoma 
- Gilbertson 
⬇	 <0.0001 **** 
pGBM - Donson Vs. Medulloblastoma 
- Pfister 
⬇	 <0.0001 **** 
pGBM - Paugh Vs. AT/RT - Kool ⬇	 <0.0001 **** 
pGBM - Paugh Vs. CNS PNET - Kool ⬇	 <0.0001 **** 
pGBM - Paugh Vs. Medulloblastoma - 
Gilbertson 
⬇	 0.0006 *** 
pGBM - Paugh Vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
pGBM - Paugh Vs. Ependymoma - 
Gilbertson 
⬆	 0.047 * 
pGBM - Pfister Vs. Non-Neoplastic 
Brain - Roth 
⬆	 0.001 *** 
pGBM - Pfister Vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
pGBM - Pfister Vs. Ependymoma - 
Gilbertson 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth Vs. 
AT/RT - Kool 
⬇	 <0.0001 **** 
Non-Neoplastic Brain - Roth Vs. CNS 
PNET - Grundy 
⬇	 0.0004 *** 
Non-Neoplastic Brain - Roth Vs. CNS 
PNET - Kool 
⬇	 <0.0001 **** 
Non-Neoplastic Brain - Roth Vs. 
Medulloblastoma - Gilbertson 
⬇	 <0.0001 **** 
Non-Neoplastic Brain - Roth Vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
AT/RT - Birks Vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
AT/RT - Kool Vs. Medulloblastoma - 
Pfister 
⬇	 0.0002 *** 
AT/RT - Kool Vs. Ependymoma - 
Gilbertson 
⬆	 <0.0001 **** 
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AT/RT - Kool Vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
CNS PNET - Grundy Vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
CNS PNET - Grundy Vs. 
Ependymoma - Gilbertson 
⬆	 <0.0001 **** 
CNS PNET - Kool Vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
CNS PNET - Kool Vs. Ependymoma - 
Gilbertson 
⬆	 <0.0001 **** 
CNS	PNET	-	Kool	Vs.	Ependymoma	-	Pfister	 ⬆	 <0.0001	 ****	
Medulloblastoma	-	Gilbertson	Vs.	
Medulloblastoma	-	Pfister	
⬇	 <0.0001	 ****	
Medulloblastoma	-	Gilbertson	Vs.	
Ependymoma	-	Gilbertson	
⬆	 <0.0001	 ****	
Medulloblastoma	-	Gilbertson	Vs.	
Ependymoma	-	Pfister	
⬆	 <0.0001	 ****	
Medulloblastoma	-	Pfister	Vs.	
Ependymoma	-	Gilbertson	
⬆	 <0.0001	 ****	
Medulloblastoma	-	Pfister	Vs.	
Ependymoma	-	Pfister	
⬆	 <0.0001	 ****	
Ependymoma	-	Gilbertson	Vs.	
Ependymoma	-	Pfister	
⬇	 0.0006	 ***	
 
HDAC2 
 
 
Dunn's Multiple Comparisons Test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. AT/RT - Birks ⬇	 0.028 * 
pGBM - Donson vs. Medulloblastoma 
- Gilbertson 
⬇	 0.0066 ** 
pGBM - Paugh vs. AT/RT - Birks ⬇	 0.0001 *** 
pGBM - Paugh vs. AT/RT - Kool ⬇	 <0.0001 **** 
pGBM - Paugh vs. CNS PNET - 
Grundy 
⬇	 0.0025 ** 
pGBM - Paugh vs. Medulloblastoma - 
Gilbertson 
⬇	 <0.0001 **** 
pGBM - Paugh vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
pGBM - Pfister vs. AT/RT - Birks ⬇	 0.0457 * 
pGBM - Pfister vs. Medulloblastoma - 
Gilbertson 
⬇	 0.0409 * 
AT/RT - Birks vs. CNS PNET - Kool ⬆	 0.0083 ** 
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AT/RT - Birks vs. Ependymoma - 
Gilbertson 
⬆	 0.0003 *** 
AT/RT - Birks vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
AT/RT - Kool vs. CNS PNET - Kool ⬆	 0.0042 ** 
AT/RT - Kool vs. Ependymoma - 
Gilbertson 
⬆	 <0.0001 **** 
AT/RT - Kool vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
CNS PNET - Grundy vs. 
Ependymoma - Gilbertson 
⬆	 0.0068 ** 
CNS PNET - Grundy vs. 
Ependymoma - Pfister 
⬆	 0.0002 *** 
CNS PNET - Kool vs. 
Medulloblastoma - Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Kool vs. 
Medulloblastoma - Pfister 
⬇	 0.0053 ** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Gilbertson 
⬆	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
Medulloblastoma - Pfister vs. 
Ependymoma - Gilbertson 
⬆	 <0.0001 **** 
Medulloblastoma - Pfister vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
 
HDAC3 
 
Dunn's Multiple Comparisons Test Increased/ 
Decreased 
Expression 
P Value Significance 
Pgbm - Donson Vs. Medulloblastoma 
- Pfister 
⬇	 <0.0001 **** 
Pgbm - Paugh Vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
Pgbm - Paugh Vs. Ependymoma - 
Pfister 
⬇	 0.0448 * 
Pgbm - Pfister Vs. Medulloblastoma - 
Pfister 
⬇	 0.0002 *** 
Non-Neoplastic Brain - Roth Vs. 
Medulloblastoma - Pfister 
⬇	 0.0002 *** 
AT/RT - Birks Vs. CNS PNET - Kool ⬇	 0.0171 * 
AT/RT - Birks Vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
AT/RT - Birks Vs. Ependymoma - 
Pfister 
⬇	 0.0044 ** 
AT/RT - Kool Vs. CNS PNET - Kool ⬇	 <0.0001 **** 
AT/RT - Kool Vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
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AT/RT - Kool Vs. Ependymoma - 
Gilbertson 
⬇	 0.0025 ** 
AT/RT - Kool Vs. Ependymoma - 
Pfister 
⬇	 <0.0001 **** 
CNS PNET - Grundy Vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
CNS PNET - Kool Vs. 
Medulloblastoma - Gilbertson 
⬆	 <0.0001 **** 
CNS PNET - Kool Vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
Medulloblastoma - Gilbertson Vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
Medulloblastoma - Gilbertson Vs. 
Ependymoma - Gilbertson 
⬇	 0.0371 * 
Medulloblastoma - Gilbertson Vs. 
Ependymoma - Pfister 
⬇	 <0.0001 **** 
Medulloblastoma - Pfister Vs. 
Ependymoma - Gilbertson 
⬆	 <0.0001 **** 
Medulloblastoma - Pfister Vs. 
Ependymoma - Pfister 
⬆	 0.0008 *** 
 
HDAC4 
 
Dunn's Multiple Comparisons Test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. pGBM - Pfister ⬆	 0.0071 ** 
pGBM - Donson vs. AT/RT - Kool ⬆	 <0.0001 **** 
pGBM - Donson vs. CNS PNET - Kool ⬆	 <0.0001 **** 
pGBM - Donson vs. Medulloblastoma 
- Pfister 
⬆	 0.0052 ** 
pGBM - Donson vs. Ependymoma - 
Gilbertson 
⬆	 <0.0001 **** 
pGBM - Donson vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
pGBM - Paugh vs. AT/RT - Birks ⬇	 0.0351 * 
pGBM - Paugh vs. Medulloblastoma - 
Gilbertson 
⬇	 0.001 ** 
pGBM - Paugh vs. Ependymoma - 
Pfister 
⬆	 0.0036 ** 
pGBM - Pfister vs. AT/RT - Birks ⬇	 0.002 ** 
pGBM - Pfister vs. Medulloblastoma - 
Gilbertson 
⬇	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
AT/RT - Kool 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. CNS 
PNET - Grundy 
⬆	 0.0394 * 
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Non-Neoplastic Brain - Roth vs. CNS 
PNET - Kool 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
Medulloblastoma - Pfister 
⬆	 0.0008 *** 
Non-Neoplastic Brain - Roth vs. 
Ependymoma - Gilbertson 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
AT/RT - Birks vs. AT/RT - Kool ⬆	 <0.0001 **** 
AT/RT - Birks vs. CNS PNET - Kool ⬆	 0.0003 *** 
AT/RT - Birks vs. Medulloblastoma - 
Pfister 
⬆	 0.004 ** 
AT/RT - Birks vs. Ependymoma - 
Gilbertson 
⬆	 <0.0001 **** 
AT/RT - Birks vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
AT/RT - Kool vs. Medulloblastoma - 
Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Grundy vs. 
Ependymoma - Pfister 
⬆	 0.0103 * 
CNS PNET - Kool vs. 
Medulloblastoma - Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Kool vs. Ependymoma - 
Pfister 
⬆	 0.0073 ** 
Medulloblastoma - Gilbertson vs. 
Medulloblastoma - Pfister 
⬆	 <0.0001 **** 
Medulloblastoma	-	Gilbertson	vs.	
Ependymoma	-	Gilbertson	
⬆	 <0.0001	 ****	
Medulloblastoma	-	Gilbertson	vs.	
Ependymoma	-	Pfister	
⬆	 <0.0001	 ****	
Medulloblastoma	-	Pfister	vs.	
Ependymoma	-	Pfister	
⬆	 0.0011	 **	
 
HDAC5 
 
Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. pGBM - Pfister ⬆	 <0.0001 **** 
pGBM - Donson vs. AT/RT - Kool ⬆	 <0.0001 **** 
pGBM - Donson vs. CNS PNET - Kool ⬆	 <0.0001 **** 
pGBM - Donson vs. Medulloblastoma 
- Pfister 
⬆	 <0.0001 **** 
pGBM - Donson vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
pGBM - Paugh vs. pGBM - Pfister ⬆	 0.0005 *** 
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pGBM - Paugh vs. AT/RT - Kool ⬆	 <0.0001 **** 
pGBM - Paugh vs. CNS PNET - 
Grundy 
⬇	 0.0105 * 
pGBM - Paugh vs. CNS PNET - Kool ⬆	 0.0001 *** 
pGBM - Paugh vs. Medulloblastoma - 
Gilbertson 
⬇	 0.0123 * 
pGBM - Paugh vs. Medulloblastoma - 
Pfister 
⬆	 0.0023 ** 
pGBM - Paugh vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
pGBM - Pfister vs. AT/RT - Birks ⬇	 <0.0001 **** 
pGBM - Pfister vs. CNS PNET - 
Grundy 
⬇	 <0.0001 **** 
pGBM - Pfister vs. Medulloblastoma - 
Gilbertson 
⬇	 <0.0001 **** 
pGBM - Pfister vs. Ependymoma - 
Gilbertson 
⬇	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
AT/RT - Kool 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. CNS 
PNET - Kool 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
Medulloblastoma - Pfister 
⬆	 0.0001 *** 
Non-Neoplastic Brain - Roth vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
AT/RT - Birks vs. AT/RT - Kool ⬆	 <0.0001 **** 
AT/RT - Birks vs. CNS PNET - Kool ⬆	 <0.0001 **** 
AT/RT - Birks vs. Medulloblastoma - 
Pfister 
⬆	 <0.0001 **** 
AT/RT - Birks vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
AT/RT - Kool vs. CNS PNET - Grundy ⬇	 <0.0001 **** 
AT/RT - Kool vs. Medulloblastoma - 
Gilbertson 
⬇	 <0.0001 **** 
AT/RT - Kool vs. Ependymoma - 
Gilbertson 
⬇	 <0.0001 **** 
CNS	PNET	-	Grundy	vs.	CNS	PNET	-	Kool	 ⬆	 <0.0001	 ****	
CNS	PNET	-	Grundy	vs.	Medulloblastoma	-	
Pfister	
⬆	 <0.0001	 ****	
CNS	PNET	-	Grundy	vs.	Ependymoma	-	
Pfister	
⬆	 <0.0001	 ****	
CNS	PNET	-	Kool	vs.	Medulloblastoma	-	
Gilbertson	
⬇	 <0.0001	 ****	
CNS	PNET	-	Kool	vs.	Ependymoma	-	
Gilbertson	
⬇	 <0.0001	 ****	
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Medulloblastoma	-	Gilbertson	vs.	
Medulloblastoma	-	Pfister	
⬆	 <0.0001	 ****	
Medulloblastoma	-	Gilbertson	vs.	
Ependymoma	-	Pfister	
⬆	 <0.0001	 ****	
Medulloblastoma	-	Pfister	vs.	
Ependymoma	-	Gilbertson	
⬇	 <0.0001	 ****	
Ependymoma	-	Gilbertson	vs.	
Ependymoma	-	Pfister	
⬆	 <0.0001	 ****	
 
HDAC6 
 
Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. Medulloblastoma 
- Pfister 
⬆	 <0.0001 **** 
pGBM - Paugh vs. Medulloblastoma - 
Pfister 
⬆	 <0.0001 **** 
pGBM - Paugh vs. Ependymoma - 
Pfister 
⬆	 0.0278 * 
pGBM - Pfister vs. CNS PNET - 
Grundy 
⬇	 0.0061 ** 
Non-Neoplastic Brain - Roth vs. CNS 
PNET - Kool 
⬆	 0.0058 ** 
Non-Neoplastic Brain - Roth vs. 
Medulloblastoma - Pfister 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
Ependymoma - Gilbertson 
⬆	 0.0062 ** 
Non-Neoplastic Brain - Roth vs. 
Ependymoma - Pfister 
⬆	 0.0017 ** 
AT/RT - Birks vs. CNS PNET - Kool ⬆	 0.0191 * 
AT/RT - Birks vs. Medulloblastoma - 
Pfister 
⬆	 <0.0001 **** 
AT/RT - Birks vs. Ependymoma - 
Gilbertson 
⬆	 0.02 * 
AT/RT - Birks vs. Ependymoma - 
Pfister 
⬆	 0.0057 ** 
AT/RT - Kool vs. Medulloblastoma - 
Pfister 
⬆	 <0.0001 **** 
CNS PNET - Grundy vs. CNS PNET - 
Kool 
⬆	 0.0001 *** 
CNS PNET - Grundy vs. 
Medulloblastoma - Pfister 
⬆	 <0.0001 **** 
CNS PNET - Grundy vs. 
Ependymoma - Gilbertson 
⬆	 0.0003 *** 
CNS PNET - Grundy vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
CNS PNET - Kool vs. 
Medulloblastoma - Gilbertson 
⬇	 0.0005 *** 
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CNS PNET - Kool vs. 
Medulloblastoma - Pfister 
⬆	 0.0004 *** 
Medulloblastoma - Gilbertson vs. 
Medulloblastoma - Pfister 
⬆	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Gilbertson 
⬆	 0.0036 ** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
Medulloblastoma - Pfister vs. 
Ependymoma - Gilbertson 
⬇	 0.0181 * 
Medulloblastoma - Pfister vs. 
Ependymoma - Pfister 
⬇	 0.0167 * 
 
HDAC7 
 
Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. Medulloblastoma 
- Gilbertson 
⬇	 <0.0001 **** 
pGBM - Donson vs. Medulloblastoma 
- Pfister 
⬇	 <0.0001 **** 
pGBM - Donson vs. Ependymoma - 
Gilbertson 
⬇	 0.0138 * 
pGBM - Paugh vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
pGBM - Pfister vs. Ependymoma - 
Pfister 
⬆	 0.0257 * 
Non-Neoplastic Brain - Roth vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
AT/RT - Birks vs. Ependymoma - 
Pfister 
⬆	 0.0268 * 
AT/RT - Kool vs. Medulloblastoma - 
Gilbertson 
⬇	 0.0005 *** 
AT/RT - Kool vs. Medulloblastoma - 
Pfister 
⬇	 0.0107 * 
AT/RT - Kool vs. Ependymoma - 
Pfister 
⬆	 0.0013 ** 
CNS PNET - Grundy vs. 
Ependymoma - Pfister 
⬆	 0.0087 ** 
CNS PNET - Kool vs. 
Medulloblastoma - Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Kool vs. 
Medulloblastoma - Pfister 
⬇	 0.0004 *** 
CNS PNET - Kool vs. Ependymoma - 
Pfister 
⬆	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
Medulloblastoma - Pfister vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
Ependymoma - Gilbertson vs. 
Ependymoma - Pfister 
⬆	 <0.0001 **** 
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HDAC8 
 
Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. CNS PNET - 
Grundy 
⬆	 0.0059 ** 
pGBM - Donson vs. Ependymoma - 
Gilbertson 
⬆	 0.0004 *** 
pGBM - Paugh vs. CNS PNET - Kool ⬇	 0.0301 * 
pGBM - Paugh vs. Medulloblastoma - 
Pfister 
⬇	 <0.0001 **** 
AT/RT - Kool vs. Medulloblastoma - 
Pfister 
⬇	 0.0214 * 
AT/RT - Kool vs. Ependymoma - 
Gilbertson 
⬆	 0.0498 * 
CNS PNET - Grundy vs. CNS PNET - 
Kool 
⬇	 0.0006 *** 
CNS PNET - Grundy vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
CNS PNET - Grundy vs. 
Ependymoma - Pfister 
⬇	 0.0147 * 
CNS PNET - Kool vs. Ependymoma - 
Gilbertson 
⬆	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Medulloblastoma - Pfister 
⬇	 0.0002 *** 
Medulloblastoma - Pfister vs. 
Ependymoma - Gilbertson 
⬆	 <0.0001 **** 
Medulloblastoma - Pfister vs. 
Ependymoma - Pfister 
⬆	 0.0106 * 
Ependymoma - Gilbertson vs. 
Ependymoma - Pfister 
⬇	 0.0001 *** 
 
HDAC9 
 
Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. CNS PNET - Kool ⬆	 <0.0001 **** 
pGBM - Donson vs. Medulloblastoma 
- Pfister 
⬆	 0.0175 * 
pGBM - Paugh vs. pGBM - Pfister ⬆	 0.002 ** 
pGBM - Paugh vs. CNS PNET - Kool ⬆	 <0.0001 **** 
pGBM - Paugh vs. Medulloblastoma - 
Pfister 
⬆	 <0.0001 **** 
pGBM - Paugh vs. Ependymoma - 
Pfister 
⬆	 0.0008 *** 
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pGBM - Pfister vs. AT/RT - Birks ⬇	 0.039 * 
pGBM - Pfister vs. CNS PNET - 
Grundy 
⬇	 0.0002 *** 
pGBM - Pfister vs. CNS PNET - Kool ⬆	 0.0153 * 
Non-Neoplastic Brain - Roth vs. CNS 
PNET - Kool 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
Medulloblastoma - Pfister 
⬆	 0.0015 ** 
Non-Neoplastic Brain - Roth vs. 
Ependymoma - Pfister 
⬆	 0.0188 * 
AT/RT - Birks vs. CNS PNET - Kool ⬆	 <0.0001 **** 
AT/RT - Birks vs. Medulloblastoma - 
Pfister 
⬆	 0.0127 * 
AT/RT - Kool vs. CNS PNET - Grundy ⬇	 0.0131 * 
AT/RT - Kool vs. CNS PNET - Kool ⬆	 <0.0001 **** 
CNS PNET - Grundy vs. CNS PNET - 
Kool 
⬆	 <0.0001 **** 
CNS PNET - Grundy vs. 
Medulloblastoma - Pfister 
⬆	 <0.0001 **** 
CNS PNET - Grundy vs. 
Ependymoma - Pfister 
⬆	 0.0001 *** 
CNS PNET - Kool vs. 
Medulloblastoma - Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Kool vs. 
Medulloblastoma - Pfister 
⬇	 <0.0001 **** 
CNS PNET - Kool vs. Ependymoma - 
Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Kool vs. Ependymoma - 
Pfister 
⬇	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Medulloblastoma - Pfister 
⬆	 0.0002 *** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Pfister 
⬆	 0.0321 * 
 
HDAC10 
 
Dunn's multiple comparisons test Increased/ 
Decreased 
Expression 
P Value Significance 
pGBM - Donson vs. AT/RT - Kool ⬆	 0.0047 ** 
pGBM - Donson vs. CNS PNET - 
Grundy 
⬆	 <0.0001 **** 
pGBM - Donson vs. Medulloblastoma 
- Pfister 
⬆	 <0.0001 **** 
pGBM - Paugh vs. AT/RT - Kool ⬆	 0.0128 * 
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pGBM - Paugh vs. CNS PNET - 
Grundy 
⬆	 <0.0001 **** 
pGBM - Paugh vs. Medulloblastoma - 
Pfister 
⬆	 <0.0001 **** 
pGBM - Pfister vs. CNS PNET - 
Grundy 
⬆	 0.0011 ** 
Non-Neoplastic Brain - Roth vs. 
AT/RT - Kool 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. CNS 
PNET - Grundy 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. CNS 
PNET - Kool 
⬆	 <0.0001 **** 
Non-Neoplastic Brain - Roth vs. 
Medulloblastoma - Gilbertson 
⬆	 0.0001 *** 
Non-Neoplastic Brain - Roth vs. 
Medulloblastoma - Pfister 
⬆	 <0.0001 **** 
AT/RT - Birks vs. CNS PNET - Grundy ⬆	 0.0015 ** 
AT/RT - Kool vs. CNS PNET - Grundy ⬆	 0.0015 ** 
AT/RT - Kool vs. Ependymoma - 
Gilbertson 
⬇	 <0.0001 **** 
AT/RT - Kool vs. Ependymoma - 
Pfister 
⬇	 <0.0001 **** 
CNS PNET - Grundy vs. CNS PNET - 
Kool 
⬇	 <0.0001 **** 
CNS PNET - Grundy vs. 
Medulloblastoma - Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Grundy vs. 
Ependymoma - Gilbertson 
⬇	 <0.0001 **** 
CNS PNET - Grundy vs. 
Ependymoma - Pfister 
⬇	 <0.0001 **** 
CNS PNET - Kool vs. 
Medulloblastoma - Pfister 
⬆	 0.0042 ** 
CNS PNET - Kool vs. Ependymoma - 
Gilbertson 
⬇	 0.0004 *** 
CNS PNET - Kool vs. Ependymoma - 
Pfister 
⬇	 <0.0001 **** 
Medulloblastoma - Gilbertson vs. 
Medulloblastoma - Pfister 
⬆	 0.0013 ** 
Medulloblastoma - Gilbertson vs. 
Ependymoma - Pfister 
⬇	 0.0033 ** 
Medulloblastoma - Pfister vs. 
Ependymoma - Gilbertson 
⬇	 <0.0001 **** 
Medulloblastoma - Pfister vs. 
Ependymoma - Pfister 
⬇	 <0.0001 **** 
 
HDAC11 
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Appendix 11: Tables of Significant Differences in HDAC Expression 
Between Paediatric Brain Tumours. There are multiple significant differences 
in expression between groups for each HDAC. Data extracted from the R2 
database after selecting for age (<18 years). Mixed Paediatric Brain 
(Normal-Tumour) – Donson (n=34); Tumour Glioma Paediatric – Paugh 
(n=37); and Tumour Glioblastoma – Pfister (n=22); Paediatric glioma DIPG –
Paugh (n=37); Normal cerebellum – Roth (n=9); Tumour AT/RT – Birks 
(n=18); Tumour AT/RT – Kool (n=49); Tumour CNS PNET – Grundy (n=24); 
Tumour CNS PNET – Kool (n=182); Tumour Medulloblastoma – Gilbertson 
(n=76); Tumour Medulloblastoma – Pfister (n=223); Tumour Ependymoma – 
Gilbertson (n=83); Tumour Ependymoma – Pfister (n=209). Data were 
analysed by a Kruskal-Wallis test (p<0.05), followed by a Dunn’s multiple 
comparisons post hoc test (p values shown). Analysis performed using 
Graphpad Prism 7 software. Green ‘up’ arrow: First group has significantly 
higher expression compared to second group; Red ‘down’ arrow: First group 
has significantly lower expression compared to second group. Statistical 
significance shown by * : * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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Appendix 12: Fold Regulation Change of mRNA expression of HDACs in Hypoxic Conditions in pGBM Cell Lines 
Compared to a Foetal Astrocyte Control Cell Line. 
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Appendix 12: Fold Regulation Change of mRNA expression of HDACs in 
Hypoxic (1%) Conditions in pGBM Cell Lines (KNS42; SF188) Compared to 
a Foetal Astrocyte Control Cell Line (CC2565). Custom real time RT2 PCR 
arrays were performed and data analysed in Qiagen’s Data Analysis Center. 
HDACs 3, 4, 6, 10 and 11 show a decrease over the 2-fold threshold, in 
expression in KNS42 compared to CC2565 with only HDAC9 showing an 
increase in KNS42. HDAC1 was shown to be the only HDAC to be increased 
above the 2-fold threshold under hypoxia, in SF188 compared to CC2565, 
with HDACs 4, 9 and 11 decreased below the 2-fold threshold. Horizontal 
lines indicate the threshold for a 2-fold difference. N=1 
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